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Cholesterol, the most prominent member of the steroid family, is an important component of eukaryotic membranes (Myant, 1981). In 
addition, it is the precursor of two major classes of steroids: steroid hormones and 
bile acids. The total body cholesterol is derived from two sources: diet and de 
novo biosynthesis. Cholesterol has many biological functions. For instance, the 
concentration of cholesterol influences the fluidity of cell membranes, and thereby 
biological activities of cells. Cholesterol biosynthetic pathway is also linked to the 
synthesis of glycoproteins, which gain their carbohydrate-moiety from a donor 
dolichol-carbohydrate intermediate, many of which function as cell surface 
receptors. The biological properties of cells are affected by the cholesterol content 
of their membranes, which changes during cellular growth, development and 
differentiation (Rao el ai, 1984; Columbano el ai, 1987). For these reasons, 
cellular cholesterol and circulating cholesterol levels are tightly regulated and are 
in a state of dynamic equilibrium. At any given time, the content of cholesterol in 
the cellular compartment is the result of synthesis, breakdown, influx and efflux 
(Myant, 1981). 
Starting from the two carbon unit acetyl-CoA, the biosynthesis of 
cholesterol proceeds through several intermediates, including mevalonate and 
isopentenyl pyrophosphate (Fig. 1.1). Isopentenyl pyrophosphate is further 
processed in a series of steps to two branched pathways, one leading to 
isopentenyl tRNA and isopentenyl adenine, and the other to farnesyl 
pyrophosphate. Farnesyl pyrophosphate is in turn channeled to synthesis of 
cholesterol, ubiquinone or dolichols (Brown and Goldstein, 1980; Rudney and 
Sexton, 1986). Several steps in the cholesterol biosynthetic pathway are subject to 
feedback regulation. The primary feedback loop appears to be at the site where 
3-hydroxy-3-mefhylglutaryl coenzyme A (HMG-CoA) is converted to mevalonic 
acid by the rate limiting enzyme HMG-CoA reductase (EC 1.1.1.34) (Luskey, 
1988). The activity of HMG-CoA reductase is regulated by three distinct 
l 
1 
ft i 
">, 
c 
a 
•** 
S 
ft. 
e 
a. 
ft. 
ft. 
Q. i 
e 
V 
3 
s 
1 
Sy
n 
ft 
ra
n
yl
-
6£ 
ra
n
y 
2 
- > 
n
th
 
a 
>> 
ft 
ft 
* 
ft. 
ft. 
es
yl
-
Fa
rn
 
| 
1 
Sy
n 
ra
n
yl
 
0 
s 
1-
0 
- > 
M 
JS 
yn
t 
i/3 
B 
-
PP
 
a 
e
ra
 
s 
c 
ra
n
sf
er
as
e
 
1 
c 
Q 
ft 
ra
n
yl
 
Ig
e 
ra
n
y 
u 
0 
£-> 
<U 
u 
1 
M 
Ep
o 
le
ne
 
so C 
o
te
i 
•-
ft. 
at
ed
 
£ 
e
ra
 
*>> 
c 
•-
o 
o 
B 
41 
m
al 
SS 
C
yc
l 
1 
a nbsc 
F ft. 3 
87" o> 
^ «s 
JS 
S 
a 
e
- > §-> "3 
s = 
ST 
C0 
O 
en 
! 
o 
l a 
•tori 
e 
Fa
rn
es
yl
-P
P 
D
ec
ap
re
ny
l-P
P 
Sy
nt
ha
se
 
D
ol
ic
hy
l-P
P 
Sy
nt
ha
se
 
Fa
rn
es
yl
 
: 
H
em
e
 
T
ra
ns
fe
ra
se
 
F
ar
ne
sy
l: 
Pr
ot
ei
n
 
T
ra
ns
fe
ra
se
 
Fa
rn
es
yl
at
ed
 
H
em
e-
a
 
D
ol
ic
hy
l-P
P 
N
on
ap
re
ny
l-
PP
 
Pr
ot
ei
ns
 
o
r 
D
ec
ap
re
ny
l-P
P 
p-
H
yd
ro
xy
be
nz
oa
te
 
Po
ly
pr
en
yl
 
T
ra
ns
fe
ra
se
 
^
 
Po
ly
p r
en
yl
-4
-
hy
dr
ox
yb
en
zo
at
e 
U
bi
qu
in
on
es
 
4-
St 
£ 
£ 
83 
£ 
09 
"O 
c 
3 
O 
a £ 
o 
u 
o 
3 
4< 
S-
a 
o 
-a 
c ,_, 
85 oo 
_ IN 
© m 
•- c> 
£ a. 
i*> — 
4i f> 
"S CO 
85 
3 
_o 
> 
CD 
en 
< 
£ F 
- ,—. 
og 
>> — 
85 w 
a g 
• • • TO 
*- £ c
 S 
•a t 
Qj CO 
6* 
mechanisms. The first control point is at the level of gene expression and post-
transcriptional level (Jakoi and Quarfordt, 1974; Kirsten and Watson, 1974; Chan 
et al, 1981; Faust et al, 1982; Koizumi et al, 1982; Clarke et al, 1983 & 1984; 
Edwards et al, 1983 a&b; Liscum et al, 1983; Sinensky and Logel, 1983). The 
amount of the HMG-CoA reductase mRNA produced is modulated by the supply 
of cholesterol. When cholesterol is in excess, the amount of mRNA for HMG-CoA 
reductase is reduced; hence, less enzyme is made. In contrast, depletion of 
cholesterol enhances synthesis of the HMG-CoA reductase mRNA. The amount of 
an enzyme in a cell is also determined by both its rate of synthesis and its rate of 
degradation. The rate of degradation of the HMG-CoA reductase also appears to 
be modulated by the supply of cholesterol. Thus, when cholesterol is abundant, the 
rate of enzyme degradation is twice as fast as when there is a limited supply of 
cholesterol. The effect of cholesterol on enzyme degradation is mediated by the 
membrane domain of the enzyme. The second regulatory mechanism involves 
control of HMG-CoA reductase activity through changes in membrane 
composition and fluidity in the microsomal environment in immediate vicinity of 
the enzyme (Finlcel and Volpe, 1979; Mitropoulous et al, 1981; Siptal and Sabine, 
1981; Richert et al, 1984). The third regulatory mechanism is phosphorylation-
dephosphorylation of the HMG-CoA reductase, which causes inactivation and 
activation, respectively (Ingebritson and Gibson, 1980; Beg and Brewer, 1981; 
Beg and Brewer, 1982; Kennelly and Rodwell, 1985). The kinases and 
phosphatases mediate short-term changes in the activity of HMG-CoA reductase 
involving phosphorylation and dephosphorylation (Ingebritson and Gibson; 1980, 
Beg et al, 1987). Cholesterol biosynthesis is also controlled by the plasma levels 
of low-density lipoproteins (LDL). HMG-CoA reductase also exhibits diurnal 
rhythm and have been shown to have its maximum activity at the mid-point of the 
dark cycle (Edwards et al, 1977). 
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The liver has a major role in the maintenance of cholesterol synthesis 
(Turley and Dietschy, 1988) and it also receives cholesterol from other organs as 
well as dietary cholesterol from the intestines by way of lipoprotein transport 
(Bierman and Glomset, 1981; Turley and Dietschy, 1988). Hepatic cholesterol 
synthesis is found to be by far the highest in the rat. The squirrel monkey shows 
about 40 per cent of this rate, the rabbit 20 per cent, man about 16 per cent and the 
guinea pig and hamster even less (Dietschy et al., 1988). A portion of the 
cholesterol within the liver undergoes fatty acid esterification catalyzed by the 
en2yme acyl-CoA : cholesterol acyltransferase (Balasubramaniam et al., 1978; 
Suckling and Stange, 1985). Cholesteryl esters can be stored in lipid droplets or 
packaged into lipoproteins for systemic transport (Schmitz and Beuck, 1990). 
Alternatively, unesterified (free) cholesterol, generated from the hydrolysis of 
cholesteryl esters by the enzyme cholesteryl ester hydrolase (Turley and Dietschy, 
1988), is available for elimination by metabolic conversion to bile acids or directly 
in association with bile acid/phosphatidyl choline micelles (Bierman and Glomset, 
1981; Suckling and Stange, 1985). Cholesterol 7 a-hydroxylase is the rate-limiting 
enzyme for the conversion of cholesterol to bile acids (Turley and Dietschy, 
1988). The liver is thus primarily responsible for directing cholesterol retention by, 
or elimination from, the body. Cholesterogenesis also occurs in the intestine, 
adrenal cortex, reproductive organs and skin. Even though, other cells and tissues 
do not synthesize cholesterol, they have the genomic information for cholesterol 
synthesis. Under normal circumstances, these cells and tissues take up cholesterol 
from serum lipoproteins (Swann et al, 1975; Goldstein and Brown, 1977). 
Extrahepatic tissues appear to satisfy their cholesterol requirements by uptake 
from the circulation (Goldstein and Brown, 1977); they also have functioning LDL 
receptors, and the rate of endogenous cholesterol synthesis in these tissues 
increases when the levels of circulating LDL are lowered (Anderson and Dietschy, 
1977; Kazanecki et al, 1989). On the other hand, intravenous infusion of LDL 
reduces the rates of cholesterol biosynthesis in extrahepatic tissues, back to low 
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baseline values (Anderson and Dietschy, 1977). Thus, not only liver HMG-CoA 
reductase, but also that present in extrahepatic tissues is subjected to feedback 
inhibition by LDL-cholesterol. Extrahepatic tissues, therefore, probably take up 
LDL (Brown et al, 1981). Blood plasma cholesterol levels and the activity of the 
lecithin : cholesterol acyltransferase enzyme increases with age, or an apparently 
physiological response to aging (Carlile et al, 1980). The genetic background also 
affects plasma cholesterol levels in both experimental animals and humans. Diet 
and nutrition, however, seem to have the most profound influence on plasma 
cholesterol levels (Myant, 1981). Dietary polyunsaturated fatty acids and bile acid 
sequestrants, decrease serum cholesterol levels and stimulate cholesterogenesis in 
several organs (Kazanecki et al, 1989). 
Unesterified fatty acids are carried in plasma by albumin. The plasma also 
transports more complex lipids, such as cholesterol, triacylglycerols (TAG), 
among the various tissues as components of lipoproteins (Morrisett et al, 1975; 
British Nutrition Foundation, 1992; Norum, 1992; Spady et al, 1993). The plasma 
lipoproteins are spherical particles composed of core of non-polar neutral lipid 
consisting of cholesteryl ester and TAG and coats of relatively polar materials 
consisting of phospholipids, free cholesterol, and proteins (Atkinson et al., 1974; 
Laggner et al, 1981). Because cholesterol and TAG are insoluble in aqueous 
medium such as plasma, these lipoproteins (which are soluble in plasma) have 
evolved for the purpose of transporting complex lipids among tissues. The 
amounts and types of lipids found in human plasma fluctuate according to the 
dietary habits and metabolic states of the individuals. In plasma these lipids are 
associated with proteins in the form of lipoproteins, which are classified into five 
major types on the basis of their density (Gofman et al, 1954). The lipoproteins of 
lowest density, the TAG-rich chylomicrons, are the largest in size and contain the 
most lipid and smallest percentage of protein. At the other extreme are the 
cholesteryl ester-rich high-density lipoproteins (HDL), which are the smallest 
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particles and contain the highest percentage by weight of protein and lowest 
percentage of lipid. Between these two classes, in both size and composition, are 
the cholesteryl ester-rich LDL, the intermediate density lipoproteins (IDL) and the 
TAG-rich very low-density lipoproteins (VLDL). Approximately 70 per cent of 
cholesterol is transported in plasma on LDL and about 20 per cent on HDL 
(Brewer etal, 1984). 
There are atleast fourteen apoproteins associated with the lipoproteins, as 
well as several enzymes and a cholesteryl ester transfer protein (Brewer el al., 
1988). The two major types of apoproteins, apoB-100 and apoB-48, are tightly 
integrated into the phospholipid monolayer. The other apoproteins are less tightly 
associated with the phospholipid and exchange among the lipoproteins. The two 
major apolipoproteins on HDL are apoA-I and apoA-II (Osborne and Brewer, 
1977; Scanu and Landsberger, 1980). The apoproteins have three major functions. 
(1) They are important structural components. (2) Some of the apoproteins 
modulate the activities of enzymes in plasma that are associated with lipoprotein 
metabolism. (3) Several of the apoproteins interact with receptors on the cell 
surface. The synthesis of the apoproteins takes place on ribosomes that are bound 
to the endoplasmic reticulum. The biosynthesis of other lipids in lipoproteins 
(cholesterol, TAG and phospholipids) also occurs on the endoplasmic reticulum 
(Alexander et al, 1976; Borchardt and Davis, 1987; Olofsson et al, 1987; Boren 
et al, 1990). The plasma lipoproteins are made mainly in the liver and intestine. In 
the rat, approximately 80 per cent of the plasma apoproteins originate from the 
liver; the rest are delivered from the intestine. 
Chylomicrons transport dietary TAG and cholesteryl ester from the 
intestine to other tissues in the body (Glauman et al, 1975). VLDL functions in a 
manner similar to the transport of endogenously made lipid from the liver to other 
tissues (Glauman et al, 1975). These two types of TAG-rich particles are initially 
degraded by the action of lipoprotein lipase (Chajek and Eisenberg, 1978), an 
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extracellular enzyme that is most active within the capillaries of adipose tissue, 
cardiac and skeletal muscle, and the lactating mammary gland. Lipoprotein lipase 
catalyzes the hydrolysis of TAG. The enzyme is specifically activated by apoC-II, 
which is associated with TAG-rich chylomicrons and VLDL, as well as IDL and 
HDL. As a result, this lipase supplies the heart and adipose tissue with fatty acids, 
derived from chylomicrons and VLDL in plasma. The fatty acids produced by the 
action of lipoprotein lipase on circulating lipoproteins can be taken into the heart, 
adipose, and muscle tissues and be used for energy or stored as a component of 
TAG. Alternatively, the fatty acids can be bound by albumin and transported to 
other tissues (Fig. 1.2). 
As the lipoproteins are depleted of TAG, the particles become smaller. 
Some of the surface molecules (apoproteins, phospholipids) are transferred to 
HDL. In the rat, remnant that result from chylomicron catabolism are removed by 
the liver. The uptake of remnant VLDL (Mjos et al.„ 1975) also occurs, but much 
of the TAG is further degraded by lipoprotein lipase to give the IDL. This particle 
is converted into LDL via the action of lipoprotein lipase and enriched in 
cholesteryl ester via transfer from HDL by cholesteryl ester transfer protein. Each 
day approximately 45 per cent of the LDL in human plasma is removed by both 
the liver and extrahepatic tissues (particularly the adrenals and adipose tissues). 
The mechanism for the uptake of LDL has been extensively described by 
Goldstein and Brown (1977). The apoB-100 in LDL particles binds to the cell 
surface by specific receptors that congregate in areas of the plasma membrane 
called coated regions, or pits. These areas of plasma membranes engulf the LDL 
particles (in a process called endocytosis) to form coated vesicles, which are 
somehow directed toward and fuse with lysosomes. The LDL particles are 
degraded within the lysosomes by the action of proteases and lysosomal acid 
lipases. The cholesterol, or a derivative of cholesterol, diffuses from the 
lysosomes, suppresses the synthesis of the mRNA for HMG-CoA reductase, and 
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Fig. 1.2. A model for plasma triacylglycerol and cholesterol transport. 
(Adapted from Biochemistry by D. Voet and J.G. Voet, J. Willey and sons, New York, 1990 
ed., p-306). 
stimulates the activity of acyl-CoA : cholesterol acyltransferase which catalyzes 
the synthesis of cholesteryl ester, which are then stored within the cell. The 
cholesterol (or a derivative) also suppresses the synthesis of the LDL receptors and 
thereby limits the uptake of LDL. 
Unlike fatty acids, cholesterol is not degraded to yield energy. Instead 
excess cholesterol is removed from tissues by HDL for delivery to the liver from 
which it is excreted in the form of bile salts into the intestine. The transfer of 
cholesterol from extrahepatic tissues to the liver is called reverse cholesterol 
transport. When HDL is secreted into the plasma from the liver, it has a discoidal 
shape and is almost devoid of cholesteryl ester. Nascent HDL, primarily in the 
form of phospholipid-apolipoprotein A-I discs, are synthesized both in the human 
liver and intestine. The nascent HDL acquire cholesterol from different tissues. 
With the increase in lipid content, the nascent HDL are converted to spherical 
lipoproteins with a hydrated density of HDL3 (d 1.125 to 1.21 gm/ml). HDL3 
lipoproteins are converted to the larger HDL2 lipoproteins (d 1.063 to 1.125 
gm/ml) by the acquisition of lipids and apolipoproteins released during the 
stepwise delipidation and remodeling of the TAG-rich chylomicrons and VLDL as 
well as the uptake of cholesterol from peripheral tissues. The free cholesterol is 
esterified and the cholesteryl esters are transferred to the hydrophobic lipid core of 
the HDL particle converting the HDL3 to the larger HDL2 particles. HDL2 is 
converted back to HDL3 by the removal of TAG and phospholipids by hepatic 
lipase as well as by the transfer of cholesteryl esters into VLDL and LDL by the 
cholesteryl ester transfer protein as well as the transfer of cholesteryl esters to the 
liver and other tissues (Glomset et al, 1966; Glomset, 1968; Brewer et at., 1979; 
Eisenberg, 1984; Brewer etal, 1988). 
In this overall process (Fig. 1.3), HDL is interconverted from HDL3 to 
HDL2 and back to HDL3 as cholesterol is picked up and transferred from 
peripheral tissues to the liver. This process is termed as reverse cholesterol 
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Fig. 1.3. General overview of "reverse cholesterol transport". 
(Adapted from Atherosclerosis and Coronary Artery Disease, edited by V. Fuster, R. Ross and 
E.J. Topol, Lippincott-Raven Publishers, Philadelphia, 1996, p-71). 
transport (Glomset et ai, 1966; Glomset, 1968; Brewer et ai, 1979; Eisenberg, 
1984). VLDL is secreted from the liver and undergo stepwise delipidation to LDL 
as already outlined. LDL, the major cholesterol-transporting lipoprotein binds to 
the LDL receptor in the liver and in peripheral cells, where it supplies cholesterol 
to the intracellular cholesterol pool. Excess cholesterol is removed from the 
peripheral cells by HDL (Brewer et ai, 1979; Eisenberg, 1984). In this proposed 
model, HDL interacts with a putative HDL receptor (Suzuki et ai, 1983; Oram et 
ai, 1983; Schmitz et ai, 1985) that facilitates the transfer of intracellular 
cholesterol to HDL. A variable portion of tissue cholesterol has been proposed to 
be transported to the liver by HDL particles containing apoE, which may interact 
with the hepatic remnant and LDL receptors (Eisenberg, 1984). 
Atherosclerosis, which is the most common form of arteriosclerosis 
(hardening of arteries), is characterized by the presence of atheromas. These 
atheromas or arterial thickenings exude a paste of yellow deposit of almost pure 
cholesteryl esters upon sectioning. Atherosclerosis is a progressive disease and 
results due to the deposition of intracellular lipids in the smooth muscle cells of 
the inner arterial wall. These lesions narrow and eventually block the arteries due 
to the formation of fibrous, calcified plaques. The rough arterial wall promotes the 
formation of blood clots, which may also block the artery. Due to the blocking of 
arteries, blood flow stops and causes the death of the deprived tissues. The 
stoppage of blood flow is known as an infarction. Atheromas mostly occur in the 
arteries supplying blood to the heart known as coronary arteries. This results in 
myocardial infarctions or heart attacks, which is the most common cause of death 
in Western man (Packer and Landvik, 1989). Atherosclerosis is a progressive 
disease process that generally begins in childhood and has clinical manifestations 
in middle to late adulthood. Two decades ago, atherosclerosis was considered to 
be a degenerative process because of the accumulation of lipid and necrotic debris 
in the advanced lesions. We now recognize that it is a multifactorial process 
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which, if it leads to clinical sequelae, requires extensive accumulation of smooth 
muscle cells within the intima of the affected artery. The form and content of the 
advanced lesions of atherosclerosis demonstrate the results of three fundamental 
biological processes. These are: (1) accumulation of intimal smooth muscle cells, 
together with variable numbers of accumulated macrophages and T-lymphocytes; 
(2) formation by the proliferated smooth muscle cells of large amounts of 
connective tissue matrix, including collagen, elastic fibers, and proteoglycans; and 
(3) accumulation of lipid, principally in the form of cholesteryl esters and free 
cholesterol within the cells as well as in the surrounding connective tissues (Ross 
and Glomset, 1976; Ross and Harker, 1976; Fuster et al, 1992; Ross and Fuster, 
1996). 
According to a WHO and World Bank report nearly 1 million people in 
India die every year due to combined cardiovascular diseases. However, experts 
say the figure may be double than that, the report added. In addition, compared to 
Americans, Indians have 150-400 per cent higher death rate from heart attacks. 
Population surveys carried out in the last few decades indicate that the prevalence 
of coronary artery disease (CAD) and hypertension has increased at least twofold 
in the last 20 years in both rural and urban populations in India (Dewan et al, 
1974; Gupta and Malhotra, 1975; Gupta et al, 1995; Singh et al, 1995b). In the 
urban population, the prevalence of hypertension and CAD is 3-4 times higher 
than in rural subjects. In South India (Malhotra, 1967; Raman Kutty et al, 1993), 
the prevalence rates are higher in the urban as well as the rural population. 
Coronary artery disease is also more common in males than females. It seems that 
differences in diet and lifestyle and the aging of populations may be important in 
the pathogenesis of hypertension and CAD in different population groups of 
Indians (Beegom and Singh, 1995; Singh et al, 1995a). 
Coronary artery disease is the single most important disease entity in the 
United States and many other industrialized nations in terms of both mortality and 
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morbidity. In United States, CAD accounts for fully one-half of the nearly 
1 million deaths each year from cardiovascular disease and is the leading cause of 
death in both genders (American Heart Association, 1994). Each year, about 
1.5 million Americans suffer acute myocardial infarction, and almost all 
myocardial infarctions are due to atherosclerosis of the coronary arteries. Among 
the two-thirds who survive the myocardial infarction, about two-thirds do not 
make a full recovery. In 19 per cent of Americans aged 15 years or older who are 
categorized as disabled, the disability is from CAD or other cardiovascular disease 
(American Heart Association, 1994). Risk factor reduction is the primary clinical 
approach to preventing CAD morbidity and mortality. Epidemiological studies 
have clearly demonstrated that risk factors such as dyslipidemia, hypertension, and 
the use of tobacco products act in a synergistic manner (Anderson et al, 1991). 
High levels of total cholesterol, TAG, LDL-cholesterol, VLDL-cholesterol, apoB, 
Lp(a) and low levels of HDL-cholesterol, HDL2-cholesterol, HDL3-cholesterol, 
apoA-I are some of the lipid risk factors associated with CAD. Other non-lipid risk 
factors include physical inactivity, obesity, family history of CAD, age, gender, 
homeostatic factors, homocysteinemia, alcohol consumption, and psychological 
factors. The identification of risk factors provides a means for decreasing CAD 
risk, through the reduction of modifiable risk factors, and for informing treatment 
decisions, through more accurate determination of overall risk status. 
Because hypercholesterolemia is the major risk factor associated with the 
increased incidence of atherosclerosis throughout the world, it is important to 
understand the role that lipids play in this process. Although, many lesions of 
atherosclerosis are fibrous and contain relatively lipid, the effects of lipid on 
endothelium, monocytes and smooth muscle and the accumulation of lipid in the 
lesions of hypercholesterolemic individuals are critical components of the process 
of atherogenesis. Increased plasma levels of three lipoproteins, LDL (Castelli et 
al, 1977; Gordon et al, 1977), 0-VLDL (Mahley, 1979; Brewer et al, 1983) and 
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Lp(a) (Berg et al, 1974; Kostner et al, 1981; Armstrong et al, 1986) and 
decreased levels of HDL (Castelli et al, 1977; Miller et al, 1977; Naito, 1980; 
Yaari et al, 1981) have been associated with the development of cardiovascular 
disease. Increased plasma levels of LDL may result from ingestion of excess 
dietary saturated fat and cholesterol as well as from primary and secondary 
hyperlipoproteinemias. p-Very low-density lipoproteins are abnormal lipoprotein 
remnant particles present in patients with type-Ill hyperlipoproteinemia and 
animals fed a high cholesterol and fat diet (Mahley, 1979; Havel, 1982; Brewer et 
ai, 1983). Elevated levels of Lp(a) are genetically determined and associated with 
an increased risk of cardiovascular disease (Berg et al, 1974; Kostner et al, 1981; 
Armstrong et al, 1986). Plasma LDL can be quantitated by the determination of 
LDL-cholesterol or LDL apoB-100, virtually the only apolipoprotein on LDL. 
Low-density lipoprotein-cholesterol quantitation has been the more widely 
employed technique. Epidemiological as well as clinical studies have definitely 
established the important correlation of the degree of elevation of plasma LDL-
cholesterol levels with the risk of CAD (Gordan et al, 1977; Jenkins et al, 1978; 
Miller et al, 1981; Brunzell et al, 1984). Plasma apoB concentrations correlate 
with LDL-cholesterol levels and have been utilized for the identification of 
patients with increased levels of plasma LDL (Miller et al, 1981; Brunzell et al, 
1984). 
Although the relation between plasma TAG and CAD is not well 
established as the relation between plasma cholesterol and CAD, epidemiological 
evidence suggests that TAG plays an important role in detennining CAD risk. 
Diabetes is frequently associated with hypertriglyceridemia, and is often combined 
with reduced HDL-cholesterol (Haward, 1987). There has been increasing 
evidence of an association between TAG and increased risk of cardiovascular 
disease (Albrink and Man, 1959; Hulley et al, 1980; Aberg et al, 1985; Freedman 
et al, 1988; Austin, 1991), a risk that is especially high in subjects with low HDL-
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cholesterol (Castelli, 1986). One of the major causes of hypertriglyceridemia with 
low HDL-cholesiterol in diabetes is the decrease in lipoprotein lipase activity, an 
enzyme that plays crucial role in both TAG removal and HDL-choIesterol 
production, due to insulin deficiency, because lipoprotein lipase is known to be an 
insulin-dependent enzyme (Garfinkel et al, 1976; Murase et al, 1981). 
Dyslipidemias may be classified according to the levels of lipoproteins that 
are abnormal (Fredrickson et al, 1967). These are mainly type I (elevated 
chylomicrons), type Ha (elevated LDL), type lib (elevated LDL and VLDL), type 
III (elevated IDL), type IV (elevated VLDL) and type V (elevated VLDL and 
chylomicrons). Elevated levels of plasma LDL-cholesterol may be due to diet rich 
in cholesterol, genetic hypercholesterolemias or other diseases. Approximately 10 
per cent of the patients with hypercholesterolemia have a monogenic disease 
causing elevated plasma LDL levels. The monogenic disease, familial 
hypercholesterolemia, is an autosomal codominant disease characterized clinically 
by tendon and tuberous xanthomas, arcus, xanthelasma and cardiovascular disease 
(Brown and Goldstein, 1986). The molecular defect in familial hypercholestero-
lemia is one of several mutations in the gene coding for the LDL receptor (Brown 
and Goldstein, 1986). The deficiency of the LDL receptor leads to a decreased rate 
of removal of plasma LDL. The reduction in the number of LDL receptors has 
been previously demonstrated to be proportional to the elevated levels of plasma 
LDL (Sprecher et al, 1985). The frequency of familial hypercholesterolemia is 
approximately 1 in 500 in heterozygotes and 1 in 1 million in homozygotes. The 
heterozygotes and homozygotes have plasma LDL-cholesterol levels >250 mg/dl 
and >750 mgftU, respectively. Plasma apoB levels are usually greater than 
140 mg/dl. The clinically important complication of familial hypercholesterolemia 
is atherosclerosis. In homozygous patients coronary and myocardial infarctions are 
frequent in young adults. For heterozygous men, the chance of having a 
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myocardial infarction is approximately 5 per cent by age 30, 51 per cent by the age 
of 50 and 85 per cent by 60. 
The extensive epidemiological, clinical trial and experimental data leave 
little question as to whether elevated levels of LDL are a causative factor in the 
development of cardiovascular disease. In addition, the question as to whether the 
correction of the hyperlipidemia in patients with or without established CAD is 
associated with a decrease in cardiac events has also been answered. On the basis 
of the results of the Coronary Primary Prevention Trial, a 1 per cent reduction in 
plasma cholesterol is associated with an approximately 2 per cent decrease in 
coronary risk (Lipid Research Clinics Program, 1984 a&b). The Lipid Research 
Clinic Trials have provided data suggesting that it would be beneficial to lower 
plasma LDL levels. These studies showed that the decrease in plasma cholesterol 
can be correlated with a reduction in the incidence of myocardial infarction and 
presumably atherosclerosis. 
Specific guidelines for the treatment of the hypercholesterolemic patients 
have been published by the National Cholesterol Education Program (Goodman et 
al, 1988). This programme established a goal of reducing LDL-cholesterol level 
below 160 mg/dl in subjects without established CAD, but with two additional risk 
factors (including male gender, hypertension, smoking, diabetes, low HDL-
cholesterol [<35 mg/dl] and severe obesity), whereas in individuals with 
established CAD and two risk factors, an LDL-cholesterol level of less than 
130 mg/dl is set as a goal. 
Over the past 30 years a considerable body of evidence has accumulated to 
establish that an elevated concentration of the Lp(a) lipoprotein, commonly 
referred to as lipoprotein little a in plasma is an important independent risk factor 
for the development of cardiovascular disease (Berg et al, 1974; Kostner et al, 
1981; Armstrong et al, 1986). Lipoprotein (a) is a cholesterol-rich lipoprotein that 
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closely resembles LDL in lipid composition and has a hydrated density (d 1.05 to 
1.1 gm/dl) intermediate between LDL and HDL. The protein moiety consists of 
apoB-100 and a specific apolipoprotein, apo(a) (Gaubatz et al, 1983; Utermann 
and Weber, 1983; Fless et al, 1984). Apolipoprotein (a) is linked by a single 
disulfide bridge to apoB-100 on LDL to form Lp(a). Lipoprotein (a) levels in 
plasma range from less than 1 mg/dl to more than 100 mg/dl. Approximately 
20 per cent of the population worldwide have levels above 30 mg/dl: this is 
associated with a twofold increase in the relative risk of coronary atherosclerosis. 
With elevations of both Lp(a) and LDL, the relative risk of vascular disease 
increases to approximately fivefold (Armstrong et al, 1986). 
An inverse association has been established between HDL-cholesterol level 
and CAD incidence in numerous epidemiological studies. For example, in the 
Framingham Heart Study, men and women with HDL-cholesterol of 35 mg/dl or 
less had an eightfold increase in CAD incidence compared with men and women 
with HDL-cholesterol of 65 mg/dl or greater (Gordon et al, 1977). Women have 
significantly higher plasma levels of HDL2 than men (James and Pometta, 1990); 
increased levels of these larger, less dense particles may be partially responsible 
for the relative cardioprotection seen in premenopausal women. Each 1 mg/dl 
increase in HDL-cholesterol is estimated to decrease CAD risk 2 per cent in men 
and 3 per cent in women (Gordon et al, 1989). The low HDL in men with 
clinically significant CAD is due to a reduction in both HDL2 and HDL3; however, 
the reduction in HDL2 is greater than that in HDL3 (Miller et al, 1981; Laakso et 
al, 1985; Wallentin and Sundin, 1985; Hamsten et al, 1986). These studies 
support the concept that HDL2 is a better predictor of CAD than is HDL3 (Drexel 
et al., 1992). The question, however, as to whether quantitation of HDL2 as a 
screening test is superior to total HDL-cholesterol has not been definitively 
answered due to variability in results of the individual reported studies. 
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The results of the studies in which apoA-I was evaluated as a discriminator 
for CAD also do not permit a definitive conclusion to be drawn as to whether 
apoA-I is a better discriminator than HDL-choIesterol. In the majority of patients 
with angiographically documented CAD or survivors of myocardial infarction, 
plasma apoA-I concentrations were lower than control groups. In some studies 
apoA-I has been shown to be a better discriminator than lipids and lipoprotein 
cholesterol levels in identifying patients with CAD, while in other studies the 
apoB/apoA-I ratio appeared to be an even more powerful predictor than the 
individual lipoproteins. However, in other studies HDL-cholesterol was found to 
be a better predictor than apoA-I (Brunzell et al, 1984; Miller, 1987; Alauporic et 
al, 1988). 
Diet has been major focus of research in relation to the environmental 
factors in cardiovascular disease. The development of atherosclerosis is an 
important aspect of cardiovascular disease and is influenced by plasma cholesterol 
levels (Thompson, 1992). Dietary fat is known to increase the concentration of 
plasma LDL in humans. A similar effect can be observed in monkeys. Masuda and 
Ross (1990 a&b) have shown that formation of fatty streaks in macaque monkeys 
in response to low level diet-induced hypercholesterolemia occurs in a similar way 
to, but at a lower rate than those observed in high level diet-induced 
hypercholesterolemia. In other studies, certain strains of mouse have been shown 
to be susceptible to the development of atherosclerosis when placed on high 
fat/cholesterol diets. Regulation of the LDL receptor and the apoB gene by dietary 
fat and cholesterol have been described in mice by Srivastava et al. (1991). 
Yokode et al. (1990) showed that over-expression of the LDL receptor in 
transgenic mice dramatically reduced the apoB and apoE containing lipoproteins 
even when the animals were fed a high cholesterol diet. Such mice were also able 
to clear Lp(a) effectively (Hofmann et al, 1990). In non-cholesterol fed mice more 
than 90 per cent of apoB and apoE was removed from the plasma in animals over-
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expressing the LDL receptor (Hofinann et al, 1988). The hamster has been shown 
to have a substantial response to dietary saturated fat in its hepatic LDL receptor 
activity, which is comparable to man. Saturated fat causes a reduction in the LDL 
receptor activity in hamster. However, the rat hepatic LDL receptor has been 
shown to be less sensitive (Spady et al, 1986). Strains of pig with abnormal lipid 
metabolism have also been discovered. Checovich et al. (1988 & 1991) described 
the defective metabolism and abnormal composition of LDL from a strain of 
mutant pigs with hypercholesterolemia. Substantial and compelling evidence 
supports the hypothesis that oxidation of LDL play an important role in 
atherogenesis (Ledwozyw et al, 1986; Steinbrecher et al, 1990). The inhibitory 
effect of antioxidants in the oxidation of human LDL is well documented 
(Esterbauer et al, 1990). But there is still inadequate information on the influence 
of various fats with varying unsaturation on the in vivo effects of antioxidants on 
LDL oxidation. 
For years it has been known that native LDL is not readily taken up by 
macrophages in vitro and that incubation with LDL does not result in the 
formation of foam cells (Haberland and Fogelman, 1987; Steinberg, 1987). 
Oxidative modification of LDL in vitro has been shown to markedly enhance LDL 
uptake by scavenger receptor on macrophages with foam cell formation (Fogelman 
et al, 1980; Haberland and Fogelman, 1987; Hiramatsu et al, 1987; Steinberg, 
1987). Oxidative modification of LDL were observed following in vitro incubation 
with endothelial cells, smooth muscle cells and macrophages, or following 
modification with malondealdehyde. Malondealdehyde is a metabolic by-product 
of arachidonic acid metabolism in the biosynthesis of prostaglandins and is also 
formed during lipid peroxidation (Fogelman et al, 1980). On the basis of these 
studies, it has been proposed that oxidative modification of LDL may occur in vivo 
and is a prerequisite for the macrophage uptake of LDL and foam cell formation. 
Endothelial cells have receptors for many different molecules on their surface, 
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including receptors for LDL (Steinberg, 1983), for growth factors, and probably 
for a number of pharmacological agents. A special capacity of endothelium that 
may be particularly important in atherogenesis is its ability to modify lipoproteins. 
LDL appears to be modified by a process of low-level oxidation when they are 
bound to LDL receptors, internalized and transported through the endothelium. 
Such modified LDL can bind to scavenger receptors, on the surface of 
macrophages, where they are ingested and contribute to the formation of foam 
cells. This activity is probably important in atherogenesis. As a scavenger cell, the 
macrophage attempts to remove injurious materials such as oxidized LDL via 
scavenger receptors (Goldstein et al, 1979) and can oxidize LDL by such means 
as lipoxygenase enzymes, e.g., 15-lipoxygenase (Rosenfeld etal., 1990). Oxidized 
LDL can be taken up by the same macrophages or by neighbouring macrophages. 
The importance of oxidized LDL in atherogenesis was first established in studies 
of the antioxidant drug probucol in hypercholesterolemic rabbits (Carew et al, 
1987; Kita et al, 1987). It was demonstrated that probucol had a marked effect in 
reducing the size and incidence of atherosclerotic lesions (Carew et al, 1987; Kita 
et al, 1987). This led to studies suggesting that oxidized LDL might play a major 
role as an injurious agent responsible for many of the early events associated with 
atherogenesis. Oxidized LDL is injurious to both endothelium and smooth muscle 
in vitro and has been found in both human and experimental lesions of 
atherosclerosis (Boyd et al, 1989). Thus, the presence of this modified lipoprotein 
in the lesions suggests that it is the principal culprit in atherogenesis in 
hypercholesterolemic individuals and that interference with its formation could be 
an important step in lesion prevention. On the basis of current concepts, HDL 
plays a major role in retarding foam cell formation and the development of the 
atherosclerotic lesion by the removal of excess cholesterol from cells by the 
process of reverse cholesterol transport. The efficiency of the HDL transport 
pathway has been proposed to be directly proportional to the peri-cellular HDL 
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concentration. If plasma levels of HDL are low, the removal of cholesterol is 
inadequate and foam cell formation progresses. 
As already shown in Fig. 1.1, the rate limiting step in the cholesterol 
biosynthetic pathway is catalyzed by HMG-CoA reductase (Rodwell et al, 1976). 
Increased activity of this enzyme increases its direct product, mevalonate, 
precursor to sterols and non-sterol isoprenoids, such as ubiquinone, dolichol, and 
isopentenyl tRNA (Goldstein and Brown, 1990). Mevalonate also incorporates 
into isoprenylated proteins (Schmidt et al, 1984), including such signal 
transduction participants as Ras and other GTP binding proteins (Maltese, 1990) 
(Fig. 4.1). An increase in the expression of HMG-CoA reductase has been 
described in certain tumours relative to normal tissue (Maltese, 1983; Engstrom 
and Schofield, 1987; Bennis el al, 1993), including its importance in cellular 
growth control. The HMG-CoA reductase activity is regulated by a negative 
feedback mechanism in which cholesterol and other end products of the sterol 
synthetic pathway suppress the enzyme in a multivalent fashion. It has been shown 
that cholesterol suppresses HMG-CoA reductase activity by inhibiting the rate of 
transcription of the HMG-CoA reductase gene (Luskey et al, 1982). It has also 
been demonstrated that HMG-CoA reductase is involved in normal cellular growth 
control. A high enzymatic activity is essential for the cellular decision to proceed 
towards DNA-synthesis and mitosis (Larsson, 1984). If the HMG-CoA reductase 
activity is suppressed by addition of 25-hydroxycholesterol, normal cells leave the 
cell cycle from Gl and enter a reversible state of quiescence, GO (Larsson, 1984). 
Dietary isoprenoids effectively suppress tumorigenesis (Elson and Yu, 1994). 
d-Limonene (Elegbede et al, 1984) and other monoterpenes (Maltzman et al, 
1985) act as anticarcinogens when added to diets of rats treated with a chemical 
carcinogen 7,12-dimethylbenz[a]anthracene (DMBA). Analogous to the carcino-
genic action of DMBA is its atherogenic action, an action expressed in the absence 
of a promoter, e.g., phorbol esters (Bond et al, 1981) that results in an elevated 
21 
cholesterol level (Albert et al, 1977). Observations from studies with cultured 
cells suggest thait the tumour growth-suppressive action of isoprenoids is linked to 
the suppression of mevalonate pathway activities (Schoff et al, 1991; Cerda et al, 
1994; Schulz et al., 1994). The rationale linking the tumour growth-suppressive 
action of the isoprenoids to the suppression of HMG-CoA reductase activity 
(Schoff et al, 1991) draws support from the studies of Bennis et al. (1993), which 
confirmed the previous reports that HMG-CoA reductase activity in tumour cells is 
elevated and resistant to sterol feedback regulation. Vasudevan et al. (1994) have 
also shown the sterol feedback resistance of HMG-CoA reductase activity in 
tumours. 
Cholesterol is mandatory for cell maintenance and proliferation (Quesney-
Huneeus et al, 1983; Chen, 1984; Langan and Volpe, 1986) and in normal 
hepatocytes and most other cells, the rate of sterol synthesis is under negative 
feedback regulation by cellular cholesterol concentrations. Studies with cell-free as 
well as whole-cell systems have implied that the rate-limiting properties of the 
HMG-CoA reductase-catalyzed reaction impose a tight control over the flux of 
carbon delivered to the remaining post-HMG-CoA reductase segment of the 
cholesterogenic pathway (Chang and Limanek, 1980; Faust and Krieger, 1987). 
Since the activity of the set of enzymes responsible for generating HMG-CoA 
from acetyl-CoA (acetoacetyl-CoA thiolase and HMG-CoA synthase) is 
modulated in concert with changes in HMG-CoA reductase activity, the rate-
limiting control over this pathway in normal tissues always remains at the HMG-
CoA reductase-catalyzed step (Mehrablan et al, 1986; Erickson et al, 1988). A 
relationship between the neoplastic state and loss of feedback inhibition in 
cholesterol metabolism was first suggested by Siperstein et al. (1971), who 
described a failure of dietary cholesterol to regulate de novo synthesis in hepatoma 
and prehepatoma cells. In rapidly proliferating tumours, sterol synthesis appears to 
be a continuous process (Edwards et al, 1977; Gregg et al, 1986; Parlo and 
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Coleman, 1986). Rapidly proliferating cancer cells may have a higher cholesterol 
requirement for membrane or synthetic purposes; consequently, these increased 
demands for cholesterol can be met either by increasing endogenous synthesis 
(Betteridge et al, 1979; dayman et al, 1986) or uptake of exogenous cholesterol 
as LDL (Norata et al, 1984; Vitols et al, 1985; Lombardi et al, 1989; Vitols et 
al, 1992) or both (Rudling et al, 1990). As a result, a significant cholesterol 
enrichment has been observed in various membranes of tumour cells. Furthermore, 
in liver, the deregulation of the cholesterol-synthesis pathway has been shown to 
occur shortly after the dietary administration of hepatocarcinogens (Gregg et al, 
1986). Azrolan and Coleman (1989), demonstrated that the rate-limiting step of the 
liver cholesterogenic pathway is absent from the cell free tumour system, resulting 
in the greater accumulation of cellular HMG-CoA reductase protein in the 
hepatoma cell. This suggests that specific synthetic and degradative mechanisms 
responsible for maintaining the cellular amount of this strategic enzyme are 
regulated differently in the tumour relative to normal liver. A small but 
significantly altered flux control over the' post-lanosterol segment of tumour 
cholesterogenesis relative to normal liver was also observed (Azrolan and 
Coleman, 1989). In view of such findings, the intrinsically decontrolled carbon 
flux through tumour cholesterogenesis could result in a discoordinate and 
dramatically elevated synthesis of mevalonate, thereby providing for the 
production of these non-sterol metabolites in tumours. Thus, the recognition of the 
pivotal role of the mevalonate pathway in cellular metabolism and manipulation of 
this regulatory system could be useful in the treatment of coronary heart disease 
(CHD) as well as certain forms of cancer. 
Cholestyramine is an insoluble quaternary ammonium anion exchange resin 
which is not absorbed from the gastrointestinal tract. Cholestyramine, if 
adrninistered orally, promotes fecal elimination of bile acids, stimulates de novo 
cholesterogenesis in liver and reduces both total and LDL-cholesterol levels in 
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plasma of humans (Myant, 1981). Indeed, clinical studies have shown that 
treatment with cholestyramine coupled with diets high in unsaturated fatty acids 
reduce total serum cholesterol levels by 8 per cent, LDL-cholesterol levels by 
12 per cent, resulting in a 19 per cent reduction in deaths due to CHD. Based on 
these studies it has been widely accepted that a reduction in the serum cholesterol 
levels will significantly reduce the risk of CHD in humans (Rifkind, 1986). While 
this conclusion may be warranted, some epidemiological studies have shown that a 
reduction in serum cholesterol levels resulted in the increased incidence of all 
cancers and colon cancer in particular (Graham, 1984). Some scientists concluded 
that treatment with cholestyramine increases the risk for cancer (Vitale and Ross, 
1985). If indeed cholestyramine or low serum cholesterol levels increase the risk 
for cancer, the mechanism by which this is brought about was unknown till the 
elucidation of farnesylation of Ras protein by farnesyl-protein transferase. There 
are some published reports, which showed conclusively that cholestyramine 
promotes cancers in rats. Asano et al. (1975) showed that cholestyramine 
promotes dimethylhydrazine induced colon cancers in germ free rats. Another 
finding reported that cholestyramine at 2, 6, and 10 per cent level in the diet 
stimulates pancreatic growth, protein and DNA synthesis in Wistar rats. It was also 
suggested that cholestyramine promotes pancreatic carcinogenesis (Brand and 
Morgan, 1982). Bile acids were implicated as the agents promoting cancers of 
colon and pancreas and the low serum cholesterol levels or some other metabolic 
changes induced by cholestyramine diet were never considered as the possible 
mitogenic signal(s). Moreover, it is not known whether orally aclministered 
cholestyramine can promote cancers other than those of digestive tract. Melhem et 
al. (1987) reported that mammary cancer promotion by a cholestyramine diet may 
occur through a reduction in serum LDL, which provides the mitogenic signal. 
They suggested that a decrease in serum LDL levels by a cholestyramine diet leads 
to reduced influx of circulating cholesterol esters which removes inhibition on 
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HMG-CoA reductase leading to enhanced de novo cholesterogenesis, DNA 
synthesis and cell proliferation in breast tissue. 
Interest in the regulatory importance of mevalonate received a tremendous 
boost by the discovery that growth-regulating p21 Ras proteins (Casey et al, 1989; 
Hancock et al., 1989; Schafer et al, 1989), encoded by ras proto-oncogenes and 
oncogenes, and nuclear envelope proteins (Beck et al, 1988; Wolda and Glomset, 
1988; Farnsworth et ai, 1989), are covalently attached to farnesyl group (derived 
from mevalonate), which anchor them to cell membranes (Fig. 4.1 & 4.2). The ras 
oncogenes and the proteins (Ras) encoded by these genes have been the subjects of 
intense investigation for nearly two decades. Much of the interest in these genes 
has been founded in their presumed roles in the pathophysiology of human cell 
transformation and the pathogenesis of human cancer. Viral ras genes were among 
the first oncogenes isolated and cloned (Lowy and Willumsen, 1993). The 
oncogene product Ras p21 plays a key role in controlling cell proliferation 
(Barbacid, 1987). Subsequently, mutated forms of cellular ras genes were found to 
be among the most common genetic abnormalities associated with human cancers. 
Mutations in Ras proteins can lead to unregulated cell division and are found in a 
significant number of human cancers (Rodenhuis, 1992), including approximately 
50 per cent of colon and 90 per cent of pancreatic carcinomas. Pivotal discoveries 
have also been made in the biology and biochemistry of Ras proteins, which are 
membrane-bound GTP-binding proteins that serve as molecular switches in 
mitogenic signal transduction (Boguski and McCormick, 1993; Lowy and 
Willumsen, 1993). 
It is known since 1984 that Ras proteins in its inactive state contains a 
bound GDP molecule. When the cell receives a growth signal, the Ras protein 
exchanges GDP for a GTP molecule and undergoes a change in conformation. 
This causes stimulation of the Ras protein to relay a message to the next molecule 
in the signal transduction system. The Ras protein then hydrolyzes the bound GTP 
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molecule to GDP and returns to its inactive state. In cancer cells, a single mutation 
in the ras oncogene impairs the ability of the Ras protein to turn off its signal-
transduction activity, and thus continues to stimulate the cell to grow. The two 
most common ras mutation sites in tumour cells are located near the protein's GTP 
binding site, and these mutations block GTP hydrolysis to GDP. The result is a 
prolonged activation of the Ras protein and uncontrolled cell growth. GTP binding 
is one of the two prerequisites that the Ras protein must meet to be active. The 
other is that the protein must be modified post-translationally involving 
isoprenylation, which anchors Ras to the cell plasma membrane. These advances 
have suggested multiple targets for pharmacological intervention against Ras in 
mammalian cells (Gibbs, 1992; Boguski and McCormick, 1993; Lowy and 
Willumsen, 1993). However, until now, attempts at blocking Ras-induced 
transforming activity with small molecule inhibitors have been largely 
unsuccessful. Progress has been made in the development of inhibitors of Ras 
activity by exploiting one of the earliest observations concerning Ras physiology, 
that is, its subcellular localization to the plasma membrane (Lowy and Willumsen, 
1993). This association of Ras with the outer membrane of the cell is mediated by 
a 15-carbon isoprenyl (farnesyl) group that is covalently linked to Ras, a post-
translational modification that is obligatory for Ras cell-transforming activity 
(Hancock et al, 1989; Cox and Der, 1992; Schafer and Rine, 1992; Newman and 
Magee, 1993). Lamin B is also modified by 15-carbon farnesyl group, whereas 
other proteins such as y-subunit of G-proteins are modified by 20-carbon geranyl-
geranyl chains involving a geranylgeranyl transferase enzyme. The prenylation 
reactions that attaches the farnesyl group to Ras may prove to be the Achille's heel 
of Ras-dependent cell transformation. The key modification, S-farnesylation 
(Casey et al, 1989) of a cysteine residue near the carboxy terminus of the protein, 
is catalyzed by the enzyme farnesyl-protein transferase (Manne et al, 1990; Reiss 
et al, 1990; Schaber et al, 1990), using farnesyl diphosphate as cosubstrate. It has 
been shown that mutation of the critical cysteine residue to serine prevents 
26 
famesylation and that the resulting cytosolic form of Ras is non-functional 
(Willumsen et al, 1984; Hancock et al, 1989; Jackson et al, 1990). Therefore, 
indirect regulation of Ras function by inhibiting farnesyl-protein transferase is an 
attractive approach to developing a new class of anticancer drug (Gibbs, 1991). 
Modification of proteins by myristoylation has been recognized as 
important in the function of various viral, oncogenic, and signal-transduction 
proteins. The importance of the myristoylation of proteins in tumorigenesis was 
first suggested by the studies demonstrating that myristoylation of the viral 
oncogenepp60vsrc is required for membrane association and cell transformation 
(Krueger et al, 1982; Cross et al, 1984; Kamps et al, 1986). Blockage of the 
myristoylation of pp6(f'src in colonic cell lines depressed colony formation, cell 
proliferation, and localization of pp6(f'src to the plasma membrane (Shoji et al, 
1990). N-Myristoylation is a cotranslational modification of proteins (Wilcox et 
al, 1987) in which myristate is covalently attached to the N-terminal of various 
cellular, viral, and oncoproteins. 
In the past decades, there has been much emphasis on the induction of 
cancer by occupational and industrial pollution factors. There is growing 
recognition, however, that these may account for only a small fraction of human 
cancers. It is becoming increasingly clear from epidemiological and laboratory 
data that diet is an important factor in the etiology of certain cancers. The 
predominance of certain foods in some countries has been related to the incidence 
of certain types of cancers in their population. The human diet contains a variety 
of naturally occurring mutagens and carcinogens (Ames, 1983). Therefore, dietary 
mutagens have attracted considerable interest in the last decades and a number of 
studies on dietary practices in relation to cancer have been undertaken. Although, 
quite a large number of dietary components have been evaluated in microbial and 
animal test systems, there is still a lack of definitive evidence about their 
carcinogenecity and mechanism of action in humans. 
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While major advances have been made in cancer therapy, they are costly 
and often inadequate when treatment is initiated at later stages of the disease. 
Thus, the best defenses are early detection and commencement of treatment at an 
early stage of the disease. Cancer development is a multi-stage process involving 
initiation, promotion and progression. While it is difficult to protect against the 
action of environmental carcinogens, the next line of defense is to circumvent the 
tumour-promotion stage which some natural compounds can inhibit. Susceptibility 
to cancer is a polygenic phenomena. In addition, the influence of non-genetic 
factors such as hormones, nutritional status or chronic inflammation may modulate 
the development of neoplasia in a manner parallel to the phase of initiation and 
promotion seen in chemical carcinogenesis (Miller, 1980). It is now generally 
recognized that most exogenous carcinogens require metabolic transformation into 
an active form and that the ability to activate these substances varies widely from 
individual to individual (Miller, 1980). Similar genetic control may be operating 
with regards to endogenous carcinogens as well (Lewon and Reilly, 1974). A 
precise parallel exists between the metabolism of exogenous carcinogens and the 
metabolism of pharmacological agents. A limited immune deficiency may also 
play a role in the etiology of primary hepatocellular carcinoma (Larouze et al, 
1977). Furth (1975) hypothesized that hormones are not direct carcinogens but are 
indispensable components in carcinogenesis. The hormones enhance cell division 
and thus, favour the somatic mutation or unmasking mutations brought about 
earlier in response to carcinogens, in effect acting as promoters. The studies in 
mice showing the enhancing effect of hormones on breast cancer induction, 
supports this view (Bittner, 1957). Dyer et al. (1975) have shown that 
hypersensitive patients carry higher risk of cancer development under certain 
circumstances. 
Cancer is a major health problem worldwide. Over 7 million new cases of 
cancer are diagnosed annually, and about half of the cases are in developing 
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countries (Kodiath and Kodiath, 1995). Cancer is now being appreciated in India 
as an emerging public health problem. Approximately 600,000 new cancer cases 
occur in India every year, and the absolute number of new cancer patients will 
increase considerably, due to growth in the size of the population and an increase 
in the proportion of elderly persons due to improved life expectancy following 
control of communicable diseases (Sankaranarayanan et al, 1992). The data-based 
cancer mortality estimates for India is nearly 433,000 every year (Gupta et al, 
1994). It is estimated that by the year 2000 there will be six million cancer patients 
in India, with nearly 2 million new patients annually (Desai, 1992). 
Epidemiological and clinical studies have revealed that oral cancer in India ranks 
number one among all cancers in male patients and number three among cancers in 
female patients (Sankaranarayanan, 1990). Head, neck and esophagus cancers in 
the male and cervix and breast cancers in the females form nearly 60 per cent of 
all cancers (Desai, 1992). Head and neck cancers alone account for 30 per cent of 
cancers in males and only 13 per cent in females (Sanghvi et al, 1989). Breast 
cancer is by far the most frequent cancer in women worldwide, and ranks third 
overall when both sexes are considered together. It is the most common cancer of 
women in all the developed areas, except for Japan, where it is second to stomach 
cancer (Parkin et al, 1993). There is a four to fivefold variation in breast cancer 
incidence rates across different countries. The lowest rates are observed in Asia, 
and the highest rates are observed in Western Europe and North America (Ursin et 
al, 1994). Breast cancer accounts for 20 per cent of all female cancers in India 
(Goel et al, 1995). Several studies about breast cancer indicated that this disease 
is the result of a combination of factors, such as ionizing radiation, diet, 
socioeconomic status, psychosocial stress and endocrinologic, familial or genetic. 
Beside breast cancer, liver cancer is considered one of the major cancers of 
developed and developing countries (Parkin et al, 1993). A number of reports 
have described the occurrence of liver cell adenomas in women using oral 
contraceptives (James et al, 1980). Circumstantial evidence derived from human 
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and early experimental animal data, together with the reports of Tapper (1978) 
suggested that oral contraceptive steroids may be liver tumour promoters. The 
incidence of pancreatic cancer is lowest in India, mid-western countries and 
Africa, whereas in Europe, North America, Soutii America and parts of Asia the 
incidence rates are higher (Faivre et al, 1990). 
Initiation of cancer is generally caused by a primary genetic event, followed 
by a series of genetic and/or epigenetic alterations that promote development from 
precancerous cells to malignant tumours. It has been demonstrated that high levels 
of dietary polyunsaturated fatty acid promote tumour growth in several animal 
models (Carroll, 1975; Cohen et ai, 1986; Reddy, 1992), including pancreatic 
cancer models (Birt et ai, 1981; Roebuck et ai, 1981; Birt, 1990). Linoleic acid 
has been implicated to cause this effect (Roebuck et ai, 1981; Ip et ai, 1985; Ip, 
1987). Considerable evidence supports a role of dietary fat and energy in the 
modulation of human cancer and experimental carcinogenesis in animals. The 
consumption of high-fat diets has been associated with elevated risk of cancer at a 
number of sites including breast, colon and pancreas (Weisburger and Wynder, 
1991). The role of high-dietary energy in the enhancement of cancer has been 
clearly demonstrated in animal models of cancer where dietary and/or energy 
restriction have inhibited carcinogenesis at numerous sites (Weindruch et ai, 
1991). Furthermore, evidence from human studies suggest that this is an important 
factor in elevated rates of cancer in populations consuming diets high in energy 
(Weisburger and Wynder, 1991). The more controversial issue has been the 
involvement of dietary energy in the enhancement of carcinogenesis by high-fat 
diets. Clearly, results from animal experiments have suggested that the dietary 
energy may account for some, if not most, of the effect of dietary fat (Pariza, 
1988; Welsch, 1992), but questions remain regarding an independent role of 
dietary fat. 
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Of late, there has also been an increasing interest in oxygen radicals and 
lipid peroxidation as a source of damage to DNA, and, therefore, as promoters of 
cancer (Gensler and Bernstein, 1981; Harman, 1981). Mammalian systems have 
evolved many defense mechanisms as protection against mutagens and 
carcinogens. The most important of such mechanisms may be those against oxygen 
radicals and lipid peroxidation, through both enzymatic and non-enzymatic 
systems (Sies, 1997). The latter includes antioxidants taken as part of normal diet. 
One of the theories of etiology of cancer which is being widely accepted, holds 
that the major cause is damage to DNA by oxygen radicals and lipid peroxidation 
(Ames, 1983). It has also been suggested that certain promoters of carcinogenesis 
act by generation of oxygen radicals, this being a common property of these 
substances. Fat and hydrogen peroxide are among the most potent promoters 
(Welsch and Aylsworth, 1983). Other well-known cancer promoters are lead, 
calcium, phorbol esters, asbestos and various quinones. Many carcinogens which 
do not require the action of promoters and are by themselves able to induce 
carcinogenesis (complete carcinogens), also produce oxygen radicals (Demopoulos 
et al, 1980). These include nitroso compounds, hydrazines, quinones and 
polycyclic hydrocarbons. 
Serum lactate dehydrogenase level has been found enhanced in all the cases 
of cancers (Ts'ao et al, 1996). Lactate dehydrogenase, serum glutamate pyruvate 
transaminase and serum glutamate oxaloacetate transaminase have been reported 
as tumour marker enzyme (Vinithaa et al, 1995). Several other marker enzymes, 
including, glutathione-S-transferases (GSTs, EC 2.5.1.18), and alkaline phospha-
tase (ALP, EC 3.1.3.1) have also been monitored during carcinogenesis (Moss, 
1986; Hendrich and Pitot, 1987; Rahmat et al, 1993). The glutathione-S-trans-
ferases are a group of multi-functional enzymes with overlapping substrate 
specificity and are involved in the metabolism of foreign compounds including 
carcinogens (Chasseaud, 1970). Alkaline phosphatase, a marker enzyme in the 
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liver-function test, has been reported to be useful as a marker of neoplastic 
transformation. 
Pharmacological control over cholesterol biosynthesis has long been sought 
as a means for regulating the amount of cholesterol in the blood and for the 
prevention and treatment of atherosclerosis (Kolata, 1983). An encouraging 
development in the treatment of hypercholesterolemia has been the introduction of 
a new class of fungal-derived compounds that are potent competitive inhibitors of 
HMG-CoA reductase. These drugs are extremely effective in lowering plasma 
concentrations of LDL-cholesterol. Four HMG-CoA reductase inhibitors have 
been studied in humans. Mevastatin (originally called compactin), the first such 
inhibitor, was shown to inhibit cholesterol synthesis in cultured human cells 
(Brown et al, 1978). Lovastatin (also called mevinolin) has been studied most 
extensively. Chemically modified versions of these compounds (pravastatin and 
simvastatin) have recently become available for clinical investigation. 
Inhibitors of HMG-CoA reductase block synthesis of cholesterol in the 
liver, thereby triggering compensatory reactions that lead to a reduction in plasma 
LDL. Much of the information about the mechanism for this reduction comes from 
studies in cell culture and in experimental animals (Groot et al., 1992). Cultured 
human fibroblasts respond to an inhibition of HMG-CoA reductase by 
accumulating increased amounts of the enzyme (Brown et al, 1978). The increase 
is attributable to an increase in the rate of transcription of the HMG-CoA 
reductase gene, an increase in the rate of translation of the mRN A, and a decrease 
in the rate of degradation of the protein. Through these compensatory mechanisms, 
cultured cells can increase the amount of HMG-CoA reductase sufficiently to 
restore rates of cholesterol synthesis almost to normal, even in the presence of 
relatively high concentrations of the inhibitor. An increase in HMG-CoA reductase 
also occurs in the livers of rabbits, hamsters, and rats (Endo et al, 1979; Tanaka et 
al, 1982) treated with these inhibitors. A similar adaptation is presumed to occur 
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in humans. Hamster has been reported to respond to hypocholesterolemic drugs 
(Suckling et al, 1991), but develop atherosclerosis under appropriate conditions 
(Nistor et al, 1987; Sima et al, 1990). Differences between the hamster and man 
which hamper the use of this species as a model for human atherosclerosis have 
also been noted (Nikkari et al, 1991). Another difference noted is that bile acid 
sequestrants tend to increase plasma VLDL-glycerides in man. In the hamster, 
however, cholestyramine produces a reduction as measured both in vivo and cell 
culture (Groot et al, 1992). Rats also respond to hypocholesterolemic drugs but in 
a different way to hamsters. Rats are very capable of modulating their hepatic 
cholesterol synthesis and this is the first response to drugs such as bile acid 
sequestrants and HMG-CoA reductase inhibitors. However, hyperlipidemia can be 
induced and in some cases this can lead to atherosclerosis (Russell et al, 1991; 
Vance and Russell, 1990). Inhibition of mevalonate and cholesterol synthesis by 
inhibitors of HMG-CoA reductase such as mevastatin and lovastatin prevents 
farnesylation and blocks cells growth (Maltese and Robishaw, 1990). It has been 
postulated that inhibitors of HMG-CoA reductase such as lovastatin used in the 
treatment of hypercholesterolemia, may be also useful for cancer chemotherapy 
(Schafer et al, 1989). HMG-CoA reductase inhibitors and/or inhibitors of Ras 
farnesyl : protein transferase could prevent farnesylation of Ras proteins, 
inhibiting the growth of Ras-dependent tumour cells (Goldstein and Brown, 1990). 
Lovastatin and sodium phenylacetate, an inhibitor of isopentenyl pyrophosphate 
synthesis are in clinical trials for the treatment of malignant gliomas, (Shack et al, 
1994). 
In recent years there has been considerable interest in the role of diet and 
nutrition related to human health. One of the areas which has attracted a great deal 
of attention is antioxidant nutrition in the control of degenerative diseases such as 
atherosclerosis and cancer (Ames, 1983; Ong and Packer, 1992). Peroxidation of 
the cellular membrane lipids is a basic reaction which results in the deterioration 
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of unsaturated fatty acids in the membrane. This process has been implicated in 
several human diseases and in the toxicity of xenobiotics (Yagi, 1982; Halliwell 
and Gutteridge, 1989; Sies, 1991). If lipid peroxidation is triggered, it can 
inactivate cellular components and its products can have serious consequences on 
almost all the crucial molecules leading to diseased conditions (Halliwell and 
Gutteridge, 1989; Sies, 1991). In particular, the oxidative modification of LDL 
enhances its atherogenecity (Steinberg, 1988; Duthie et al, 1989; Palinski et al, 
1989). Recent studies have demonstrated that oxidized lipids, especially oxidized 
fatty acids and cholesterol in the diet are atherogenic (Staprans et al, 1998). The 
peroxidation products can also cause the formation of 8-hydroxydeoxyguanosine 
whose presence in the genetic material can lead to mutagenesis and carcinogenesis 
(Kuchino et al, 1987; Park and Floyd, 1992). The susceptibility of tissues to lipid 
peroxidation is influenced by the lipid and antioxidant composition of cellular 
membranes which in turn may be controlled by dietary composition (Clegg, 1973; 
Manorama and Rukmini, 1992). 
The greater stability of vegetable oils versus animal fats under oxidative 
conditions is known to be due to the higher levels of natural antioxidants in the 
oils. An important and commonly occurring class of natural antioxidants in 
vegetable oils is tocopherols (T) of vitamin E family. There are 8 naturally 
occurring forms of vitamin E; a-, P-, y-, 8-tocopherols and tocotrienols (T3). 
Tocotrienols are minor plant constituents especially abundant in cereal grains 
(such as barley, oat, wheat and rye), rice bran, palm oil and latex (Kasparek, 
1980b). The vitamin E antioxidant property reflects the similarity in chemical 
structures of T and T3, which differ only in possessing a farnesyl or unsaturated 
phytyl side chain, respectively (Kasparek, 1980a) (Fig. 1.4). Tocopherols 
predominate in certain oils such as corn oil, soyabean oil and olive oil. Whereas 
the T3 series predominates in rice bran oil (RBO), palm oil and barley oil. Small 
amounts of T3 are found in carrots, sweetcorn and germ oils (Shin and Godber, 
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Tocotrienol 
Tocopherol 
Position of methyl group Tocotrienols Tocopherols 
5,7,8-TrimethyI 
5,8-Dimethyl 
7,8-Dimethyl 
8-Monomethyl 
a-T3 
P-T3 
Y-T3 
5-T3 
a-T 
p-T 
Y-T 
8-T 
Fig. 1.4. Structures of tocotrienols and tocopherols. 
1994). Several lines of research have established that populations which consume 
large amounts of cereal grain and vegetable oils tend to have a lower incidence of 
cardiovascular disease (Sacks et al, 1975; Burslem et al, 1978; Gould et al, 
1980). Furthermore, studies on cereal grains demonstrated that barley is 
particularly effective in lowering lipid levels in animal models (Qureshi et al, 
1980 a,b&c). The ability of barley extracts to lower lipids in vivo led to the 
purification and identification of biologically active compound, T3 (Qureshi et al, 
1986). There are scattered reports regarding the hypocholesterolemic activity of 
rice bran or RBO and some have shown that neither rice bran nor RBO lowered 
cholesterol levels. These findings may be explained by reports that some, but not 
all, rice cultivars contain T3, which exert a powerful hypocholesterolemic action 
(Qureshi el al, 1986; Qureshi et al, 1989). Out of a-, (3-, y- and 8-T3, y- and 
5-form are most potent in terms of cholesterol lowering effect, followed by 
a-form, which has very low effect. P-Tocotrienol has no anticholesterol effect. 
Rice bran oil is the richest source of T3, whereas corn, peanut, mustard, soyabean 
and coconut oils and butter fat contain only T, which have no lipid lowering effect. 
Tocotrienols are highly effective in lowering total blood cholesterol and LDL-
cholesterol apparently by reducing the HMG-CoA reductase activity. Tocopherols, 
on the other hand, do not inhibit cholesterol synthesis and thus do not lower serum 
cholesterol. 
Since the discovery of vitamin E in Berkeley by H.M. Evans in 1992, when 
it was first described as an antisterility agent, many scientists and physicians have 
sought to elucidate its biochemistry, health benefits, and clinical applications 
(Packer, 1992). Vitamin E is the major, if not the only, chain breaking antioxidant 
in membranes, but its membrane concentration is very low, yet the rate of lipid 
radical generation in membranes can be very high. Nevertheless, under normal 
conditions rancidification, that is oxidation of membrane lipids and proteins, does 
not occur. Moreover, it is very difficult to render animals deficient in vitamin E, 
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and vitamin E deficiency is seldom found in adult humans. Hence, there must exist 
a remarkably efficient mechanism for permitting low concentrations of vitamin E 
to have such high efficiency in protecting membranes against damage and in 
supporting normal biological activity (Packer and Landvik, 1989). Vitamin E is 
well accepted as the first line of defense against lipid peroxidation, protecting 
polyunsaturated fatty acids in cell membranes through its free-radical quenching 
activity in biomembranes at an early stage of free-radical attack (Horwitt, 1986; 
Van Gossum et ai, 1988). Vitamin E appears to be highly efficient as an 
antioxidant. After being oxidized and before being decomposed, vitamin E can be 
reduced by ascorbic acid and glutathione. This reaction is dependent on the 
concentration of these substances and/or the enzymes that maintain them in their 
reduced form (Packer, 1991). 
The antioxidant activity of T and T3 is mainly due to their ability to donate 
their phenolic hydrogens to lipid free radicals (Burton and Ingold, 1986; Pokorny, 
1987; Burton and Ingold, 1988; Burton and Traber, 1990). The mechanism for the 
inhibition of lipid peroxidation in biological membranes by T and T3 can be 
outlined as follows: The peroxidation proceeds in 3 phases; initiation, propagation 
and termination (Burton and Traber, 1990). In the initiation phase a carbon-
centered lipid radical R* is produced from a polyunsaturated fatty acid RH. This R" 
reacts with molecular oxygen in the propagation phase to form ROO", which reacts 
with other RH forming a hydroperoxide, ROOH. 
R" + 02 -> ROO* 
ROO' + RH -> ROOH + R" 
This propagation process continues and consumes the valuable polyunsaturated 
fatty acids. In the termination phase, the chain reaction stops when a peroxyl 
radical (ROO") combines with another ROO". 
ROO" + ROO" -> Inactive product 
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However, many antioxidants such as tocotrienols (T3-OH) and tocopherols (T-OH) 
can intercept the peroxyl radical more rapidly than can polyunsaturated fatty acids 
by the following reactions 
T3-OH + ROCT -> T3-0' + ROOH 
T3-0' + ROO' -> Inactive product 
The T3-O* radical is unable to continue the chain and reacts with the peroxyl to 
form inactive product. 
Although, it is generally agreed that the relative antioxidant activity of T in 
vivo is in the order of a>p>y>8 (Dillard et al, 1983; Burton and Ingold, 1986; 
Burton and Traber, 1990; VER1S, 1993), there is a wide spread confusion 
concerning their relative potency in vitro (Burton and Ingold, 1981). The chemical 
structures of T and T3 support hydrogen-donating power in the order of a>P>y>6 
(Pokorny, 1987). This order also was obtained when the activity of the four T was 
compared in a homogenous solution in dichlorobenzene (Burton and Ingold, 
1981), but a reverse order (5>ys|3>a) was obtained when the relative antioxidant 
properties were compared in fats, oils and lipoproteins in vitro (Lea and Ward, 
1959; Olcott and Van Der Ven, 1968; Parkhurst et al, 1968; Chow and Draper, 
1974; Koskas et al, 1984; Esterbauer et al, 1989; Gottstein and Grosch, 1990). 
The reason behind this order is not yet clearly understood. Even though, a-T has 
been labeled as the most efficient chain-breaking antioxidant, but T3 has been 
shown to have much higher antioxidant potency than a-T (Suzuki et al, 1993; 
Kamat and Devasagayam, 1995; Kamat et al, 1997). Suarna et al. (1993) have 
shown that dietary T3 become incorporated into circulating human lipoproteins 
were they react with peroxyl radicals more efficiently. Tocotrienols have been 
shown to have greater free radical scavenging properties as cell membrane 
constituents than tocopherols (Yamaoka and Carrillo, 1990; Serbinova et al, 
1991). Recently, it was shown that compared to a-T, a-T3 possesses a 40-60 times 
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higher antioxidant activity against Fe ++-ascorbate and Fe ++-NADPH induced 
lipid peroxidation in rat liver microsomal membranes and 6.5 times greater 
protection of cytochrome P-450 against oxidative damage (Serbinova et al, 1991). 
This higher antioxidant potency of a-T3 as compared to a-T is attributed to the 
combined effects of three properties; its higher recycling efficiency from 
chromanoxyl radical, its more uniform distribution in membrane bilayer, and its 
stronger disordering of membrane lipids which makes interaction of chromanols 
with lipid radicals more efficient. 
The quantity and the quality of dietary fat is known to play a crucial role in 
plasma lipid concentration (Nichaman and Hamm, 1987), and there is 
overwhelming evidence to support the hypocholesterolemic effect of vegetable oils 
that are rich in polyunsaturated fatty acids, mainly linoleic acid (Grundy, 1994). 
Quig and Zilversmit (1989) showed that feeding coconut oil to rabbits doubled the 
plasma HDL concentration. Plasma cholesterol levels are modulated by the 
amount and the type of dietary fats and various micronutrients such as T and T3 
(Tan et al, 1991; Watkins et al, 1993). Hyperlipidemia, hypertension, cigarette 
smoking and obesity are important predisposing factors for CHD. Hyperlipidemia 
and obesity are diet related abnormalities, hence dietary manipulation is known to 
play an important role in the management of hyperlipidemia and obesity. Dietary 
recommendations to optimize plasma lipid profiles and reduce the risk of CHD are 
currently focused on total fat content, the fatty acid profile, and cholesterol content 
of the diet (Dietary Guidelines, 1988; The Expert Panel, 1988). Although strong 
and consistent evidence has demonstrated that alterations in any one of these 
dietary compositions will alter plasma lipid levels, the data are highly variable 
among studies (Fats and other Lipids, 1989). Explanation for this variability 
include differences in characteristics of the study population (i.e., age, sex and 
baseline plasma lipids), experimental conditions and degree of dietary 
perturbation. An additional explanation may relate to variable amounts of other 
39 
less well characterized components in the diet or dietary fat, such as the 
unsaponifiable fraction, which also has been shown to affect plasma lipid 
concentrations (Lees et al, 1977; Heinemann et al, 1991; Vanhanen et al, 1993). 
The expert panel on detection, evaluation and treatment of high blood 
cholesterol in adults has recommended that fat constitute less than 30 per cent of 
total calories, saturated fatty acids less than 10 per cent calories and cholesterol 
less than 300 mg per day (The Expert Panel, 1988). The Expert Panel 
recommended this considering usual nutritional habits which should not be 
changed abruptly. Polyunsaturated fatty acids are abundantly available in 
vegetable oils like safflower oil, sunflower oil and corn oil which were found to 
lower blood total and LDL-cholesterol levels, as revealed by epidemiological 
studies (Berkson and Stamler, 1981). A number of studies in humans and animals 
have shown that RBO is as effective as other vegetable oils in lowering plasma 
cholesterol levels (Rukmini and Raghuram, 1991; Lichtenstein et al, 1994). In 
some cases, RBO lowered plasma cholesterol more effectively than other 
commonly used vegetable oils rich in linoleic acid (Rukmini and Raghuram, 
1991); this effect was attributed to the presence of T and T3 in the RBO (Nicolosi 
etal, 1991). 
Rice bran, an inexpensive milling by-product largely used as animal 
feedstock, is potentially an underutilized resource of value-added products. India is 
the major rice producing country in the world, but only a fraction of rice bran, rich 
in oil and several beneficial micronutrients, including tocotrienols and tocopherols 
(vitamin E), is utilized as health food. Rice bran oil, though not a popular edible 
oil worldwide, is in steady demand as the so called healthy oil not only in Japan 
but also in other Asian countries, particularly India. Rice bran oil corresponds to 
less than 10% of total vegetable oils consumed annually in India (Source: Central 
Organisation for Oil Industry and Trade, India, 1998). Similarly, RBO 
corresponding to 3.5% of total vegetable oils is consumed in Japan. Furthermore, 
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RBO is characterized by its relatively high content of unsaponifiable material. The 
content of the unsaponifiable material in refined edible grade RBO is less than 5% 
under Japan Agricultural Standards. This value of non-saponifiable fraction of 
RBO is considerably higher than that of other vegetable oils including palm oil, 
where it is less than 1.0-1.5%. 
There are no systematic studies available on RBO. Chemical, nutritional 
and toxicological studies on RBO have been carried out at National Institute of 
Nutrition, India and reported to be safe for human consumption (Rukmini, 1988). 
Studies in rats also indicated that the oil has plasma cholesterol lowering effect 
(Sharma and Rukmini, 1986 & 1987). Compared with other vegetable oils or oil 
blends of similar fatty acid composition, RBO has been reported to have 
hypocholesterolemic effect when fed to rodents and non-human primates (Sharma 
and Rukmini, 1986; Seetheramaiah and Chandrasekhara, 1989; Nicolosi et al, 
1991; Kahlon et al, 1992; Sugano and Tsuji, 1996). In some cases this diet 
induced hypocholesterolemia resulted from a selective decrease in the LDL-
cholesterol fraction (Sharma and Rukmini, 1986; Seetheramaiah and Chandra-
sekhara, 1989; Nicolosi et al, 1991). In addition, the hypocholesterolemic effect 
of RBO was greater than predicted from the fatty acid composition of the oil itself. 
This discrepancy between predicted and observed changes in plasma cholesterol 
levels at the end of the RBO consumption period has been attributed to the oils 
relatively high concentration of unsaponifiable compounds, including plant sterols, 
oryzanols and T3 related to other vegetable oils generally available for human 
consumption (Nicolosi et al, 1991). Tocotrienols have been reported to decrease 
plasma lipid concentrations (Qureshi et al, 1991 a&b) by regulating the hepatic 
HMG-CoA reductase (Qureshi et al, 1986). Pearce et al (1992) examined the 
impact of a- and y-T3 on avian hepatic HMG-CoA reductase. Unlike the 
competitive inhibitors of HMG-CoA reductase activity (Goldstein and Brown, 
1990), the inhibitory action of T3 (Pearce et al, 1992; Parker et al, 1993), famesyl 
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acetate (Bradfute and Simoni, 1994), P-carotene (Moreno et al, 1994) and cyclic 
monoterpenes (Clegg et al, 1982) is mediated via a decrease in enzyme mass. A 
post-transcriptional action is postulated because T3, P-carotene and farnesyl 
acetate do not lower HMG-CoA reductase mRNA levels, whereas both reductase 
mass and activity are substantially decreased. Synthetic y-T3 were significantly 
more effective in suppressing HMG-CoA reductase activity and mass than a-T3. 
y-Tocotrienol has been shown to mediate the suppression of enzymatic activity and 
protein mass of HMG-CoA reductase in HepG2 cells, through decreased synthesis 
(57% of control) and enhanced degradation (2.4 fold versus control) of the enzyme 
(Parker et al, 1993). The modulation of short-term regulation of HMG-CoA 
reductase involving phosphorylation/dephosphorylation by T3 has not been 
reported. In contrast to the effects of 25-hydroxycholesterol, T3 does not suppress 
LDL receptor protein in HepG2 cell membranes as demonstrated by western 
blotting. 
Several animal studies have been conducted to test the hypothesis that 
antioxidants delay atherosclerosis. Wojcicki et al. (1991) reported a statistically 
significant 25 per cent reduction in aortic atherosclerotic lesions in hypercholes-
terolemic mongrel rabbits fed 10 mg/kg/day of vitamin E compared to controls and 
Verlangieri and Bush (1992) reported a 54 per cent lesion reduction in monkeys 
fed 108 IU of vitamin E per day compared to controls. Qureshi et al. (1991 a&b) 
have reported a reduction in both total and LDL-cholesterol in human hyperlipide-
mics and pigs supplemented with T3. Supplementation of y-T3 along with an 
atherogenic diet to rats for six weeks have been shown to lead to decreased plasma 
lipid and lipoprotein concentrations. In addition, a decrease in the plasma lipid 
peroxidation was shown (Watkins et al, 1993). Similar observations were reported 
in hypercholesterolemic rabbits by Teoh et al. (1994). Wahlquist et al (1992), 
however, observed a differential response to T and T3 supplementation in human 
subjects without any change in serum lipids. Tomeo et al (1995) also reported that 
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T3 significantly decreased plasma lipid peroxidation in patients with 
hyperlipidemia and carotid stenosis with no change in their lipid and lipoprotein 
parameters. Similarly, Mensink el al. (1999) recently reported that T3 had no 
markedly favourable effects on the serum lipoprotein profile in men with slightly 
elevated lipid concentrations. Experiments involving the effects of T3 on apoB 
(LDL) and apoA-I (HDL) and apoB/apoA-I ratio has been reported in chickens, 
swine and humans. The apoB/apoA-I ratio, considered to be a better indicator than 
LDL/HDL ratio, for assessment of CHD, was reduced in T3 treated subjects 
(Qureshi et al, 1991 a&b). Recently, the mechanism of action of T3 on apoB 
metabolism in HepG2 cells has been investigated (Wang et al, 1998; Theriault et 
al, 1999b). 
Earlier studies have shown that palm oil does not promote chemically-
induced mammary tumours in rats like other dietary fats and oils (Sylvester et al, 
1986; Sundram et al, 1989; Kritchevsky et al, 1992). Furthermore, the growth of 
cells derived from a spontaneously arising mouse mammary tumour, when injected 
into animals pre-fed with various dietary lipids, was halved when 20 per cent (of 
energy) palm oil was fed compared with 20 per cent safflower oil, and was 
reduced to one-sixth in animals fed 5 per cent palm oil (Hubbard and Erickson, 
1987). It has been suggested that this inhibition might be due to the fact that palm 
oil is not rich in linoleic acid, which has been shown to promote cancer in in vivo 
and in vitro studies (Gammal et al, 1967; Hopkins and Carroll, 1979; Clinton et 
al, 1984; Rose and Connolly, 1989). A second explanation may be found in the 
anticarcinogenic potential of palm oil's minor components, mainly its vitamin E, as 
recent studies have shown that palm oil stripped of the vitamin E fraction enhances 
tumorigenesis. Data indicate that reactive oxygen species are involved in the 
process of cancer initiation and promotion (Ames, 1983; Harman, 1984). Increased 
incidence of cancer with advancing age may be due, at least in part, to the 
increasing level of free radical reactions with age, along with diminishing ability 
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of immune system to eliminate the altered cells (Harman, 1984). Several functions 
of vitamin E are relevant in considering its role in cancer prevention and control. 
In addition to its role in free radical scavenger, vitamin E has been shown to 
enhance the body's immune response when taken in excess (Packer, 1991). 
Vitamin E and other antioxidants have been shown to have a protective effect 
against chemical carcinogenesis in animal models (Birt, 1986). In animal and cell 
culture studies vitamin E and C, acting as a scavengers of nitrite compounds, 
prevented the formation of cancer-promoting nitrosamines (Tannenbaum and 
Mergens, 1980; Lathia et al, 1988). Vitamin E also inhibits the conversion of 
nitrites to nitrosamrnes in the stomach (Watson and Leonard, 1986). Various in 
vivo animal model systems have been used to demonstrate the protective effect of 
T in neoplasia induced by various chemical carcinogens. a-Tocopherol was 
reported to decrease the incidence of cancer by quenching and scavenging the free 
radicals or their products that were formed in carcinogenesis (Packer and Landvik, 
1989; Gould et al, 1991). The antitumour activity of T3 is higher than that of a-T 
(Komiyama et al, 1989; Goh et al, 1994; Elson and Qureshi, 1995; Guthrie et al, 
1997; Nesaretnam et al, 1998). Tocotrienols were shown to exhibit antitumour 
activity against several transplantable murine tumours. Komiyama et al. (1989) 
extended the life of mice after the intraperitoneal transplant of Ehrlich carcinoma, 
IMC carcinoma and sarcoma 180 tumours with 10 daily doses of a- and y-T3 
administered intraperitoneally (5-40 jjg/g body weight). Although controlled 
human studies on antioxidants and cancer are very limited, the majority of 
epidemiological data suggest that vitamin E and other antioxidants may decrease 
cancer incidence. In several studies, subjects with the highest serum concentration 
of vitamin E and other antioxidants had a lower subsequent risks of certain cancers 
than did subjects with lower serum antioxidant concentrations (Stahelin et al, 
1984; Salomen et al, 1985; Menkes et al, 1986; Willet, 1986; Miyamoto et al, 
1987; Knekt, 1988; Knekt et al, 1988). Other studies did not show significant 
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relationship between serum antioxidant concentration and subsequent cancer risk 
or showed a relationship with one of the antioxidants (Willett et al, 1984; Nomura 
etal., 1985). 
It was also demonstrated that addition of the tocotrienol rich fraction (TRF) 
isolated from palm oil to corn oil caused a delay in the appearance of tumours in 
chemically induced mammary carcinogenesis in female rats, when compared with 
the corn oil control group (Nesaretnam et al, 1992). Tocotrienols also caused a 
delay in the onset of subcutaneous lymphoma by 2-4 weeks in HRS/J hairless 
mice, a strain genetically susceptible to subcutaneous lymphoma (Tan, 1992). The 
life span of mice inoculated with transplanted tumour cells was increased with T3 
(Kato et al, 1985). An inhibition of tumour cell growth of Hela and p388 cells by 
T3 in culture also has been reported (Komiyama et al, 1989). The two forms of 
vitamin E were tested for chemopreventive activity in two chemically-induced rat 
mammary tumour models. It was found that only the T3 group had a statistically 
significant increase in tumour latency when mammary tumours were induced with 
DMBA and neither analogue modified latency when nitrosomethylurea was used 
(Gould et al, 1991). It has been shown that TRF markedly inhibited the 
proliferation of MDA-MB-435 (Nesaretnam et al, 1995; Guthrie et al, 1997), 
MDA-MB-231 (Nesaretnam et al, 1998) and MCF-7 (Guthrie et al, 1997; 
Nesaretnam et al, 1998) human breast cancer cells in culture. Goh et al. (1994) 
have shown that y- and 8-T3 derived from palm oil exhibit a strong activity against 
tumour promotion by inhibiting Epstein-Barr virus early antigen expression in Raji 
cells induced by 12-0-tetradecanoylphorbol-13-acetate. However, a- and y-T and 
dimers of y-T3 and y-T lack this activity. Tocotrienols have also been shown to 
inhibit the increase in plasma y-glutamyltranspeptidase activity, a recognized 
marker of early neoplasia in rats treated with the hepatocarcinogen, 2-acetyl-
aminofluorene (Ngah et al, 1991). Supplementation of T3 simultaneously with 
hepatocarcinogen, diethylnitrosamine, administration has been shown to attenuate 
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the elevation of several tumour marker enzymes (Rahmat et al, 1993; Makpol et 
al, 1997). Activities of marker enzymes have also been shown to decrease in 
hepatocarcinogenic rats, induced by 2-acetylaminofluorene, treated with T3 
(Shamaan et al, 1993). The effect of vitamin E on the induction and evolution of 
enzyme altered foci in the liver of the rats treated with diethylnitrosamine and 
2-acetylaminofluorene was also investigated (Ura et al, 1987). Results obtained 
from these studies suggested that vitamin E prevented the very early events during 
hepatocarcinogenesis but could no longer effect the later stages when the 
preneoplastic foci progressed into persistent nodules. These findings suggest that 
vitamin E reduces incidence of certain cancers, by its ability of trapping free 
radicals in lipid membranes (Witting, 1980) and by preventing carcinogen induced 
chromosomal breaks (Shamberger et al, 1973). Results of current and future 
studies will, one hopes, provide additional documentation of the functions of 
vitamin E and other antioxidants in cancer prevention and risk. Recently, 
biological properties of tocotrienols such as hypolipidemic, antioxidant and anti-
tumour, have been reviewed in detail (Theriault et al, 1999a). 
1.1 Objectives of the present investigation 
Current worldwide interest in the use of tocotrienols (T3) in the prevention 
and treatment of cardiovascular diseases and possibly cancer, creates a need to 
develop a simple and cost-effective methodology for the isolation of 
tocotrienol/tocopherol rich fraction (TRF) from rice bran/rice bran oil (RBO). To 
our knowledge, a detailed investigation related to hypolipidemic, antioxidant and 
anti-tumour activities of TRF isolated from RBO in normolipidemic and 
hyperlipidemic rats has been lacking. Therefore, we have undertaken a detailed 
investigation pertaining to hypolipidemic, antioxidant and anti-tumour impacts of 
TRF in normolipidemic and hyperlipidemic rats. Several lines of research have 
established that population which consume large amount of cereal grains and 
vegetable oils tend to have a lower incidence of cardiovascular disease. These 
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studies further led to the discovery that secondary products of plant isoprenoid 
pathways lower cholesterol levels and also suppress tumorigenesis. Present study 
was undertaken to investigate in detail the hypolipidemic properties of TRF or 
purified TRF isolated from refined edible grade RBO in normal and 
hyperlipidemic rats. The minimum dose of TRF required to exert the maximum 
effect was also determined in hyperlipidemic rats. It was reported that RBO from 
different cultivars of rice differ in their T3 type and content. Because of these 
variation in types and content of T3, one finds variation in the cholesterol lowering 
effects of different RBO. Out of a-, p-, y- and 8-T3, y- and 8-tocotrienols are most 
potent in terms of cholesterol lowering effect. a-Tocotrienol has very low effect, 
whereas p-form has no anticholesterol activity. We have investigated the 
hypolipidemic potency of TRF isolated from RBO of two rice cultivars, Sarju-52 
and Mansuri, based on their y- and 8-T3 content. Administration of a-, y- and 5-T3 
isolated from palm oil to chickens have been shown to exert their in vivo 
hypocholesterolemic effect by reducing the HMG-CoA reductase activity. 
Incubation of HepG2 cells with a-, y- and 8-T3 have also been shown to suppress 
cholesterol formation by reducing the enzymatic activity of HMG-CoA reductase. 
A post-transcriptional process involving enhanced degradation of HMG-CoA 
reductase has been demonstrated in HepG2 cells using y-T3. However, mechanism 
of T3 mediated in vivo regulation of HMG-CoA reductase activity has not been 
reported. In the present study, we have investigated the in vivo role and possible 
mechanism of action of TRF in the regulation of rat hepatic HMG-CoA reductase 
involving its activity and protein mass. 
It has been previously established that in hepatoma and other tumours, 
unlike normal cells, the rate-limiting step of cholesterogenesis is unregulated, thus 
causing the accumulation of more HMG-CoA reductase protein mass than normal 
cells. This intrinsically decontrolled cholesterogenesis in tumour cells results in a 
discoordinate and dramatically elevated mevalonate synthesis, thereby providing 
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for the production of non-sterol metabolites, such as isoprenyl pyrophosphates, for 
rapidly proliferating tumours. Studies have shown that ras protein, a proto-
oncogene, must unite with farnesyl pyrophosphate, a cholesterol precursor, in 
order to execute its biological activity. The normal ras protein is essential for cell 
growth. Mutants of ras gene can produce proteins that are oncogenic; they are 
unable to constrain cell growth and often lead to tumour formation. Therefore, in 
view of the above fact, role of TRF in the suppression of experimental 
carcinogenesis in rat liver and mammary glands and its impact on different marker 
enzymes, such as alkaline phosphatase (ALP) and glutathione-S-transferases 
(GSTs), was elucidated. We have utilized the carcinogens, diethylnitrosamine 
(DEN)/2-acetylaminofluorene (AAF), which are associated with the induction of 
hepatic carcinogenesis. Since tocotrienols, being a potent suppressor of HMG-CoA 
reductase, limit the availability of mevalonate-derived products required for 
tumour growth, carcinogen 7,12-dimethylbenz[a]anthracene (DMBA), which is 
known to induce both carcinogenesis and hypercholesterolemia, was also utilized. 
The impact of TRF on initiation and/or promotion/progression of cancer in the 
above two models has been investigated. Furthermore, in rats with DMBA-induced 
carcinogenesis; and hypercholesterolemia, in addition to TRF mediated anti-cancer 
impacts at initiation and/or promotion/progression levels, anticholesterol effects on 
plasma lipids and HMG-CoA reductase were also investigated. The role of TRF in 
the suppression of carcinogen-induced cancer at pre- and post-initiation and 
progression stages was also examined histologically in liver. 
Published reports have linked processes involving oxygen-derived free 
radicals with a number of degenerative diseases such as, atherosclerosis and 
cancer. Oxidized-LDL has been shown to be more atherogenic than native-LDL. 
Tocotrienols have been reported to exert more powerful antioxidant property than 
tocopherols, in vitro and ex vivo in hepatic microsomes and plasma LDL of normal 
rats. Therefore, in vivo impact of TRF, as antioxidant, in the prevention of lipid 
48 
peroxidation and LDL oxidation was carried out in rats with experimental 
hyperlipidemia and DMBA-induced carcinogenesis along with hypercholestero-
lemia. In addition, antioxidant impact of TRF on DEN/AAF induced hepatic 
carcinogenesis of rats was also investigated. 
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MATERIALS 
2.1.1 Chemicals 
The chemicals were obtained from various sources listed below. 
Chemical 
2-Acetylaminofluorene 
Bovine Serum Albumin 
1 -Chloro-2,4-dinitrobenzene 
Cholesterol 
Cholic Acid 
Commassie Brilliant Blue G250 
Diethylnitrosoamine 
Digitonin 
7,12-Dimethylbenz[a]anthracene 
Glutathione 
Heparin 
HMG-CoA 
HRP-Conjugate 
TMB/H202 Substrate 
NADPH 
p-Nitrophenol 
p-Nitrophenyl Phosphate 
Rat Chow 
Refined Edible Grade RBO 
2-Thiobarbituric Acid 
(±)-a-Tocopherol 
Source 
Sigma Chemical Co., USA 
Miles Laboratories Inc., USA 
SRL, India 
Sigma Chemical Co., USA 
CDH, India 
Polysciences Inc., USA 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Pharmacia, Sweden 
Bangalore Genei, India 
Bangalore Genei, India 
Calbiochem, USA 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Hindustan Lever Ltd., India 
Foods, Fats and Fertilizers Ltd., 
India 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
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kindly providing HMG-CoA, NADPH, purified hamster HMG-CoA reductase and 
its antibody and leupeptin as gifts. y-Tocorrienol was a gift from Dr. R.A. Parker, 
Department of Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical 
Research Institute, Princeton, USA. a-Tocotrienol and tocotrienol rich fraction 
were a gift from Dr. A.A. Qureshi, Advanced Research Laboratory, Madison, 
Wisconsin, USA. HMG-CoA reductase and anti-rat hepatic HMG-CoA reductase 
antiserum were a gift from Dr. Z.H. Beg. 
All other chemicals and reagents used were of analytical grade. 
2.1.2 Animals 
Male albino rats weighing 175-200 g, were purchased from the Central 
Animal House, JN Medical College, AMU, Aligarh (India). Male and female 
Sprague-Dawley rats weighing about 110-125 g, were purchased from Rass Fauna 
Store, Bangalore (India) and conditioned to animal house environment prior to the 
experiment. The rats were housed in a light-controlled isolator in which the dark 
period was maintained from 3.00 a.m. to 3.00 p.m. two weeks before the killing. 
The rats were sacrificed at sixth hour of dark cycle at the peak of diurnal rlrythm 
of HMG-CoA reductase (Edwards et al, 1977). 
2.1.3 Diet 
The rats were given pelleted rat chow and water ad libitum unless 
otherwise stated. For the induction of hyperlipidemia, rats were given an 
atherogenic diet consisting of 5% hydrogenated fat, 0.5% cholic acid and 1% 
cholesterol. The atherogenic diet, which was given in addition to the pelleted rat 
chow, was administered as a suspension through gastric intubation in two divided 
doses (morning and evening) of 0.5 ml each/rat/day. TRF was also adWnistered 
through gastric intubation in two equal doses of 0.5 ml in saline/rat/day. 
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METHODS 
2.2.1 Isolation and Purification of Tocotrienol Rich Fraction from Crude 
and Refined Edible Grade Rice Bran Oil 
2.2.1.1 Procurement of rice brans and extraction of crude rice bran oil 
Raw and parboiled paddies of different rice cultivars, namely Sarju-52 
(short grain), Mansuri (medium grain) and Basmati (long grain) were procured. 
The brans from these cultivars of rice, representative of different rice growing 
zones of U.P. (India), were obtained by Sheller milling method. Rice brans 
obtained from each raw and parboiled paddies of Sarju-52, Mansuri and Basmati 
were soaked in hexane (7.0 ml/g bran) within 24 h of milling. The crude rice bran 
oil (RBO) was extracted in hexane for 72 h with intermittent stirring. The crude 
RBO fraction was obtained by evaporating hexane under vacuum in a rotary 
evaporator. 
2.2.1.2 Extraction of tocotrienol rich fraction from crude and refined edible 
grade rice bran oil 
Tocotrienol rich fraction (TRF) from crude and refined edible grade 
RBO (refined edible grade RBO was procured commercially and was isolated 
from a combination of brans from different cultivars of rice) was extracted in 
methanol by stirring in a container for 1 h. The minimum amount of methanol 
essential for extraction of maximum amount of TRF had been worked out to be 7.0 
ml per gram of RBO. Methanol layer containing TRF was evaporated at 65 °C 
under vacuum in a rotary evaporator and TRF was recovered. 
2.2.1.3 Isolation of purified tocotrienol rich fraction 
The procedure for purification of TRF was based on the method reported 
previously (He et ai, 1996) with following modifications. 100 g silica gel (230-
400 mesh) w£is soaked in hexane and layered on a 500 ml sintered glass funnel 
52 
connected to a water aspirator tube for generating a mild vacuum. The silica gel 
was washed with 500 ml of hexane and then loaded with 0.5 g of TRF in 20 ml of 
hexane. The gel was washed with 1.5 lit of hexane in order to remove non-
tocotrienol/tocopherol components such as triacylglycerols, fatty acids, sterols, 
etc. Purified mixture of tocotrienols (T3) and tocopherols (T) was then rapidly 
eluted with diethyl ether. The elution was speeded by the application of vacuum 
produced by water aspirator. The solvent was evaporated under vacuum in order to 
obtain purified mixture of T3 and T. The silica gel was regenerated by thoroughly 
washing with methanol, which removes all the bound components and reused 
again for the purification of TRF. 
2.2.1.4 Analytical HPLC of tocotrienol rich fraction and purified tocotrienol 
rich fraction 
The analytical HPLC system that was used consisted of Beckman System 
Gold 127 Programmable Solvent Module (127 Pump) and 166 Programmable 
Detector Module. Samples (20 \iX) were injected into Beckman Ultrasphere Silica 
Column (4.6 mm x 25 cm) using a 20 JLXI loop. The mobile phase consisted of 0.3% 
isopropanol in hexane at a flow rate of 1.0 ml/min and the eluant was monitored at 
290 nm by UV detector. The chromatogram obtained were monitored on a HP 
3395 integrator. The TRF and purified TRF were characterized by comparing the 
retention time of each peak with the standard TRF. The concentration of individual 
T3 and T was calculated from each peak area of the chromatogram. 
2.2.2 Experimental Design 
For investigating the hypolipidemic effect of TRF, the experiments were 
carried out in different groups. Male albino rats were divided into the following 
groups in each experiment, as described below: 
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2.2.2.1 Experiment No. I 
=> Normolipidemic Control (NLP-C) 
Five rats were given 0.5 ml saline through gastric intubation for one 
week. 
=> Normolipidemic Treated-1 (NLP-T1) 
Five rats in this group were given 125 mg TRF/kg/day for one week. 
=> Normolipidemic Treated-2 (NLP-T2) 
Five rats in this group were given 81.25 mg purified TRF/kg/day 
(equivalent to 125 mg TRF/kg/day) for one week. 
2.2.2.2 Experiment No. II 
=> Normolipidemic Control (NLP-C) 
Three rats were given 0.5 ml saline through gastric intubation for three 
weeks. 
=> Hyperlipidemic Control (HLP-C) 
Three rats in this group were given an atherogenic diet for three weeks. 
=> Hyperlipidemic Untreated Control (HLP-UC) 
Three rats in this group were given an atherogenic diet for three weeks. 
After 3 weeks, atherogenic diet was withdrawn and were given 0.5 ml 
saline/rat/day for 7 days. 
=> Hyperlipidemic Treated-1 (HLP-T1) 
Three rats in this group, after giving atherogenic diet for three weeks, 
were administered 16.25 mg purified TRF/kg/day (equivalent to 25 mg 
TRF/kg/day) for 7 days. 
=> Hyperlipidemic Treated-2 (HLP-T2) 
Three rats in this group, after giving atherogenic diet for three weeks, 
were fed 32.50 mg purified TRF/kg/day (equivalent to 50 mg 
TRF/kg/day) for 7 days. 
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2.2.2.3 Experiment No. HI 
=> Normolipidemic Control (NLP-C) 
Three rats were given 0.5 ml saline through gastric intubation for three 
weeks. 
=> Hyperlipidemic Control (HLP-C) 
Three rats in this group were given an atherogenic diet for three weeks. 
=> Hyperlipidemic Untreated Control (HLP-UC) 
Three rats in this group were given an atherogenic diet for three weeks. 
After 3 weeks, atherogenic diet was withdrawn and were given 0.5 ml 
saline/rat/day for 7 days. 
=> Hyperlipidemic Treated-1 (HLP-T1) 
Three rats in this group, after giving atherogenic diet for three weeks, 
were administered 4 mg TRF/kg/day for 7 days. 
==> Hyperlipidemic Treated-2 (HLP-T2) 
Three rats in this group, after giving atherogenic diet for three weeks, 
were fed 8 mg TRF/kg/day for 7 days. 
=> Hyperlipidemic Treated-3 (HLP-T3) 
Three rats in this group, after giving atherogenic diet for three weeks, 
were ao^ninistered 12 mg TRF/kg/day for 7 days. 
2.2.2.4 Experiment No. IV 
=> Normolipidemic Control (NLP-C) 
Four rats were given 0.5 ml saline through gastric intubation for three 
weeks. 
=> Hyperlipidemic Control (HLP-C) 
Four rats in this group were given an atherogenic diet for three weeks. 
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=> Hyperlipidemic Untreated Control (HLP-UC) 
Four rats in this group were given an atherogenic diet for three weeks. 
After 3 weeks, feeding of atherogenic diet was stopped and were 
administered 0.5 ml saline/rat/day for 7 days. 
=> Hyperlipidemic Treated-1 (HLP-T1) 
Four rats in this group, after giving atherogenic diet for three weeks, 
were given 1.22 mg purified TRF/kg/day from raw Sarju-52 (equivalent 
to 3 mg TRF/kg/day) for 7 days. 
=> Hyperlipidemic Trealed-2 (HLP-T2) 
Four rats in this group, after giving atherogenic diet for three weeks, 
were given 2.44 mg purified TRF/kg/day from raw Sarju-52 (equivalent 
to 6 mg TRF/kg/day) for 7 days. 
=> Hyperlipidemic Treated-3 (HLP-T3) 
Four rats in this group, after giving atherogenic diet for three weeks, 
were given 3.32 mg purified TRF/kg/day from raw Mansuri (equivalent 
to 3 mg TRF/kg/day) for 7 days. 
=> Hyperlipidemic Treated-4 (HLP-T4) 
Four rats in this group, after giving atherogenic diet for three weeks, 
were given 6.64 mg purified TRF/kg/day from raw Mansuri (equivalent 
to 6 mg TRF/kg/day) for 7 days. 
2.2.2.5 Experiment No. V 
To investigate the anticarcinogenic effect of TRF, the carcinogenesis in 
Sprague-Dawley rats was induced by two chemical carcinogens. In order to induce 
carcinogenesis of mammary glands, female rats were given 7,12-dimethylbenz[a]-
anthracene (DMBA), whereas for the induction of hepatic carcinogenesis, male 
rats were treated with diemylrutrosarnine (DEN) and 2-acetylarninofluorene 
(AAF). The female Sprague-Dawley rats were divided into following groups: 
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=> Normal Control Group (NC) 
Four rats were given a single dose of 0.5 ml peanut oil through gastric 
intubation. 
=> Experimental Control Group-I (EC-I) 
Eleven rats in this group were given a single dose of 65 mg/kg body 
weight of DMBA in peanut oil through gastric intubation and were fed 
0.5 ml saline/rat/day for 6 months. 
=> Experimental Treated Group-I (ET-I) 
Two weeks before the carcinogen treatment as above, five rats in this 
group were given 10 mg of TRF/rat/day for 6 months. 
=> Experimental Treated Group-II (ET-II) 
Five rats in this group were given 10 mg of TRF/rat/day, 2 weeks after 
the carcinogen treatment, for 6 months. 
The male Sprague-Dawley rats were divided into following groups: 
==> Normal Control Group (NC) 
Four rats were injected intraperitoneally with a single dose of 0.5 ml 
saline. 
=> Experimental Control Group-I (EC-I) 
Eleven rats were injected intraperitoneally with a single dose of 200 
mg/kg body weight of DEN in saline. Two weeks later, the rats were kept 
on powdered rat chow containing 0.02% (w/w) AAF for 2 months, after 
which they were fed pelleted rat chow. They were also fed 0.5 ml 
saline/rat/day for 6 months. 
=> Experimental Treated Group-I (ET-I) 
Five rats in this group were fed 10 mg of TRF/rat/day, 2 weeks prior to 
the carcinogen treatment, as above for 6 months. 
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=> Experimental Treated Group-II (ET-II) 
Five rats in this group were administered 10 mg of TRF/rat/day for 
6 months, 2 weeks after the carcinogen treatment. 
All the rats, except 6 rats from each experimental control group, were 
sacrificed after 6 months of treatment. At the end of 6 months, 6 rats from each 
experimental control group were further sub-divided into 2 groups of 3 rats each. 
=> Experimental Control Group-II (EC-II) 
Three rats in this group were given 0.5 ml of saline/rat/day and were 
killed at the end of 12 months. 
=> Experimental Treated Group-Ill (ET-III) 
Three rats in this group were given 10 mg of TRF/rat/day and were killed 
at the end of 12 months. 
2.2.3 Collection of Blood and Different Organs for Various Analytical 
Studies 
2.2.3.1 Collection of blood 
At the end of the treatment, the rats in all groups were anaesthetized and 
blood drawn by cardiac puncture. The blood from each rat in a given group was 
collected using heparin as anticoagulant. Blood was mixed gently by inversion 2 or 
3 times and immediately cooled to 2-4 °C in an ice bath. The samples were 
centrifuged for 30 min at 2,500 rpm. Plasma was aliquoted in micro-centrifuge 
tubes and stored at -20 °C. 
2.2.3.2 Collection of different organs 
In addition to the blood, liver, brain, colon and pancreas from male and 
female rats, and mammary glands from female rats, were excised and kept into ice 
cold saline. Portion of liver was immediately fixed in 10% neutral formalin for 
histological studies. 
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2.2.4 Analytical Procedures 
2.2.4.1 Fractionation of plasma lipoproteins 
Lipoproteins were fractionated from plasma by precipitation as described 
by Kastener (1976). Isolation of HDL-cholesterol and VLDL-cholesterol + LDL-
cholesterol was done by using phosphotungstate and magnesium chloride. The 
following solutions were used: 
• 9.7 mM phosphotungstic acid 
• 0.4 M magnesium chloride 
0.2 volume of 1:1 mixture of phosphotungstic acid and magnesium 
chloride was added to 1 volume of plasma. The samples were mixed immediately, 
allowed to stand for 5 min at room temperature and then centrifuged for 10 min at 
12,000 rpm at room temperature. The clear supernatant was used for the analysis 
of HDL-cholesterol as well as for the fractionation of HDL3-cholesterol and 
HDL2-cholesterol. The precipitate was dissolved in 1 volume of freshly prepared 
0.1 M sodium citrate and used for the analysis of VLDL-cholesterol + LDL-
cholesterol. 
Fractionation of HDL-cholesterol subfraction and VLDL-cholesterol was 
done by precipitation method described by Bachorik and Albers (1986). The 
following solutions were used for the fractionation of HDL-cholesterol: 
• Dextran sulfate (Mr 50,000) 40 gm/L, pH 7.0. 
• MgCl2.6H20, 2 M, pH 7.0. 
• Reagent 'X' was prepared by mixing 1 volume of 40 gm/L dextran 
sulfate with 3 volumes of 2 M MgCl2.6H20. 
For HDL-cholesterol fractionation, 0.1 volume of reagent 'X' was added 
to 1 volume of HDL-cholesterol sample and mixed immediately. The samples 
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were allowed to stand at room temperature for 15 min and then centrifuged at 
5,000 rpm for 30 min at 4 °C. Aliquots of clear supernatant were used for HDL3-
cholesterol analysis. HDL2-cholesterol lipids were then calculated as the 
difference between HDL-cholesterol lipids and HDL3-cholesterol lipids. 
For the isolation of VLDL-cholesterol, 0.075 volume of 10% SDS 
solution was added to 1 volume of plasma. After mixing them well, the samples 
were incubated for 2 h at 37 °C. These were then centrifuged at 10,000 rpm for 10 
min at room temperature. The VLDL pellicle floats at the top of the tube. The 
subnatant was carefully removed with a hypodermic syringe and discarded. The 
pellicle residue was dissolved in 1 volume of 1% SDS by warming at 37 °C for 15 
min. 
2.2.4.2 Determination of cholesterol 
Total, free and esterified cholesterol were estimated in plasma and 
lipoproteins as described by Annino and Giese (1976). To glass centrifuge tubes, 
containing 4.8 ml of isopropanol, were added 0.2 ml of the test sample or 0.2 ml of 
the standard cholesterol (200 mg/100 ml isopropanol). The contents were mixed, 
allowed to stand for 5 min and centrifuged at 3,000 lpm for 10 min. 
For the determination of cholesterol in plasma and subtractions, 1.0 ml 
of the supernatant was taken in glass test tubes and treated with 2.0 ml of ferric 
chloride reagent (70 mg of ferric chloride hexahydrate/100 ml of glacial acetic 
acid), mixed immediately, followed by the addition of 2.0 ml of sulphuric acid 
with thorough mixing. For reagent blank, 1.0 ml of isopropanol was used instead 
of supernatant. After 5 min, the absorbance was read at 550 nm in a Beckman DU 
640 spectrophotometer. 
For the determination of free cholesterol and cholesterol ester, 1.0 ml of 
the above supernatant was treated with 2.0 ml of acetone and 1.0 ml of digitonin 
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solution (1.0 g of digitonin dissolved in 60 ml of absolute ethanol, diluted to 100 
ml with distilled water and mixed well). The tubes were allowed to stand in an ice 
bath for 30 min and then centrifuged for 10 min at 4,000 rpm. The supernatant was 
decanted completely. The precipitate was again washed with 3.0 ml of acetone and 
dissolved in 1.0 ml of isopropanol. At the same time, 1.0 ml isopropanol was taken 
in a clean tube to serve as blank. To all the tubes, 2.0 ml of ferric chloride reagent 
and 2.0 ml sulphuric acid were added and the contents were mixed well. After 5 
min, the absorbance was read at 550 nm in a Beckman DU 640 spectrophotometer. 
Calculations: Total, free and esterified cholesterol were calculated as follows : 
Total cholesterol (mg/dl) = Absorbance of test sample x 200 
Absorbance of standard 
Free cholesterol (mg/dl) = Absorbance of test sample x 200 
Absorbance of standard 
Cholesterol ester (mg/dl) = Total cholesterol - Free cholesterol. 
2.2.4.3 Determination of triglycerides 
Triglycerides were determined by using enzymatic kit purchased from 
Pointe Scientific, Inc. (USA). The method uses a modified Trinder colour reaction 
to produce a fast, linear, end point reaction (Trinder, 1969). 
Principle: 
Lipase 
Triglycerides > Glycerol + Fatty acids 
Glycerol kinase 
Glycerol + ATP • G3P + ADP 
Glycerophosphate oxidase 
G3P + 02 • DAP + H202 
Peroxidase 
H202 + 4-AAP + TBHB • Qumoneirnine Dye + 2H20 
61 
Triglycerides in the sample are hydrolyzed by lipase to glycerol and fatty 
acids. The glycerol is then phosphorylated by adenosine-5-triphosphate (ATP) to 
glycerol-3-phosphate (G3P) and adenosine-5-diphosphate (ADP) in a reaction 
catalyzed by glycerol kinase. Glycerol-3-phosphate is then converted to 
dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H202) by 
glycerophosphate oxidase. The hydrogen peroxide then reacts with 4-
aminoantipyrine (4-AAP) and 3-hydroxy-2,4,6-tribomobenzoic acid (TBHB) in a 
reaction catalyzed by peroxidase to yield a red coloured quinoneimine dye. The 
intensity of the colour produced after incubation is directly proportional to the 
concentration of triglycerides in the sample when measured at 540 nm. 
Calculations: Triglycerides in a plasma sample were calculated as follows: 
Triglycerides (mg/dl) = OP Sample x n 
OD Standard 
[ n = standard concentration (200 mg/dl)] 
2.2.4.4 Determination of apolipoproteins A-l and B 
ApoA-1 and apoB were determined in plasma samples by using kit from 
Spectrum (India). This test system permits the quantitative determination of apoA-
1 and apoB in plasma samples by turbidimetric analysis. 
The reaction is based on the precipitation of antigen-antibody complexes 
provided from the monospecific antibody in determined quantity and the antigen, 
the apoA-1 or apoB present in the sample. The formation of this insoluble 
immuno-complex is accelerated in presence of polyethylene glycol buffer. The 
reaction is started by the addition of plasma containing the antigens. The optical 
density measured after incubation at 340 nm is proportional to the quantity of 
antigen present in the sample. 
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Calculations: ApoA-1 and apoB concentrations were determined by utilizing the 
optical density of each sample on a calibration curve constructed by using apoA-1 
and apoB standards. The results were expressed as mg/dl. 
2.2.4.5 Determination of lipid peroxidation in rat liver microsomes 
Lipid peroxidation was induced by the method of Kamat et al. (1997) by 
using ascorbate-Fe system. The incubation mixture (0.5 ml) contained i) 0.35 ml 
of Tris-HCl, pH 7.4 containing 1 mM KH2P04; ii) 50 ul FeS04 in 0.1 mM HCl 
(final cone. 50 uM); iii) 50 |il microsomes; and iv) 50 ul ascorbic acid to give a 
final concentration of 0.4 mM. Incubation was carried out at 37 °C for 10 min in a 
shaker water bath. After incubation, the peroxidation product formed was 
measured as thiobarbituric acid reactive substances (TBARS) as described by 
Pushpendran et al. (1993). For estimating TBARS, the reactants were boiled for 15 
min in a water bath with thiobarbituric acid reagent (0.5% 2-thiobarbituric 
acid/10% trichloro acetic acid/6 mM EDTA/0.63 M hydrochloric acid). After 
cooling, the precipitate formed was removed by centrifugation at 1,000 g for 10 
min. The absorbance of the sample was determined at 532 nm against blank that 
contained all the reagents minus the microsomes. 
Calculations: The values were calculated on the basis of molar extinction 
coefficient (MEC) of malondehyde (1.56 x 105 M"Icm"1). 
TBARS cone. = Absorbance 
MEC x Protein cone. 
= nmole/min/mg protein 
Absorbance = Absorbance per min 
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2.2.4.6 Determination ofLDL oxidation in plasma 
2.2.4.6.1 Isolation ofLDLfrom plasma 
Plasma LDL were isolated by a precipitation method described by 
Wieland and Seidel (1983). The precipitation buffer consisted of 64 mM trisodium 
citrate adjusted to pH 5.05 with 5 N HC1, and contained 50,000 IU/L heparin. 
Before precipitation of LDL, plasma samples and precipitation reagents were 
allowed to equilibrate to room temperature. One milliliter of the sample was added 
to 7.0 ml of the heparin-citrate buffer. After mixing with a vortex mixer, the 
suspension was allowed to stand for 10 min at room temperature. The insoluble 
lipoproteins were then sedimented by centrifugation at 1,000 g for 10 min. The 
pellet was resuspended in 1.0 ml of 0.1 M Na-phosphate buffer, pH 7.4, 
containing 0.9% of NaCl. 
2.2.4.6.2 Oxidation of LDL 
LDL oxidation was induced by ascorbate-Fe -system (Kamat et al, 
1997). The incubation mixture contained 0.35 ml of Tris-HCl, pH 7.4 containing 1 
mM KH2P04; 50 uM FeS04 in 0.1 mM HCl; 50 \i\ of LDL and 0.4 mM of 
ascorbic acid. Incubation was carried out at 37 °C for 10 min in a shaker water 
bath. The oxidation products formed were measured by the method of Buege and 
Aust (1978). The amount of conjugated dienes formed during LDL oxidation was 
assayed by measuring the absorbance of LDL at 234 nm against a buffer blank 
containing all the constituents except LDL. 
Calculations: The amount of conjugated dienes formed were calculated on the 
basis of MEC of conjugated dienes (2.52 x 104 M"1cm"1). 
Cone, of conjugated dienes = P.P. 
MEC x Vol. of LDL 
= nmole/min/ml plasma 
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O.D. = Change in optical density per min 
2.2.4.7 Determination of alkaline phosphatase activity in plasma and different 
tissue homogenates 
Alkaline phosphatase activity was measured by a modified method of 
King (1947). For the assay of alkaline phosphatase activity in plasma, 495 fil of 
buffered substrate was pipette into each of two test tubes, labeled as T and 'C 
corresponding to test and control. The buffered substrate was prepared as follows: 
• Stock substrate of p-nitrophenyl phosphate (20 mM) 
• Glycine buffer (alkaline): 0.1 M glycine, 1 mM MgCl2, pH 10.3. 
• Working substrate: Mix equal volumes of glycine buffer and stock 
substrate of PNPP. 
The tubes were preincubated at 37 °C for 5 min and 5 jil of plasma was 
added to the 'T' tube and mixed well. The tubes were incubated at 37 °C for 
exactly 10 min. At the end of 10 min, 500 \i\ of 0.1 N NaOH was added to both 
tubes to stop the reaction. Before adding NaOH to ' C tube, 5 jil of plasma was 
added to it. Tubes were mixed well to stop the reaction. The absorbance was read 
at 405 nm against 0.1 N NaOH blank. 
Different tissues (liver, brain, colon, pancreas and mammary) of rats 
were homogenized in waning blender containing chilled 0.2 M phosphate buffer, 
pH 6.5. For the assay of alkaline phosphatase activity in the homogenates of liver, 
brain, colon, pancreas and mammary glands, reaction was carried out in 200 pi 
buffered substrate and 50-100 p.g of homogenate protein was used. Reaction was 
stopped by the addition 800 ul of 0.1 N NaOH after 10 min of incubation. 
Calculations: For the estimation of alkaline phosphatase activity in plasma and 
different tissues, absorptive factor was determined first. For the determination of 
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absorptive factor 2, 4, 6, 8 & 10 jil standard p-nitrophenol (2 mM) was diluted to 
1.0 ml by 0.1 N NaOH and read at 405 nm against 0.1 N NaOH as blank. 
Specific activity = 
(Plasma) 
Specific activity = 
(Homogenate) 
T 
C 
F 
Time = 
(T-C)xF 
Time x Vol. of plasma 
(T - Q x F 
Time x Protein cone. 
Absorbanceof test 
Absorbance of control 
Absorptive factor 
Time of incubation 
nmole/min/ml 
nmole/min/mg 
2.2.4.8 Determination of glutathione-S-transferase activity in different tissues 
Homogenates of rat liver, brain, colon, pancreas and mammary glands 
were made in chilled 0.2 M phosphate buffer, pH 6.5 and centrifuged at 10,000 g 
for 20 min at 4 °C. Glutathione-S-transferase activity was measured in the 
supernatant of each tissue by the method of Habig et al. (1974) with minor 
modification. To 0.01 ml of tissue supernatant, 0.27 ml 1 mM glutathione solution 
(in 0.2 M phosphate buffer, pH 6.5) and 0.02 ml of 1 mM l-chloro-2,4-
dinitrobenzene (CDNB) were mixed. The reaction was carried out at 37 °C for 10 
min. To control tube 0.02 ml of 1 mM CDNB was added after the incubation. The 
reaction was stopped by placing the tubes in a chilled water bath at 4 °C. The 
change in absorbance was recorded at 340 nm against blank containing all the 
reagents except the enzymes. 
Calculations: The values were calculated on the basis of MEC of CDNB (9.6 x 
O i l 
10 M cm") and specific activity of enzyme was expressed in jjmoles of GSH-
CDNB conjugate formed per min per mg protein. 
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Specific activity = P.P. 
MEC x Protein cone. 
= pmole/min/mg protein 
O.D. = Change of optical density per min 
2.2.4.9 Determination of HMG-CoA reductase activity in rat liver microsomes 
2.2.4.9.1 Isolation of microsomes 
Rat liver microsomes were isolated by the method of Edwards and Gould 
(1972) with minor modifications. Livers were homogenized at 4 °C in buffer A 
containing 0.04 M potassium phosphate, pH 7.2, 0.05 M KG, 0.03 M potassium 
EDTA, 0.1 M sucrose (2.0 ml/g of liver) in a warring blender. The homogenate 
was centrifuged at 10,000 g for 20 min. The post-mitochondrial supernatant was 
centrifuged at 100,000 g for 1 h at 4 °C. The microsomal pellet was stored frozen 
at-20°C. 
2.2.4.9.2 Solubilization ofHMG-CoA reductase 
For optimal solubilization of the HMG-C6A reductase, method of 
Edwards el al. (1979) was used. The frozen microsomes were allowed to thaw 
either at room temperature or at 37 °C before addition of an equal volume of 50% 
glycerol in buffer B (buffer A plus 20 mM pME) preheated to 37 °C. The 
suspension was rehomogenized with 10 downward passes of a hand driven, all 
glass Potter-Elvejhem homogenizer and then incubated at 37 °C for 60 min. The 
suspension was diluted three fold with buffer B preheated to 37 °C to a final 
glycerol concentration of 8.3%, rehomogenized with 10 downward passes of the 
glass homogenizer pestle and centrifuged at 100,000 g for 1 h at 25 °C. The 
supernatant containing solubilized HMG-CoA reductase was removed and stored 
at-20 °C for future use. 
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2.2.4.9.3 Assay ofHMG-CoA reductase 
HMG-CoA reductase activity in solubilized fractions (above) was 
assayed spectrophotometrically by the method of Kleirisek et al. (1977) with minor 
modifications. The activity of the solubilized HMG-CoA reductase was 
determined at 37 °C in a total volume of 0.25 ml using Beckman DU 640 
spectrophotometer. Assay was carried out in buffer C containing 0.16 M 
potassium phosphate, pH 6.8, 0.2 M KC1, 0.004 M EDTA and 0.02 M pME. The 
reaction cell contained 100-200 \ig protein, 0.2 mM NADPH and 0.1 mM HMG-
CoA, whereas control cell contained only 100-200 ug protein and 0.2 mM 
NADPH. Before the addition of HMG-CoA, the tubes were pre-incubated for 15 
min. The reaction was stopped in cold water bath at 4 °C after incubation for 5 min 
at 37 °C. The change in absorbance from zero time was monitored at 340 nm 
against blank containing all the reagents except NADPH. The rate of oxidation of 
NADPH obtained in the linear range in control cell was subtracted from the rate 
obtained in the reaction cell. 
One unit of enzyme activity is defined as the amount required to oxidize 
2 nmole NADPH per min. Hence, one unit is equivalent to the synthesis of 1 
nmole mevalonate per min. 
Calculations: 
Specific activity 
O.D. 
F 
O.D.xF 
Protein cone. 
nmole of mevalonate/min/mg protein 
Change in optical density per min 
Factor 
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2.2.4.10 Determination of HMG-CoA reductase protein mass by enzyme-linked 
immunosorbant assay (ELISA) 
HMG-CoA reductase protein mass was determined by the method of 
Duckworth el al. (1991) with minor modifications. Assay was performed in 96 
well maxisorp E plates (Nalgene NUNC). Plates were coated with 100 ul of 
microsomal enzyme (1-6 jig protein) diluted in 0.05 M carbonate-bicarbonate-
coaring buffer, pH 9.6. This was allowed to sit overnight at 4 °C. The protein 
solution was removed, and the wells were filled with 100 JJ.1 of 5% non-fat dry 
milk in Tris-buffered saline (TBS). This blocking solution was allowed to incubate 
for 3-4 h at room temperature. The blocking solution was removed and the plates 
were washed three times, for 2 min each, with 100 \A of Tween-Tris-buffered 
saline (TTBS) (20 mM Tris, pH 7.5, 500 mM NaCl, 0.05% Tween-20). The plates 
were then incubated with 50 jul of rat hepatic HMG-CoA reductase antibody for 2 
h at 37 °C. The wells were again washed two times with TTBS. The secondary 
antibody consisted of 50 JJ.1 of goat anti-rabbit IgG conjugated with horseradish 
peroxidase (1:1000). This was allowed to incubate on the plates for 1-2 h. The 
wells were again washed two times with TTBS. Plates were developed by the 
addition of 100 \i\ of the 3,3',5,5'-tetramethyl benzidine peroxidase system. The 
colour reagent remained on the plates for 30 min, and the development was 
terminated by the addition of 100 pi of 1 M phosphoric acid. The absorbance was 
read at 450 nm on an automatic microplate reader. 
Calculations: HMG-CoA reductase protein mass was calculated by utilizing the 
known amount of purified HMG-CoA reductase protein. 
HMG-CoA protein mass = Absorbance of Unknown x n 
Absorbance of Purified 
= pg/g of microsomal protein 
[n = Protein mass of purified HMG-CoA reducatse] 
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2.2.4.11 Protein estimation 
The protein was determined by the method of Bradford (1976), using 
bovine serum albumin as standard. Aliquots of liver, brain, colon, pancreas and 
mammary gland homogenates and post-mitochondrial supernatants, microsomal 
suspension and solubilized HMG-CoA reductase fractions were first precipitated 
with 20% trichloroacetic acid. The protein pellets were dissolved in IN NaOH and 
suitable aliquots were used for protein determination. 
2.2.4.12 Histological studies 
Normal microtechnique procedure was followed for microscopic 
preparation by method of Disbrey and Rach (1970). 
Samples of liver were fixed in 10% neutral formalin, embedded in 
paraffin and sectioned. The sections were double-stained with Ehrlich's 
haematoxylin and eosin and studied microscopically. 
Photographs were taken in the photography section of Department of 
Anatomy, J.N. Medical College, AMU, Aligarh. 
2.2.4.13 Statistical analysis 
Statistical analysis of data was done by employing two tailed student t-
test (Bennet and Franklin, 1967). P values less than 0.05 were considered 
significant. 
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3.1 Percent Yield of Oil From Brans of Sarju-52 and Mansuri Cultivars 
and Percent Yield of Tocotrienol Rich Fraction Isolated From These 
Oils and From Refined Edible Grade Rice Bran Oil 
As seen in Table 1, the percent yield of crude rice bran oil (RBO) 
isolated from raw and parboiled cultivars of Sarju-52 was 15% and 16%, 
respectively. Similarly, the percent yield of crude RBO from raw and parboiled 
Mansuri was also 15% and 16%, respectively. The yield of tocotrienol rich 
fraction (TRF) isolated from refined edible grade RBO was 4.3%, whereas yield of 
TRF isolated from raw and parboiled Sarju-52 was 8.4% and 5.8%, respectively. 
On the other hand, yield of TRF isolated from raw and parboiled Mansuri was 
approximately 6.9%. After purification of TRF on silica gel bed, the yield of 
purified TRF of commercial refined edible grade RBO was reduced from 4.3% to 
2.8% due to removal of non-tocotrienol and non-tocopherol contaminants. The 
yield of purified TRF from raw and parboiled Sarju-52 was 5.0% and 3.9%, 
respectively, whereas that of raw and parboiled Mansuri was around 4.6% 
(Table 1). The TRF and purified TRF, however, may be contaminated with minor 
amounts of oryzanol, polyphenols and/or steroids/terpenes. These results 
demonstrate that yield of oil from parboiled cultivars of rice is slightly higher than 
the yield from the raw cultivars. The results also indicate that yield of purified 
TRF from crude RBO of Sarju-52 and Mansuri was approximately 68% higher 
than the TRF yield obtained from commercial refined edible grade RBO. 
3.2 Quantification of Types and Content of Tocotrienols and Tocopherols 
by HPLC, Present in Tocotrienol Rich Fraction and Purified 
Tocotrienol Rich Fraction Isolated From Refined Edible Grade Rice 
Bran Oil and From Crude Rice Bran Oil of Two Cultivars of Rice 
Table 2 represents the type and percent content of tocotrienols (T3) and 
tocopherols (T) in TRF isolated from refined edible grade RBO, procured 
commercially, and from Sarju-52 and Mansuri, as determined by HPLC. The 
results were calculated from each peak area of the chromatogram of HPLC and are 
71 
TABLE 1 
PERCENT YIELD OF OIL, TOCOTRIENOL RICH FRACTION (TRF) AND 
PURIFIED TRF ISOLATED FROM TWO CULTIVARS OF RICE, AND YIELD 
OF TRF AND PURIFIED TRF FROM EDIBLE GRADE REFINED RICE BRAN 
OIL (RBO) 
Type % Yield of Oil* % Yield of TRF % Yield of Purified 
TRF 
Refined RBO 
Raw Sarju-52 
Parboiled Sarju-52 
Raw Mansuri 
Parboiled Mansuri 
14.7 ± 0.25 
16.3 ±0.21 
14.6 ± 0.22 
15.5 ±0.17 
4.3 ± 0.27 
8.4 ± 0.20 
5.8 ± 0.15 
6.9 ±0.10 
6.8 ± 0.12 
2.8 ± 0.26 
5.0 ± 0.13 
3.9 ± 0.10 
4.6 ± 0.13 
4.6 ± 0.14 
* Values are mean (g/100 g) ± SD of 3 separate determinations. 
TABLE 2 
QUANTIFICATION OF TYPES AND CONTENT OF TOCOTRIENOLS AND 
TOCOPHEROLS BY HPLC, PRESENT IN TRF AND PURIFIED TRF 
ISOLATED FROM REFINED EDIBLE GRADE RBO AND FROM CRUDE RBO 
OF TWO CULTIVARS OF RICE 
Type 
Tocotrienols 
cc-T3 
P-T3 
Y-T3 
5-T3 
Total 
Tocopherols 
a-T 
P-T 
7-T 
8-T 
Total 
Refined RBO 
TRF 
14.6 
2.2 
6.2 
6.2 
29.2 
14.7 
10.6 
3.1 
10.7 
39.1 
Purified TRF 
20.6 
2.2 
9.7 
9.6 
42.1 
20.6 
16.1 
4.8 
16.4 
57.9 
Sari 
Raw 
11.5 
3.5 
11.0 
19.5 
45.4 
23.6 
19.9 
-
11.0 
54.5 
u-52 
Parboiled 
14.6 
4.0 
11.0 
21.2 
50.8 
24.1 
17.7 
-
7.4 
49.2 
Mansuri 
Raw 
28.9 
-
2.3 
8.9 
40.1 
34.4 
-
17.0 
8.5 
59.9 
Parboiled 
30.7 
-
3.8 
10.3 
44.8 
27.1 
-
15.6 
12.5 
55.2 
representative of the percent of the amount of sample loaded. The combined 
amount of different T3 in TRF and purified TRF from refined edible grade RBO 
was 29% and 42%, respectively, whereas that of T was 39% and 58%, 
respectively. Purified TRF from RBO of raw Sarju-52 contained 45% T3 and 55% 
T, whereas purified TRF from RBO of parboiled Sarju-52 contained 51% T3 and 
49% T. Purified TRF from raw Mansuri contained 40% T3 and 60% T, whereas 
purified TRF from parboiled Mansuri contained 45% T3 and 55% T (Table 2). The 
combined content of y- and 8-T3 in TRF from refined edible grade RBO was 
approximately 12%, whereas y- and 8-T3 content in purified TRF from refined 
edible grade RBO was around 19%. Purified TRF obtained from RBO of raw and 
parboiled Sarju-52 contained, respectively, 31% and 32% of combined amount of 
y- and 8-T3, whereas raw and parboiled Mansuri contained 11% and 14%, 
respectively (Table 2). These results demonstrate that TRF content as well as the 
individual type and quantity of T3 and T differ from cultivar to cultivar. In 
addition, this variation in types and total content of T3 and T was also evident 
between TRF isolated from raw and parboiled Sarju-52 or Mansuri. 
3.3 Effect of Tocotrienol Rich Fraction and Purified Tocotrienol Rich 
Fraction on Plasma Lipids, Plasma Lipoprotein Lipids, 
Apolipoproteins B and A-l, Activity and Protein Mass of HMG-CoA 
Reductase, Microsomal Lipid Peroxidation and Plasma LDL 
Oxidation in Normolipidemic Rats After One Week of Treatment 
In the experiments described below, the lipid lowering as well as 
antioxidant property of TRF and purified TRF isolated from refined edible grade 
RBO was investigated in normolipidemic rats after one week of adrriinistration. 
The dose of purified TRF (81.25 mg/kg/day) was adjusted to the dose calculated 
for TRF (125 mg/kg/day) after removing the non-tocotrienol and non-tocopherol 
contaminants, which were approximately 35%. 
7.4 
3.3.1 Impact on plasma lipids 
As seen in Table 3, plasma lipids, except free cholesterol, showed a 
significant reduction in both the normolipidemic treated groups, NLP-T1 and 
NLP-T2, after the administration of TRF and purified TRF for one week. Plasma 
triglycerides showed a highly significant decrease of 30% in both the TRF treated 
groups in comparison to untreated control (NLP-C) rats. Esterified cholesterol 
showed a significant decline of 9-11% in both the treated groups, whereas total 
cholesterol significantly decreased by 7-9% when compared to NLP-C (Table 3). 
These results demonstrate that TRF significantly reduces the plasma lipids in 
normolipidemic rats. 
3.3.2 Effect on plasma lipoprotein lipids, apoB and apoA-1 
TRF and purified TRF had a very significant effect on VLDL-C, LDL-C, 
HDL2-C, HDL3-C and apoB (Table 4). VLDL-C decreased significantly by 36% 
and 45% in NLP-T1 and NLP-T2, respectively, compared to normal control 
(NLP-C) rats. NLP-T1 and NLP-T2 also showed a significant decline in LDL-C, 
which was reduced by 17-19%, but there was no significant change in HDL-C in 
both the treated groups. On the other hand, the cholesterol content of HDL 
subtractions, HDL2-C and HDL3-C, were significantly changed in NLP-TI and 
NLP-T2 in comparison to NLP-C after one week of TRF administration. As 
depicted in Table 4, HDL2-C was significantly increased by 34% and 42%, 
whereas HDL3-C was decreased by 11% and 16%, respectively, in NLP-TI and 
NLP-T2. ApoB showed a significant decline of 15-16% in both the treated groups 
when compared to NLP-C, whereas ApoA-1 levels were not affected (Table 4). 
These results show that in addition to plasma lipids, TRF also reduces plasma 
lipoprotein lipids and the decline in total cholesterol level is apparently due to a 
decrease in VLDL-C and LDL-C levels. 
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TABLE 3 
EFFECT OF TRF AND PURIFIED TRF ON TRIGLYCERIDES, TOTAL, 
ESTERIFIED AND FREE CHOLESTEROL IN NORMOLIPIDEMIC RATS 
TREATED FOR ONE WEEK 
Parameters 
Triglycerides 
Total cholesterol 
Esterified cholesterol 
Free cholesterol 
NLP-C 
46.7 ± 2.3* 
70.7 ± 2.8 
52.0 ± 1.9 
18.8 ± 1.1 
NLP-T1 
32.8 ± 2.2 
(-29.8%)* 
65.9 ± 0.5 
(-6.8%)' 
47.1 ± 1.8 
(-9.4%)f 
18.8 ±1.2 
(0.0%) 
NLP-T2 
32.8 ± 1.2 
(-29.8%)* 
64.5 ± 1.6 
(S.S%f 
46.2 ± 1.3 
(-ll . l%) f 
18.2 ± 0.9 
(-3.2%) 
* Values are mean (mg/dl) ± SD from plasma of 5 individual rats in each group. 
NLP-C, saline-fed control; NLP-T1 & NLP-T2, given 125 mg TRF/kg/day and 81.25 mg 
purified TRF/kg/day, respectively, for one week. 
Significantly different from NLP-C at *p<0.001, rp<0.01 & V^.05. 
TABLE 4 
IMPACT OF TRF AND PURIFIED TRF ON VLDL-C, LDL-C, HDL-C, HDL2-C, 
HDL3-C, ApoA-1 AND ApoB IN NORMOLIPIDEMIC RATS AFTER ONE WEEK 
OF ADMINISTRATION 
Parameters NLP-C NLP-T1 NLP-T2 
VLDL-choIesteroI 8.3 ±0.6* 5.3 ±0.6 4.6 ±0.2 
(-36.1%)* (-44.6%)* 
LDL-choIesterol 18.5 ±1.2 15.4 ±0.7 14.9 ±0.8 
(-16.8%)f (-19.4%)f 
HDL-cholesterol 43.2 ±1.6 45.1 ± 1.3 44.8 ±0.9 
(+4.4%) (+3.7%) 
HDLrncholesterol 14.8 ±0.9 19.9 ±0.8 21.0 ±0.8 
(+34.4%)* (+41.9%)* 
HDL3-choIesteroI 28.4 ±1.2 25.3 ± 1.2 23.8 ±0.9 
(-10.9%)f (-16.2%)* 
ApoB 13.5 ±0.5 11.4 ±0.7 11.5 ±0.6 
(-15.5%)* (-14.8%)* 
ApoA-1 90.9 ±4.1 91.8 ±3.3 91.6 ±3.9 
(+1.0%) (+0.8%) 
* Values are mean (mg/dl) ± SD from plasma of 5 individual rats in each group. 
NLP-C, saline-fed control; NLP-T1 & NLP-T2, given 125 mg TRF/kg/day and 81.25 mg 
purified TRF/kg/day, respectively, for one week. 
Significantly different from NLP-C at *p<0.001 & fp<0.01. 
3.3.3 Regulation of enzymatic activity and protein mass of hepatic 
microsomal HMG-CoA reductase 
Since TRF treatment resulted in the reduction of plasma cholesterol 
levels, it was logical to conclude that the hypolipidemic action of TRF is related to 
its interference with HMG-CoA reductase activity, which is the rate controlling 
enzyme in cholesterol biosynthetic pathway. Therefore, effect of TRF on hepatic 
HMG-CoA reductase activity as well as its protein mass was investigated. As seen 
in Table 5, both the enzyme activity and protein mass of solubilized microsomal 
HMG-CoA reductase were significantly affected by the administration of TRF and 
purified TRF. HMG-CoA reductase activity was significantly decreased by 55% 
and 58% in NLP-T1 and NLP-T2, respectively, when compared to normal control 
rats. Feeding of TRF (NLP-T1) and purified TRF (NLP-T2) to rats also resulted in 
a significant decline of 48% and 51% in HMG-CoA reductase protein mass 
(Table 5). These results demonstrate that TRF mediated decrease in HMG-CoA 
reductase activity is due to reduction in protein mass, which in turn causes the 
reduction in plasma cholesterol levels. 
3.3.4 Effect on hepatic microsomal lipid peroxidation and plasma LDL 
oxidation 
As depicted in Table 6, administration of TRF and purified TRF to 
normolipidemic rats for one week significantly prevented the hepatic microsomal 
lipid peroxidation and LDL oxidation, when compared to untreated control rats. A 
significant decrease of approximately 29% was observed in the formation of 
thiobarbituric acid reactive substances (TBARS) in both the treated groups, 
NLP-T1 and NLP-T2, when compared to NLP-C rats. Formation of conjugated 
dienes was also markedly decreased by 38-39% after the administration of TRF 
(NLP-T1) and purified TRF (NLP-T2) for one week (Table 6). These results 
demonstrate that TRF acts as a potent antioxidant in normolipidemic rats. 
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TABLE 5 
IN VIVO MODULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC 
HMG-CoA REDUCTASE IN NORMOLIPIDEMIC RATS TREATED WITH TRF 
AND PURIFIED TRF FOR ONE WEEK 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
NLP-C 7.3 ± 1.2 225 ± 18 
NLP-T1 3.3 ±0.8 118 ± 9 
(-54.7%): (-47.5%)* 
NLP-T2 3.1 ±0.7 110 ± 7 
(-57.5%): (-51.1 %)* 
*VaIues are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (jig/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, saline-fed control; NLP-T1 & NLP-T2, given 125 mg TRF/kg/day and 81.25 mg 
purified TRF/kg/day, respectively, for one week. 
Significantly different from NLP-C at *p<0.001. 
TABLE 6 
EFFECT OF TRF AND PURIFIED TRF ON MICROSOMAL LIPID 
PEROXIDATION AND PLASMA LDL OXIDATION IN NORMOLIPIDEMIC 
RATS TREATED FOR ONE WEEK 
Group TBARS* Conjugated Diene** 
NLP-C 1.89 ± 0.08 5.21 ± 0.25 
NLP-T1 1.34 ± 0.09 3.24 ± 0.20 
(-29.1%)* (-37.8%)* 
NLP-T2 1.35 ±0.09 3.17 ±0.26 
(-28.6%)* (-39.1%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, saline-fed control; NLP-T1 & NLP-T2, given 125 mg TRF/kg/day and 81.25 mg 
purified TRF/kg/day, respectively, for one week. 
Significantly different from NLP-C at *p<0.001. 
3.4 Effect of Purified Tocotrienol Rich Fraction on Plasma Lipids, 
Plasma Lipoprotein Lipids, Apolipoproteins B and A-l, Activity and 
Protein Mass of HMG-CoA Reductase, Microsomal Lipid Peroxida-
tion and Plasma LDL Oxidation in Hyperlipidemic Rats Treated for 
7 Days 
As expected, the efficacy in terms of lipid lowering property of TRF at 
125 mg/kg/day and purified TRF at an equivalent dose of 81.25 mg/kg/day was 
quite similar in normolipidemic rats after one week of administration. In order to 
find out the impact of purified TRF on cholesterol dynamics in experimentally 
induced hyperlipidemic rats, a dose of 16.25 and 32.50 mg purified TRF/kg/day, 
equivalent to 25 and 50 mg TRF/kg/day, respectively, was administered for 7 
days. 
3.4. J Effect on plasma lipids 
Experimental hyperlipidemia induced in rats by feeding an atherogenic 
diet for 3 weeks had a profound impact on the lipid parameters when compared to 
normal rats. As shown in Table 7, triglycerides, total cholesterol, esterified 
cholesterol and free cholesterol increased from 48, 75, 54 and 20 mg/dl in NLP-C 
to 168, 185, 145 and 40 mg/dl, respectively, in HLP-C. After 7 days of withdrawal 
of atherogenic diet (HLP-UC), levels of triglycerides, total cholesterol, esterified 
cholesterol and free cholesterol were decreased to 134, 130, 98 and 32 mg/dl, 
respectively. However, a highly significant decrease of 34% in triglycerides 
concentration was observed in hyperlipidemic rats treated with 16.25 mg 
(HLP-T1) and 32.50 mg (HLP-T2) of purified TRF for 7 days when compared to 
HPL-UC, the saline-fed untreated control rats. Similarly, total, esterified and free 
cholesterol levels showed a significant reduction of 36%, 38% and 33%, 
respectively, in HLP-T1, whereas the reduction in HLP-T2 was approximately 
same as in HLP-T1 (Table 7). These results demonstrate that reduction in lipid 
parameters was achieved at a faster rate when treated with TRF as compared to 
untreated hyperlipidemic control group. 
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3.4.2 Effect on plasma lipoprotein lipids, apoB and apoA-1 
All the plasma lipoprotein lipids along with apoB and apoA-1 were 
increased on feeding atherogenic diet for three weeks. However, a reduction in 
these parameters was observed after one week of the withdrawal of atherogenic 
diet, as shown in Table 8. In TRF treated hyperlipidemic rats, the reduction in the 
levels of VLDL-C, LDL-C and apoB was most prominent after 7 days. VLDL-C 
decreased significantly by approximately 23% in HLP-T1 and HLP-T2 when 
compared to HLP-UC after 7 days of treatment. The decline in LDL-C was 
approximately 58% in HLP-T1 and HLP-T2 rats. Reduction in HDL-C (9.0%) and 
HDL2-C (16.0%) was approximately same in both the treated groups, with no 
significant change in HDL3-C concentration. ApoB levels showed a significant 
decline of 53% in both the treated groups as compared to HLP-UC group, whereas 
apoA-1 levels were not affected after 7 days of purified TRF treatment (Table 8). 
These results demonstrate that decline in total cholesterol was due to a significant 
decrease in VLDL-C and LDL-C. In addition, a reduction in apoB levels, which is 
associated with LDL was also seen. 
3.4.3 Regulation of hepatic HMG-CoA reductase activity and protein mass 
As depicted in Table 9, feeding of atherogenic diet caused a suppression 
of HMG-CoA reductase activity and protein mass. The specific activity of HMG-
CoA reductase in HLP-C was 2.1 units/mg as compared to 7.4 units/mg in NLP-C, 
indicating a suppression of 72%. Similarly, a reduction of 49% in protein mass 
was observed in HLP-C. After 7 days of withdrawal of the atherogenic diet, 
however, an increase in both activity as well as protein mass of HMG-CoA 
reductase was observed. As seen in Table 9, after 7 days of purified TRF 
treatment, HMG-CoA reductase activity and protein mass remained decreased by 
60% and 52%, respectively, in HLP-T1 as compared to HLP-UC group. Similarly 
a decrease of 59% and 53% in enzymatic activity and protein mass of HMG-CoA 
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TABLE 9 
REGULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC HMG-CoA 
REDUCTASE IN HYPERLIPIDEMIC RATS TREATED WITH PURIFIED TRF 
FOR 7 DAYS 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
NLP-C 
HLP-C 
HLP-UC 
HLP-T1 
HLP-T2 
*VaIues are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (jig/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T1 & HLP-T2, given 16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 7 
days. 
Significantly different from HLP-UC at *p<0.001. 
7.4 ± 0.8 
2.1 ± 0.4 
6.5 ± 0.5 
2.6 ± 0.3 
(-60.0%)* 
2.7 ± 0.3 
(-58.5%)* 
247 ± 3 
125 ± 3 
219±5 
105 ± 5 
(-52.0%)* 
104 ± 3 
(-52.5%)* 
reductase was observed in HLP-T2 (Table 9). These results demonstrate that 
reduction in HMG-CoA reductase activity and protein mass at the two doses of 
purified TRF is almost similar. 
3.4.4 Effect on hepatic microsomal lipid peroxidation and plasma LDL 
oxidation 
Formation of TBARS in microsomes was increased from 1.9 units/mg in 
NLP-C to 3.8 units/mg in HLP-C, whereas LDL oxidation in plasma was increased 
from 5.5 units/ml in NLP-C to 9.9 units/ml in HLP-C, after feeding an atherogenic 
diet for three weeks (Table 10). These values were reduced to 2.2 units/mg and 
6.4 units/ml in HLP-UC after 7 days of the withdrawal of atherogenic diet. 
However, the decrease was enhanced significantly by the treatment with purified 
TRF for 7 days. As shown in Table 10, lipid peroxidation in microsomes was 
decreased by approximately 40%, whereas formation of conjugated dienes in 
plasma LDL was reduced by around 44%, in both the treated groups, when 
compared to saline-fed hyperlipidemic untreated control rats (HLP-UC). These 
results demonstrate that the induction of hyperlipidemia in rats is associated with a 
significant increase in the microsomal lipid peroxidation as well as plasma LDL 
oxidation, which is significantly prevented by the administration of purified TRF. 
3.5 Dose-Dependent Impact of Tocotrienol Rich Fraction on Plasma 
Lipids, Plasma Lipoprotein Lipids, Apolipoproteins B and A-l, 
Activity and Protein Mass of HMG-CoA Reductase, Microsomal 
Lipid Peroxidation and Plasma LDL Oxidation in Hyperlipidemic 
Rats Treated For 7 Days 
As evident from the above combined results, the hypolipidemic impact of 
purified TRF in experimentally induced hyperlipidemic rats at an equivalent dose 
of 25 and 50 mg TRF/kg/day was quite similar after 7 days of aoininistration. 
Therefore, to find out the optimal dose of TRF in terms of its maximal cholesterol 
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TABLE 10 
IMPACT OF PURIFIED TRF ON MICROSOMAL LIPID PEROXIDATION AND 
PLASMA LDL OXIDATION IN HYPERLIPIDEMIC RATS AFTER 7 DAYS OF 
ADMINISTRATION 
Group TBARS* Conjugated Diene* 
NLP-C 1.94 ±0.08 5.50 ±0.26 
HLP-C 3.81 ± 0.13 9.85 ± 0.58 
HLP-UC 2.21 ±0.16 6.40 ±0.31 
HLP-T1 1.36 ±0.10 3.66 ±0.39 
(-38.5%): (-42.8%)* 
HLP-T2 1.30 ±0.10 3.56 ±0.32 
(-41.2%): (-44.4%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/mi) ± SD of 3 separate assay in each group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T1 & HLP-T2, given 16.25 and 32.50 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC at :p<0.001. 
lowering efficiency, 4, 8 and 12 mg TRF/kg/day was administered to 
experimentally induced hyperlipidemic rats. 
3.5.1 Effect on plasma lipids 
Experimental hyperlipidemia induced in rats by feeding an atherogenic 
diet for 3 weeks had a profound impact on the lipid parameters when compared to 
normal rats. As shown in Table 11, triglycerides, total cholesterol, esterified 
cholesterol and free cholesterol increased by 208%, 140%, 166% and 70%, 
respectively. After 7 days of withdrawal of atherogenic diet (HLP-UC), levels of 
triglycerides, total cholesterol, esterified cholesterol and free cholesterol were 
decreased by 11%, 21%, 23% and 15%, respectively, when compared to HLP-C. 
However, administration of 4, 8 and 12 mg TRF/kg/day for 7 days significantly 
reduced these parameters in a dose-dependent manner at a much faster rates than 
untreated hyperlipidemic control (Table 11). When compared to HLP-UC, level of 
triglycerides decreased by 28-33% in HLP-T1, HLP-T2 and HLP-T3. Total 
cholesterol decreased by 14% at 4 mg TRF, whereas it was reduced by 33% at 8 
mg TRF. However, at 12 mg TRF the percent decline remained unchanged (35%). 
Similarly, esterified cholesterol showed a significant decline of 15% in HLP-T1, 
35% in HLP-T2 and 38% in HLP-T3 (Table 11). Free cholesterol was 
insignificantly reduced by 9% in HLP-T1, whereas it was significantly declined by 
23% and 19% in HLP-T2 and HLP-T3, respectively. These results demonstrate 
that maximal anticholesterol effect on plasma lipids of hyperlipidemic rats was 
exerted at 8 mg TRF/kg/day. 
3.5.2 Impact on plasma lipoprotein lipids, apoB and apoA-1 
All the plasma lipoprotein lipids along with apoB and apoA-1 were 
increased on feeding atherogenic diet for three weeks. However, a reduction in 
these parameters was observed after one week of the withdrawal of atherogenic 
diet, as shown in Table 12. In TRF treated hyperlipidemic rats, the reduction in the 
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levels of VLDL-C, LDL-C and apoB was most prominent after 7 days. When 
compared to saline-fed hyperlipidemic untreated control (HLP-UC), HLP-T1, 
HLP-T2 and HLP-T3 showed a significant decline in VLDL-C by 24%, 34% and 
33%, whereas LDL-C was reduced by 22%, 48% and 52%, respectively. The 
change in HDL-C and HDL3-C was insignificant at all the three doses (Table 12). 
Howevei, HDL2-C showed an insignificant decrease of 14% at 4 mg TRF, whereas 
it was significantly reduced by approximately 19% at 8 mg and 12 mg TRF. ApoB 
showed a significant decrease of 28%, 60% and 58%, whereas apoA-1 levels 
decreased by 2% (insignificant), 6% (p<0.05) and 5% (p<0.05) in HLP-T1, 
HLP-T2 and HLP-T3, respectively, when compared to HLP-UC (Table 12). These 
results indicate that the increase in the total cholesterol by feeding an atherogenic 
diet for three weeks is due to the significant increase of VLDL-C and LDL-C. As 
expected, feeding of atherogenic diet results in the increase of apolipoprotein B 
associated with LDL. These results also demonstrate that administration of TRF 
significantly prevents the increase in these lipid parameters in a dose-dependent 
manner with a maximum effect at 8 mg TRF/kg/day. 
3.5.3 Regulation of hepatic microsomal HMG-CoA reductase activity and 
protein mass 
As shown in Table 13, a significant reduction in both HMG-CoA 
reductase activity as well as protein mass was observed in HLP-C as compared to 
NLP-C. The specific activity of HMG-CoA reductase in NLP-C was 7.9 units/mg, 
whereas it was significantly decreased to 2.0 units/mg in HLP-C. Similarly, 
protein mass was decreased from 239 ug/g of microsomal protein in NLP-C to 
102 ug/g of microsomal protein in HLP-C. After 7 days of withdrawal of the 
atherogenic diet, however, an increase in both activity as well as protein mass of 
HMG-CoA reductase was observed (Table 13). On the other hand, adininistration 
of TRF to hyperlipidemic rats prevented the increase in HMG-CoA reductase 
activity and protein mass by 44% and 28% in HLP-T1, 59% and 52% in HLP-T2 
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TABLE 13 
DOSE-DEPENDENT REGULATION OF ACTIVITY AND PROTEIN MASS OF 
HEPATIC HMG-CoA REDUCTASE IN HYPERLIPIDEMIC RATS TREATED 
WITH TRF FOR 7 DAYS 
Group HMG-CoA Reductase 
NLP-C 
HLP-C 
HLP-UC 
HLP-T1 
HLP-T2 
HLP-T3 
Specific activity* 
7.88 ± 0.20 
1.97 ±0.19 
5.74 ± 0.22 
3.20 ±0.15 
(-44.2%)* 
2.33 ± 0.14 
(-59.4%)* 
2.23 ± 0.12 
(-61.1%)* 
Protein mass** 
239 ± 10 
102 ±11 
165 ± 15 
119±6 
(-27.9%)* 
80 ±6 
(-51.5%)+ 
77 ±6 
(-53.3%)* 
*Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (ng/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T1, HLP-T2 & HLP-T3, given 4,8 and 12 mg TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC at *p<0.001. 
and 61% and 53% in HLP-T3, respectively, as compared to HLP-UC. These 
results demonstrate that feeding of atherogenic diet to normolipidemic rats 
significantly decrease the HMG-CoA reductase activity by negative feedback 
regulation mediated via decrease in HMG-CoA reductase protein mass. Feeding of 
TRF causes a further decline in HMG-CoA reductase activity by decreasing its 
protein mass. 
3.5.4 Effect on hepatic microsomal lipid peroxidation and plasma LDL 
oxidation 
Formation of TBARS in microsomes was increased from 2.2 units/mg in 
NLP-C to 4.0 units/mg in HLP-C, whereas, LDL oxidation in plasma was 
increased from 5.3 units/ml in NLP-C to 9.4 units/ml in HLP-C, after feeding an 
atherogenic diet for three weeks (Table 14). These values were reduced to 
2.5 units/mg and 7.5 units/ml in HLP-UC after 7 days of the withdrawal of 
atherogenic diet. However, the decrease was enhanced significantly by the 
treatment with TRF for 7 days. As shown in Table 14, lipid peroxidation in 
microsomes was decreased by 24%, 39% and 39% in HLP-T1, HLP-T2 and 
HLP-T3, whereas formation of conjugated dienes in plasma LDL was reduced by 
34%, 46% and 51%, respectively, when compared to saline-fed hyperlipidemic 
untreated control rats (HLP-UC). These results demonstrate that the induction of 
hyperlipidemia in rats is associated with a significant increase in the microsomal 
lipid peroxidation as well as plasma LDL oxidation, which is significantly 
prevented by the administration of TRF. 
Based on the above combined results, an optimal dose of 8 mg 
TRF/kg/day and a 4.3% TRF yield of refined edible grade RBO, intake of an 
equivalent amount of 186 mg dietary refined edible grade RBO/kg/day should 
exert similar hypolipidemic impacts. Similar experiments carried out in our 
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TABLE 14 
DOSE-DEPENDENT IMPACT OF TRF ON MICROSOMAL LIPID 
PEROXIDATION AND PLASMA LDL OXIDATION IN HYPERLIPIDEMIC 
RATS AFTER 7 DAYS OF ADMINISTRATION 
Group TBARS* Conjugated Diene* 
NLP-C 2.23 ± 0.15 5.26 ± 0.45 
HLP-C 3.98 ± 0.17 9.35 ± 0.63 
HLP-UC 2.49 ±0.16 7.45 ± 0.54 
HLP-Tl 1.89 ± 0.14 4.89 ± 0.39 
(-24.1 %)+ (-34.4%)+ 
HLP-T2 1.53 ± 0.14 3.99 ± 0.34 
(-38.6%)* (-46.4%)* 
HLP-T3 1.51 ± 0.14 3.68 ± 0.26 
(-39.3%)* (-50.6%)* 
* Values are mean (nmole/miu/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T1, HLP-T2 & HLP-T3, given 4,8 and 12 mg TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC at :p<0.001 and Tp<0.01. 
laboratory in hypercholesterolemic humans also showed the maximal cholesterol 
lowering efficiency of TRF at 8 mg/kg/day. 
3.6 Dose-Dependent Effect of Purified Tocotrienol Rich Fraction Isolated 
from the Bran of Sarju-52 on Plasma Lipids, Plasma Lipoprotein 
Lipids, Apolipoproteins B and A-l, Activity and Protein Mass of 
HMG-CoA Reductase, Microsomal Lipid Peroxidation and Plasma 
LDL Oxidation in Hyperlipidemic Rats After 7 Days of Treatment 
Earlier reports have indicated that neither rice bran nor RBO lowered 
cholesterol levels. These findings may be explained by other reports that some, but 
not all, rice cultivars contain tocotrienols which exert a powerful 
hypocholesterolemic action. These variation in hypocholesterolemic potency of 
rice bran/RBO differ from cultivar to cultivar due to large variation in types and 
content of tocotrienols present in TRF (Qureshi et al, 1986; Qureshi et al., 1989). 
Out of a-, (3-, y- and 8-T3, y- and 5-form are most potent in terms of cholesterol 
lowering effect. a-Tocotrienol has very low effect, whereas p-form has no 
anticholesterol activity. Based on the above optimal dose of 8 mg TRF/kg/day, we 
have investigated the hypolipidemic impacts of purified TRF isolated from two 
cultivars of rice, raw Sarju-52 and Mansuri, in a linear range of 3 and 6 mg 
TRF/kg/day. As seen in Table 15, the combined percent content of y- and 8-T3 in 
each cultivar was adjusted equivalent to that present in 3 and 6 mg of TRF isolated 
from refined edible grade RBO. Hence, based on 12.4% of combined 
concentration of y- and 5-T3 quantified in TRF of refined edible grade RBO, 
equivalent calculated doses of purified TRF from raw Sarju-52, containing 30.5% 
of y- and 8-T3, was 1.22 and 2.44 mg. Similarly, equivalent calculated doses of 
purified TRF from raw Mansuri, containing 11.2% of y- and 8-T3, was 3.32 and 
6.64 mg (Table 15). Therefore, impact of 1.22 and 2.44 mg/kg/day of purified 
TRF from raw Sarju-52 and 3.32 and 6.64 mg/kg/day of purified TRF from raw 
Mansuri was investigated in hyperlipidemic rats after 7 days of treatment. 
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TABLE 15 
CALCULATED EQUIVALENT DOSE OF PURIFIED TRF, FROM TWO 
CULTIVARS OF RICE, BASED ON OPTIMAL ANTICHOLESTEROL 
ACTIVITY OF y- AND S-TOCOTRIENOLS PRESENT IN TRF ISOLATED 
FROM EDIBLE GRADE REFINED RBO 
%of 
Type Y-and5-T3 3mgTRF* 6 mg TRF* 8 mg TRF* 
Refined RBO 
Raw Sarju-52 
Raw Mansuri 
Raw Basmati 
12.4 
30.5 
11.2 
32.6 
3.00 
1.22 
3.32 
1.14 
6.00 
2.44 
6.64 
2.28 
8.00 
3.20 
8.85 
3.04 
* Values of equivalent doses are calculated on the basis of 12.4% content of y- and 6-T3 
present in TRF isolated from edible grade refined RBO. 
3.6.1 Impact on plasma lipids 
The data presented in Table 16 show a dose-dependent impact of 
purified TRF isolated from the bran of Sarju-52 on plasma lipids of hyperlipidemic 
rats treated for 7 days. Plasma triglycerides level was increased from 54 to 
162 mg/dl, total cholesterol from 73 to 183 mg/dl, esterified cholesterol from 53 to 
144 mg/dl and free cholesterol from 21 to 39 mg/dl, after the feeding of 
atherogenic diet for 3 weeks. A decline in the levels of triglycerides, total 
cholesterol, esterified cholesterol and free cholesterol to 136, 145, 114 and 
31 mg/dl in HLP-UC was seen after 7 days of withdrawal of atherogenic diet. 
However, feeding of purified TRF caused a significant and dose-dependent 
reduction in these lipid parameters (Table 16). Level of triglycerides was reduced 
by 22% and 29% in HLP-T1 and HLP-T2, respectively. Total cholesterol showed 
a significant decrease of 12% at 1.22 mg of purified TRF and 25% at 2.44 mg of 
purified TRF, when compared to saline-fed hyperlipidemic untreated control 
(HLP-UC) rats. Similarly, esterified cholesterol registered a decrease of 13% and 
27% in HLP-T1 and HLP-T2, respectively. There was an insignificant reduction of 
about 6% in free cholesterol of HLP-T1, whereas a significant reduction of 17% 
was observed in HLP-T2. These results indicate that purified TRF mediate a dose-
dependent decrease in the levels of cholesterol. 
3.6.2 Effect on plasma lipoprotein lipids, apoB and apoA-1 
Plasma lipoprotein lipids along with apoB and apoA-1 were significantly 
elevated after the feeding of atherogenic diet for 3 weeks, as shown in Table 17. 
These parameters, however, decreased after 7 days of withdrawal of atherogenic 
diet. The decrease was highly significant in VLDL-C and LDL-C in rats treated 
with 1.22 mg (HLP-T1) and 2.44 mg (HLP-T2) purified TRF. When compared to 
HLP-UC, the decline in VLDL-C was 30% and 26%, whereas LDL-C was reduced 
by 17% and 37% in HLP-T1 and HLP-T2, respectively. As depicted in Table 17, 
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HDL-C, HDL2-C and HDL3-C did not show any significant change as compared to 
saline-fed hyperlipidemic untreated control (HLP-UC) rats. ApoB was 
insignificantly reduced by 11% in HLP-T1, but decreased significantly by 41% in 
HLP-T2. ApoA-1 did not show any significant decline (Table 17). These results 
demonstrate that feeding of atherogenic diet causes a significant increase of 
VLDL-C and LDL-C which in turn increase the level of total cholesterol. As 
evident, feeding of atherogenic diet also results in a concomitant increase of apoB 
which is associated with LDL. However, administration of purified TRF 
substantially decrease these lipid parameters. 
3.6.3 Regulation of enzymatic activity and protein mass of hepatic 
microsomal HMG-CoA reductase 
As seen in Table 18, feeding of an atherogenic diet to rats for 3 weeks 
was associated with a significant decrease in enzymatic activity as well as protein 
mass of HMG-CoA reductase. The HMG-CoA reductase specific activity 
decreased from 8.2 units/mg in NLP-C to 1.9 units/mg in HLP-C, whereas protein 
mass decreased from 246 |ig/g of microsomal protein in NLP-C to 102 p.g/g of 
microsomal protein in HLP-C. These parameters, however, increased after 7 days 
of withdrawal of atherogenic diet. But administration of purified TRF to 
hyperlipidemic rats for 7 days prevented the increase in HMG-CoA reductase 
enzyme activity by 36% in HLP-T1 and 53% in HLP-T2. Protein mass also 
remained significantly decreased by 16% and 41% in HLP-T1 and HLP-T2, 
respectively, when compared to HLP-UC (Table 18). These results indicate that 
feeding of exogenous cholesterol or TRF to rats decrease the synthesis of 
endogenous cholesterol via decrease in HMG-CoA reductase activity which in turn 
is mediated by the decrease in its protein mass. However, withdrawal of 
atherogenic diet relieves this inhibition which is evident from the increase in 
HMG-CoA reductase activity as well as its protein mass. 
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TABLE 18 
DOSE-DEPENDENT IN VIVO MODULATION OF ACTIVITY AND PROTEIN 
MASS OF HEPATIC HMG-CoA REDUCTASE IN HYPERLIPIDEMIC RATS 
TREATED FOR 7 DAYS WITH PURIFIED TRF ISOLATED FROM BRAN OF 
SARJU-52 
Group HMG-CoA Reductase 
NLP-C 
HLP-C 
HLP-UC 
HLP-T1 
HLP-T2 
Specific activity* 
8.20 ± 0.32 
1.90 ±0.15 
5.91 ± 0.25 
3.80 ± 0.21 
(-35.7%)* 
2.79 ± 0.18 
(-52.8%)* 
Protein mass** 
246 ± 17 
102 ± 6 
173 ±12 
146 ± 7 
(-15.6%)f 
103 ±4 
(-40.5%)* 
*Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (ng/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T1 & HLP-T2, given 1.22 and 2.44 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC at *p<0.001 and tp<0.01. 
3.6.4 Effect on hepatic microsomal lipid peroxidation and plasma LDL 
oxidation 
As seen in Table 19, hyperlipidemia caused an increase in the formation 
of TBARS. An increase of 4.1 units/mg in HLP-C from 2.4 units/mg in NLP-C 
was achieved. Similarly, conjugated dienes also showed an increase from 
5.3 units/ml in NLP-C to 10.2 units/ml in HLP-C (Table 19). After 7 days of the 
withdrawal of atherogenic diet, lipid peroxidation decreased to 2.8 units/mg, 
whereas LDL oxidation was reduced to 7.8 units/ml. However, administration of 
purified TRF to hyperlipidemic rats for 7 days significantly prevented the 
microsomal lipid peroxidation by 31% in HLP-T1 and 41% in HLP-T2, whereas 
plasma LDL oxidation was reduced by 34% and 45% in HLP-T1 and HLP-T2, 
respectively, as compared to HLP-UC (Table 19). These results demonstrate that 
hyperlipidemia also leads to an increase in microsomal lipid peroxidation and 
plasma LDL oxidation, which in turn are significantly prevented by the 
administration of purified TRF, showing its antioxidant property. 
3.7 Dose-Dependent Impact of Purified Tocotrienol Rich Fraction 
Isolated from the Bran of Mansuri on Plasma Lipids, Plasma 
Lipoprotein Lipids, Apolipoproteins B and A-l, Activity and Protein 
Mass of HMG-CoA Reductase, Microsomal Lipid Peroxidation and 
Plasma LDL Oxidation in Hyperlipidemic Rats After 7 Days of 
Administration 
3.7.1 Effect on plasma lipids 
As already described in Table 16, there was an increase in the lipid 
parameters of hyperlipidemic rats after the feeding of an atherogenic diet for 
3 weeks, which showed a decline after 7 days of withdrawal of atherogenic diet. 
These parameters, however, declined significantly at a faster rate in rats treated 
with purified TRF, isolated from the bran of Mansuri (Table 20). Compared to 
saline-fed hyperlipidemic control rats, the decrease observed in the level of 
triglycerides was 23% and 27% in HLP-T3 and HLP-T4, respectively. Total 
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TABLE 19 
DOSE-DEPENDENT EFFECT OF PURIFIED TRF ISOLATED FROM BRAN OF 
SARJU-52 ON MICROSOMAL LIPID PEROXIDATION AND PLASMA LDL 
OXIDATION IN HYPERLIPIDEMIC RATS TREATED FOR 7 DAYS 
Group TBARS* Conjugated Diene* 
NLP-C 2.41 ± 0.15 5.31 ± 0.40 
HLP-C 4.14 ±0.23 10.17 ±0.58 
HLP-UC 2.81 ±0.18 7.78 ±0.43 
HLP-T1 1.95 ±0.13 5.11 ±0.31 
(-30.6%)^ (-34.3%)* 
HLP-T2 1.67 ±0.12 4.25 ±0.35 
(-40.6%): (-45.4%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T1 & HLP-T2, given 1.22 and 2.44 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC at *p<0.001. 
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cholesterol showed a significant decrease of 15% at 3.32 mg purified TRF and 
31% at 6.64 mg purified TRF. Similarly, esterified cholesterol also showed a dose-
dependent decrease of 15% and 32% in HLP-T3 and HLP-T4, respectively. Free 
cholesterol showed a marked decline of 18% at 3.32 mg purified TRF and 24% at 
6.64 mg purified TRF (Table 20). These results demonstrate that TRF mediate a 
dose-dependent linear decrease in total and esterified cholesterol with a non-linear 
decrease in the levels of triglycerides and free cholesterol. 
3.7.2 Impact on plasma lipoprotein lipids, apoB and apoA-1 
A significant increase in the plasma lipoprotein lipids as well as apoB 
and apoA-1 was observed after the induction of hyperlipidemia in the rats fed an 
atherogenic diet for 3 weeks (Table 21). The withdrawal of atherogenic diet 
caused a decline in these parameters after 7 days. The reduction was highly 
significant in rats treated with purified TRF. In comparison to HLP-UC, VLDL-C 
decreased by 28% in HLP-T3 and 34% in HLP-T4. LDL-C showed a dose-
dependent decrease of 22% at 3.32 mg purified TRF and 43% at 6.64 mg purified 
TRF (Table 21). However, HDL-C, HDL2-C and HDL3-C did not show any 
significant change after the administration of purified TRF. ApoB levels were 
reduced by 18% at 3.32 mg purified TRF, whereas it declined by 53% at 6.64 mg 
purified TRF. On the other hand, apoA-1 showed only a slight decrease of 2% in 
HLP-T3, but decreased significantly by 7% in HLP-T4, when compared to saline-
fed hyperlipidemic untreated control (HLP-UC) rats (Table 21). These results 
indicate that TRF has a significant effect on the levels of VLDL-C, LDL-C and 
apoB in hyperlipidemic rats. On the other hand, it does not change the levels of 
HDL-C or its subfractions (HDL2-C and HDL3-C), whereas it has some effect on 
the lipoprotein, apoA-1, associated with HDL. 
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3.7.3 Regulation of enzymatic activity and protein mass of hepatic 
microsomal HMG-CoA reductase 
As already seen in Table 18, experimental hyperlipidemia was associated 
with a significant decline in the enzymatic activity and protein mass of HMG-CoA 
reductase. Seven days after the withdrawal of atherogenic diet, the inhibition of 
HMG-CoA reductase was relieved, which resulted in an increase of 211% and 
70% in enzyme activity and protein mass, respectively, in comparison to HLP-C 
(Table 22). Administration of purified TRF to hyperlipidemic rats for 7 days 
prevented the increase in HMG-CoA reductase activity and protein mass due to its 
inhibitory property. HMG-CoA reductase activity remained decreased by 39% and 
57% in HLP-T3 and HLP-T4, respectively, whereas increase in protein mass was 
significantly prevented by 20% and 46% in comparison to saline-fed 
hyperlipidemic untreated control (HLP-UC) rats (Table 22). These results show 
that TRF mediate its action via decrease in HMG-CoA reductase protein mass 
which in turn results in decreased enzyme activity and cholesterol production. 
3.7.4 Impact on microsomal lipid peroxidation and plasma LDL oxidation 
As shown in Table 23, experimental hyperlipidemia in rats induced a 
higher rate of microsomal lipid peroxidation and plasma LDL oxidation, but the 
presence of TRF significantly prevented the increase in the formation of TBARS 
and conjugated dienes. In comparison to saline-fed hyperlipidemic control 
(HLP-UC) rats, a reduction of 36% and 44% in the formation of TBARS was 
observed in HLP-T3 and HLP-T4, respectively. Similarly, there was a decline of 
37% in the oxidation of plasma LDL at 3.32 mg of purified TRF and 48% at 
6.64 mg of purified TRF (Table 23). These results demonstrate that TRF acts as a 
strong antioxidant agent. 
The combined results demonstrate that hypolipidemic efficiency of 
purified TRF from raw Sarju-52 (at 1.22 and 2.44 mg/kg/day) and raw Mansuri (at 
107 
TABLE 22 
DOSE-DEPENDENT REGULATION OF ACTIVITY AND PROTEIN MASS OF 
HEPATIC HMG-CoA REDUCTASE IN HYPERLIPIDEMIC RATS TREATED 
FOR 7 DAYS WITH PURIFIED TRF ISOLATED FROM BRAN OF MANSURI 
Group HMG-CoA Reductase 
NLP-C 
HLP-C 
HLP-UC 
HLP-T3 
HLP-T4 
*Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean ()j.g/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T3 & HLP-T4, given 3.32 and 6.64 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC at *p<0.001. 
Specific activity* 
8.20 ± 0.32 
1.90 ±0.15 
5.91 ± 0.25 
3.62 ± 0.22 
(-38.7%)* 
2.56 ± 0.18 
(-56.7%)* 
Protein mass** 
246 ±17 
102 ±6 
173 ±12 
138 ±6 
(-20.2%)* 
94 ± 5 
(-45.7%)* 
TABLE 23 
DOSE-DEPENDENT IMPACT OF PURIFIED TRF ISOLATED FROM BRAN OF 
MANSURI ON MICROSOMAL LIPID PEROXIDATION AND PLASMA LDL 
OXIDATION IN HYPERLIPIDEMIC RATS AFTER 7 DAYS OF 
ADMINISTRATION 
Group TBARS* Conjugated Diene* 
NLP-C 2.41 ± 0.15 5.31 ± 0.40 
HLP-C 4.14 ±0.23 10.17 ±0.58 
HLP-UC 2.81 ±0.18 7.78 ±0.43 
HLP-T3 1.79 ±0.14 4.91 ± 0.35 
(-36.3%)* (-36.9%)* 
HLP-T4 1.58 ±0.13 4.03 ±0.29 
(-43.8%)* (-48.2%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T3 & HLP-T4, given 3.32 and 6.64 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC at *p<0.001. 
3.32 and 6.64 mg/kg/day) was comparable with the anticholesterol impact of TRF 
from refined edible grade RBO (at 4 and 8 mg/kg/day). These results also indicate 
that dose-dependent hypolipidemic impact of TRF on cholesterol dynamics is 
directly related to the quantity of y- and 8-T3 present in TRF, isolated from a given 
cultivar of rice. 
Based on the above results and the presence of y- and 8-T3 content in a 
given cultivar of rice, one can calculate the optimal dose of TRF in terms of its 
maximal cholesterol lowering efficiency. For example, as shown in Table 15, the 
combined content of y- and 5-T3 in raw Basmati is 32.6%. Based on this value, the 
equivalent doses at 3 and 6 mg/kg/day will be 1.14 and 2.28 mg/kg/day, 
respectively. Similarly, an optimal dose of TRF in terms of its cholesterol lowering 
efficiency, equivalent to 8 mg/kg/day, will be 3.04 mg/kg/day. 
The combined results indicate that variety of edible oils lacking in 
tocotrienols can be supplemented with an optimal dose of 8 mg TRF/kg/day for its 
therapeutic benefits. Based on strong hypolipidemic action of TRF in 
normolipidemic and hyperlipidemic rats, daily intake of TRF, RBO or edible oils 
supplemented with TRF by normal population will prevent the occurrence of 
hypercholesterolemia and cardiovascular diseases. In addition, TRF will be useful 
in the treatment of patients with hypercholesterolemia and coronary heart disease. 
3.8 Effect of Tocotrienol Rich Fraction on Plasma Lipids, Plasma 
Lipoprotein Lipids, Apolipoproteins B and A-l, Activity and Protein 
Mass of HMG-CoA Reductase, Microsomal Lipid Peroxidation and 
Plasma LDL Oxidation in Experimentally Induced Mammary 
Carcinogenic Rats After 6 and 12 Months of Treatment 
3.8.1 Impact on plasma lipids 
As seen in Table 24, a significant increase in all the lipid parameters, 
except triglycerides, was observed in experimentally induced mammary 
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carcinogenic rats. After 6 months of induction of carcinogenesis, the levels of 
triglycerides, total cholesterol, esterified cholesterol and free cholesterol were 
significantly increased by 19%, 30%, 31% and 30%, respectively, in comparison 
to normal control (NC) rats. These results are consistent with earlier reports that 
the chemical carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), induces 
hyperlipidemia along with mammary carcinogenesis in rats (Albert et ah, \917; 
Bond et ai, 1981). Administration of TRF to the rats in both experimental treated-
I (ET-I) and experimental treated-II (ET-II) groups, not only prevented the increase 
in these parameters, but also resulted in a significant decline in the levels of 
triglycerides, total cholesterol, esterified cholesterol and free cholesterol by about 
27-30% in comparison to saline-fed experimental control-I (EC-I) rats (Table 24). 
In addition, a slight increase in the lipid parameters of saline-fed experimental 
control-II (EC-II) rats after 12 months were observed. This increase in the levels of 
triglycerides, total cholesterol, esterified cholesterol and free cholesterol was 
insignificant (Table 24). However, in experimental treated-III (ET-III) rats, the 
increase in lipid parameters was prevented by the administration of TRF. 
Compared to EC-II, rats in TRF-fed treated group (ET-III) showed a significant 
decline in all lipid parameters, with a maximum decrease of 24% in free 
cholesterol, followed by triglycerides (20%), total cholesterol (19%) and esterified 
cholesterol (15%) (Table 24). These results indicate that TRF has a pronounced 
hypocholesterolemic effect on plasma lipids in DMBA-induced mammary 
carcinogenesis. 
3.8.2 Effect on plasma lipoprotein lipids, apoB and apoA-l 
Results presented in Table 25, demonstrate that induction of mammary 
carcinogenesis by DMBA increased the LDL-C and apoB, whereas VLDL-C, 
HDL-C, HDL2-C, HDL3-C and apoA-l did not register any significant change. 
TRF treatment significantly decreased the levels of VLDL-C, LDL-C, apoB and 
apoA-l, whereas HDL-C, HDL2-C and HDL3-C decreased insignificantly. A 
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highly significant increase in the concentration of LDL-C from 32 mg/dl in NC 
rats to 67 mg/dl in EC-I rats was observed, with an increase in the levels of apoB 
from 29 mg/dl to 73 mg/dl, respectively. Other lipid parameters registered an 
insignificant increase when compared to the normal control (NC) rats. 
Administration of TRF significantly decreased the levels of VLDL-C by 14% in 
both the treated groups (ET-I and ET-II) when compared to saline-fed 
experimental control group (EC-I). The magnitude of decrease in LDL-C was very 
high, which declined by about 67% in both the TRF treated groups. ApoB also 
showed a reduction of 68-72% in ET-I and ET-II, when compared to EC-I. 
Although the decrease in apoA-1 in both the treated groups (ET-I and ET-II) was 
significant, the magnitude of decline was only 8-9%. There was a further increase 
in these parameters after 12 months in saline-fed experimental control (EC-II) rats, 
but this change was not significant as compared to EC-I. Treatment of the 
carcinogenic rats with TRF (ET-III) again had a marked effect on LDL-C and 
apoB, which were reduced by 45% and 58%, respectively, when compared to 
EC-II. Interestingly, HDL2-C level was significantly increased by 25% after 
12 months of TRF treatment (ET-III) in comparison to saline-fed control (EC-II) 
rats (Table 25). These results demonstrate that induction of mammary 
carcinogenesis was associated with an increase in the level of LDL-C, which in 
turn increases the cholesterol level. Concomitant with the increase of LDL-C, an 
increase in the level of apoB associated with LDL was observed. However, 
feeding of TRF significantly prevents this increase, showing its lipid lowering 
properties in experimental hyperlipidemia induced by carcinogen, DMBA, in rats. 
3.8.3 Regulation of hepatic enzymatic activity ofHMG-CoA reductase and 
its protein mass 
As seen in Table 26, induction of carcinogenesis resulted in a significant 
increase in HMG-CoA reductase activity from 15.5 units/mg in NC to 
19.0 units/mg in EC-I. A similar increase of 29% in the protein mass was seen in 
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TABLE 26 
IN VIVO MODULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC 
HMG-CoA REDUCTASE IN EXPERIMENTALLY INDUCED MAMMARY 
CARCINOGENESIS IN RATS AFTER 6 AND 12 MONTHS OF TRF 
TREATMENT 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
6 MONTHS 
NC 
EC-I 
ET-I 
ET-II 
15.5 ± 0.80 
19.0 ± 0.84 
4.3 ± 0.38 
(-77.4%)* 
4.4 ± 0.27 
(-76.8%)* 
229 ± 14 
293 ± 13 
75 ± 5 
(-74.4%)* 
79 ± 7 
(-73.0%)* 
12 MONTHS 
EC-H 
ET-HI 
20.8 ± 1.03 
5.1 ± 0.43 
(-75.5%)* 
327 ±11 
145 ± 10 
(-55.7%) t 
*Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**VaIues are mean (ng/g of microsomal protein) ± SD from three separate assay in each 
group. 
NC, normal control; EC-I, saline-fed control for 6 months; ET-I & ET-II, given 
10 mg TRF/rat/day 2 weeks before and after carcinogen treatment, respectively, for 
6 months; ECU, saline-fed control for 12 months; ET-HI, TRF treatment of 10 mg 
TRF/rat/day was initiated 6 months after the administration of carcinogen and continued for 
6 months. 
Significantly different from their respective controls, EC-I and EC-II at 6 and 12 months, at 
Jp<0.001. 
EC-I. Treatment with TRF not only prevented this increase, but also decreased the 
activity and protein mass of HMG-CoA reductase in both the treated groups. After 
6 months of TRF treatment, ET-I and ET-II showed a highly significant reduction 
of about 77% in the activity of HMG-CoA reductase with a concomitant decline of 
73-74% in the immunoreactive protein mass in both the treated groups when 
compared to saline-fed experimental control (EC-I) rats (Table 26). No significant 
change in activity as well as protein mass of HMG-CoA reductase was observed 
after 12 months in saline-fed experimental control (EC-1I) rats. However, HMG-
CoA reductase activity remained significantly low (76%) in TRF treated group 
(ET-I11). Similarly, its protein mass also declined significantly by 56%, when 
compared to saline-fed experimental control group. These results demonstrate that 
trie increase in the cholesterol levels of experimentally induced mammary 
carinogenic rats is due to an increase in the activity of HMG-CoA reductase, 
which in turn is mediated by an increase in its protein mass. These results also 
show that feeding of TRF prevents the increase in HMG-CoA reductase protein 
mass with a concomitant decrease in its activity, thereby decreasing the cholesterol 
levels. 
3.8.4 Effect on hepatic microsomal lipid peroxidation and plasma LDL 
oxidation 
As shown in Table 27, a higher rate of hepatic microsomal lipid 
peroxidation and LDL oxidation in plasma by ascorbate-Fe system in chemically 
induced mammary carcinogenesis was observed. However, both lipid peroxidation 
as well as LDL oxidation were significantly prevented by the administration of 
TRF for 6 months. The increase in lipid peroxidation observed was from 
3.2 units/mg in NC to 6.3 units/mg in EC-I, whereas LDL oxidation increased 
from 7.4 units/ml in NC to 14.7 units/ml in EC-I. There was a significant reduction 
in the formation of TBARS by 62-65% in ET-I and ET-II, when compared to EC-I. 
Similarly, a significant decrease of about 53-56% in the formation of conjugated 
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TABLE 27 
EFFECT OF TRF ON MICROSOMAL LIPID PEROXIDATION AND PLASMA 
LDL OXIDATION IN EXPERIMENTALLY INDUCED MAMMARY 
CARCINOGENESIS IN RATS AFTER 6 AND 12 MONTHS OF TREATMENT 
Group TBARS* Conjugated Diene* 
6 MONTHS 
NC 3.17 ±0.18 7.35 ±0.24 
EC-I 6.25 ±0.18 14.67 ±0.62 
ET-I 2.22 ±0.17 6.50 ±0.31 
(-64.5%)* (-55.7%)* 
ET-II 2.36 ± 0.15 6.89 ± 0.26 
(-62.2%)* (-53.0%)* 
12 MONTHS 
EC-H 8.13 ± 0.32 19.17 ± 0.89 
ET-III 7.00 ± 0.31 16.53 ± 1.09 
(-13.9%)^ (-13.8%) 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NC, normal control; EC-I, saline-fed control for 6 months; ET-I & ET-II, given 
10 mg TRF/rat/day 2 weeks before and after carcinogen treatment, respectively, for 
6 months; EC-II, saline-fed control for 12 months; ET-III, TRF treatment of 10 mg 
TRF/rat/day was initiated 6 months after the administration of carcinogen and continued for 
6 months. 
Significantly different from their respective controls, EC-I and EC-II at 6 and 12 months, at 
*p<0.001 & V0.05. 
clienes was observed in both the treated groups. After 12 months, saline-fed 
experimental control (EC-II) rats showed a further significant increase in both 
microsomal lipid peroxidation as well as plasma LDL oxidation, which was 
significantly prevented by the feeding of TRF in ET-III by approximately 14% 
(Table 27). These results indicate that chemically induced mammary carcinogenic 
rats show a higher rate of microsomal lipid peroxidation and plasma LDL 
oxidation, which is significantly prevented by the feeding of TRF demonstrating 
its potent antioxidant property. 
3.9 Effect of Tocotrienol Rich Fraction on Plasma Lipids, Plasma 
Lipoprotein Lipids, Apolipoproteins B and A-l, Activity and Protein 
Mass of HMG-CoA Reductase, Microsomal Lipid Peroxidation and 
Plasma LDL Oxidation in Experimentally Induced Hepatic 
Carcinogenic Rats After 6 and 12 Months of Treatment 
3.9. J Effect on plasma lipids 
As evident from Table 28, lipid parameters were not significantly 
changed by the induction of hepatic carcinogenesis in experimental control-I 
(EC-I) rats. However, treatment of the rats with TRF, before and after the 
carcinogen administration, significantly lowered the concentration of all the lipids, 
except free cholesterol, when compared to saline-fed experimental control (EC-I) 
rats. Magnitude of decrease was higher in triglycerides (16-20%), whereas it was 
lower in total cholesterol (11-12%). Esterified cholesterol showed a decline of 
13-14%. On the other hand, free cholesterol registered an insignificant decrease of 
only 7-9% (Table 28). No significant increase in lipid parameters in saline-fed 
experimental control (EC-II) rats was observed after 12 months. However, level of 
these lipid parameters was significantly decreased in TRF treated hepatic 
carcinogenic rats (Table 28). These results demonstrate that although induction of 
hepatic carcinogenesis was not associated with an increase in the lipid parameters, 
feeding of TRF do decrease the levels significantly. 
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3.9.2 Impact on plasma lipoprotein lipids, apoB and apoA-1 
There was no significant change in either the plasma lipoprotein lipids or 
the apolipoproteins, apoB and apoA-1, after the administration of hepatic 
carcinogen. However, treatment with TRF registered a significant decline in the 
levels of LDL-C and apoB in comparison to EC-I. LDL-C showed a highly 
significant reduction of about 42-45% in ET-I and ET-II, whereas, apoB was 
decreased by 36% in both the treated groups (Table 29). On the other hand, TRF 
did not alter significantly other plasma lipoprotein lipids and apoA-1 in both the 
treated groups. Although, there was an increase in the lipid parameters in EC-II 
after 12 months, but again this increase was not significant when compared to 
EC-I rats. There was an increase in the concentration of HDL2-C by 10% after the 
treatment with TRF with a concomitant decrease in HDL3-C by 12%, but these 
changes were not significant when compared to saline-fed experimental control 
(EC-II) rats after 12 months (Table 29). These results again show that hepatic 
carcinogen does not have any significant impact on the plasma lipoprotein lipids 
and apolipoproteins B and A-l in experimentally induced hepatic carcinogenesis, 
whereas TRF significantly decrease these parameters. 
3.9.3 Regulation of hepatic microsomal activity and protein mass of HMG-
CoA reductase 
Consistent with above results, HMG-CoA reductase activity and its 
protein mass were not significantly affected by the induction of hepatic 
carcinogenesis. The data in Table 30 show that after administration of TRF to rats 
for 6 months, there was a significant reduction in HMG-CoA reductase activity 
(77-78%) and protein mass (71-73%) in ET-I and ET-II, when compared to EC-I. 
Again after 12 months, no significant change in the activity and protein mass of 
HMG-CoA reductase was observed in saline-fed control (EC-II) rats. But 
treatment with TRF (ET-III) resulted in a highly significant decrease in both 
enzymatic activity as well as protein mass of HMG-CoA reductase by 77% and 
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TABLE 30 
REGULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC HMG-CoA 
REDUCTASE IN EXPERIMENTALLY INDUCED HEPATIC 
CARCINOGENESIS IN RATS AFTER 6 AND 12 MONTHS OF TRF 
ADMINISTRATION 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
6 MONTHS 
NC 
EC-I 
ET-I 
ET-H 
15.7 ± 0.93 
16.3 ± 0.98 
3.6 ± 0.35 
(-77.9%)* 
3.8 ± 0.46 
(-76.7%)* 
242 ±8 
252 ±9 
69 ± 5 
(-72.6%)* 
73 ±4 
(-71.0%)* 
12 MONTHS 
EC-H 
ET-ffl 
7.0 ± 0.99 
4.0 ± 0.31 
(-76.5%)* 
262 ± 10 
77 ±4 
(-70.6%)* 
*Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**VaIues are mean (ptg/g of microsomal protein) ± SD from three separate assay in each 
group. 
NC, normal control; EC-I, saline-fed control for 6 months; ET-I & ET-II, given 
10 mg TRF/rat/day 2 weeks before and after carcinogen treatment, respectively, for 
6 months; EC-Ill, saline-fed control for 12 months; ET-III, TRF treatment of 10 mg 
TRF/rat/day was initiated 6 months after the administration of carcinogen and continued for 
6 months. 
Significantly different from their respective controls, EC-I and EC-II at 6 and 12 months, at 
*p<0.001. 
71%, respectively (Table 30). These results indicate that hepatic carcinogenesis 
does not have any significant effect on the enzymatic activity and protein mass of 
HMG-CoA reductase. However, administration of TRF significantly decrease the 
protein mass of HMG-CoA reductase, thus causing a reduction in its enzyme 
activity. 
3.9.4 Effect on microsomal lipid peroxidation and plasma LDL oxidation 
The results of ascorbate-Fe induced microsomal lipid peroxidation and 
plasma LDL oxidation in experimentally induced hepatocarcinogenic rats and its 
protection by TRF are given in Table 31. Administration of hepatic carcinogen to 
the rats resulted in an increase in the peroxidation of lipids from 3.0 units/mg in 
NC to 8.6 units/mg in EC-1 rats, with an increase in LDL oxidation from 
6.9 units/ml to 19.0 units/ml, respectively. The increase in lipid peroxidation and 
LDL oxidation was, however, significantly prevented by the administration of TRF 
in both the treated groups (ET-I and ET-II). As evident from the data, ET-I and 
ET-II showed a significant decrease of about 65-67% hi lipid peroxidation when 
compared to EC-I. A significant reduction of approximately 62% in the oxidation 
of LDL in both the treated groups was observed. After 12 months, microsomal 
lipid peroxidation as well as plasma LDL oxidation were further increased to 
10.1 units/mg and 23.6 units/ml, respectively. This increase was significantly 
prevented by 13% and 21%, respectively, after the administration of TRF, in 
comparison to EC-II (Table 31). These results demonstrate that induction of 
hepatic carcinogenesis significantly increase the generation of free radicals which 
in turn are involved in the peroxidation of lipids and oxidation of LDL. However, 
feeding of TRF substantially quenches these free radicals, thus preventing the 
peroxidation of lipids or oxidation of LDL. 
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TABLE 31 
IMPACT OF TRF ON MICROSOMAL LIPID PEROXIDATION AND PLASMA 
LDL OXIDATION IN EXPERIMENTALLY INDUCED HEPATIC 
CARCINOGENESIS IN RATS AFTER 6 AND 12 MONTHS OF 
ADMINISTRATION 
Group TBARS* Conjugated Diene* 
6 MONTHS 
NC 
EC-I 
ET-I 
ET-II 
2.99 ±0.14 
8.56 ±0.15 
2.79 ±0.14 
(-67.4%): 
3.00 ± 0.20 
(-64.9%)t 
6.85 ± 0.39 
19.04 ± 0.90 
7.15 ±0.34 
(-62.4%)* 
7.27 ± 0.32 
(-61.8%)* 
12 MONTHS 
EC-II 
ET-III 
10.09 ± 0.44 
8.83 ± 0.29 
(-12.5%)' 
23.60 ± 1.81 
18.61 ± 0.91 
(-21.4%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NC, normal control; EC-I, saline-fed control for 6 months; ET-I & ET-II, given 
10 mg TRF/rat/day 2 weeks before and after carcinogen treatment, respectively, for 
6 months; EC-II, saline-fed control for 12 months; ET-III, TRF treatment of 10 mg 
TRF/rat/day was initiated 6 months after the administration of carcinogen and continued for 
6 months. 
Significantly different from their respective controls, EC-I and EC-II at 6 and 12 months, at 
Jp<0.001 & V0.05. 
3.10 Effect of Tocotrienol Rich Fraction on Alkaline Phosphatase Activity 
in Plasma and Different Tissues and GIutathione-S-Transferase 
Activity in Different Tissues of Chemically Induced Mammary 
Carcinogenic Rats After 6 and 12 Months of Treatment 
3.10.1 Impact on plasma alkaline phosphatase activity 
Administration of chemical carcinogen, DMBA, resulted in a significant 
increase of plasma alkaline phosphatase (ALP) activity from 265 units/ml in NC to 
516 units/ml in EC-I (Table 32). However, feeding of TRF to the carcinogenic rats 
in ET-I and ET-II resulted in a significant decrease of about 8-10% in the ALP 
activity after 6 months as compared to saline-fed experimental control (EC-I) rats. 
After 12 months, there was a further significant increase in the activity of ALP to 
592 units/ml in EC-1I rats, which was, however, insignificantly reduced by 6% 
after the treatment of ET-II1 rats with TRF, indicating that TRF was not effective 
at the later stages (beyond 6 montiis) of carcinogenesis (Table 32). 
3.10.2 Effect on alkaline phosphatase activity in different tissues 
Even though DMBA is considered to be a specific carcinogen for 
mammary carcinogenesis when administered orally, it had a profound effect on the 
ALP activity in the liver after 6 months. As seen in Table 33, the activity of ALP 
in the liver increased from 14.5 units/mg in NC to 22.6 units/mg in EC-I. TRF 
further elevated the ALP activity significantly by 49-54% in ET-I and ET-II, when 
compared to EC-I. Apart from liver, only mammary tissue showed a significant 
increase in the activity of ALP from 5.1 units/mg in NC to 7.3 units/mg in EC-I, 
whereas supplementation of TRF significantly prevented this increase in activity 
by 10-13% in both the treated groups. All other tissues were least affected by the 
chemical carcinogen or by the treatment with TRF (Table 33). After 12 months, 
there was a substantial increase in the ALP activity in the liver (42.3 units/mg), 
which was insignificantly increased by 7% in ET-III after the administration of 
TRF, when compared to EC-II. There was an insignificant decrease of about 
9-11% in the ALP activity of brain and pancreas, after the treatment with TRF. 
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TABLE 32 
EFFECT OF TRF ON ALKALINE PHOSPHATASE (ALP) ACTIVITY IN 
PLASMA OF EXPERIMENTALLY INDUCED MAMMARY CARCINOGENESIS 
IN RATS AFTER 6 AND 12 MONTHS OF ADMINISTRATION 
Group Specific activity* 
6 MONTHS 
NC 264.7 ±11.7 
EC-I 516.4 ± 16.2 
ET-I 463.4 ±11.5 
(-10.3%)f 
ET-II 473.5 ± 12.4 
(-8.3%)* 
12 MONTHS 
EC-H 591.9 ± 21.8 
ET-IH 554.9 ± 22.3 
(-6.3%) 
* Values are mean (nmole/min/ml) ± SD from plasma of individual no. of rats as given in 
experimental procedure in each group. 
NC, normal control; EC-I, saline-fed control for 6 months; ET-I & ET-II, given 
10 mg TRF/rat/day 2 weeks before and after carcinogen treatment, respectively, for 
6 months; EC-II, saline-fed control for 12 months; ET-IH, TRF treatment of 10 mg 
TRF/rat/day was initiated 6 months after the administration of carcinogen and continued for 
6 months. 
Significantly different from EC-I at *p<0.01. 
< 
< 
Q 
Q H 
>- H 
J
 z 
< a 
CfJ O 
U c/3 
Cu 
X 
w 
O 
<*> 
w 
( / } 
H 
H 
Z 
W 
[2 . 
Q 
Z 
I 
H 
Z 
o 
s 
Q 
Z 
H 
< 
H 
> 
H 
U 
< 
< 
z 
o 
H 
o 
H 
U 
w 
C a -
fe 
w 
W 
z 
o 
o 
z 
u 
os 
<: 
u 
£ 
£ 
OS 
U 
c 
« 0. 
c 
O 
U 
u 
o 
o 
a 
H 
z 
o 
f> 
**i d 
-H 
t^ 
© 
m' 
<M 
w 
o 
+1 
00 
<s 
r-" 
r-
• — 
-H ON 
"*f ci 
CO r^ 
VO ^ 
«M 
«/5 
o 
-H 00 
V5 
vo" 
? 
vo 
ON 
1 
ro 
V) 
© 
-H 
o 
CJ 
VO* 
Tt 
vo 
o" 
-H 
if) 
VO 
VO* 
fM 
• < * 
o 
-H 
r-
fO 
VO* 
r-^  
6s-
r< 
-<t 
1 
*a 
m 
o 
-H 
<s 
f> 
vo* 
J 
o 
V* 
1 
00 IT) 
00 ON 
+1 
o 
VO 
d 
+1 
41 
o 
-H 
VO 
w 
o 
41 Cp~ 
o ** 
c" «-* T *-* n i-^ 
O f> f ) 
U U H 
z w w 
o 
-H C? 
f > 0 0 
0 0 0 0 
d d 
-+H Co" "H ^ 
rH ON fO OV 
* 
ON 
00 
d 
41 
fS 
VJ 
TT 
rH 
ON 
f^ 
r* 
41 
«S 
vo 
ri 
<s 
f-
vo 
r" 
4H 
«M 
t^ 
rt 
tn 
++ 
5%
) 
• f> 
*f) 
+ s^* 
ON 
ON 
y—t 
4) 
t-
vo 
CO 
m 
++ 
0 s 
00 
00 
rt 4-
• 
H 
a 
H 
Z 
o 
ON 
t^ 
— 
41 
O 
vq 
ri 
00 
00 
d 
41 
o 
ON 
«s 
0 s 
• ^
, 
C< 4-
ON 
00 
d 
41 
o 
ON 
r-* 
vo 
ON 
d 
-H 
O 
<s 
t-* 
? 
°i 00 
1 
41 
o 
CO 
41 C? 
O ^ 
V) — 
vo* *7 
OS 
o 
V ) 
vo 
41 41 ? 
o o *©. 
-H vq o 
00 
41 
o 
-H ^ 
O vo 
C T5 
<u <u 
O .S 
C ,*J 
'S C 
v. • — 
rt 1/3 
U eS 
•- » 
41
 ^ 
« et 
58
 -O 
T3 ^3 
C « 
eS j -
4 2 0X1 5
 I 
OJ O 
fa **' 
H OS 
os ^" 
E -
2 *"? 
= U 
w " 
•a 5 
Q . r V 
3 ^ * o a 
on 
^1 
0> 
°-«2 
-* £ 
G S 
- H «a» 
^ s 
E ^? 
^ o 
E « 
c » 
S c 
>- E 
<a •-
- £ 
h "° 1 = ° c u .-
_ -H W 
^ C o 
u o • 
«V " o i - , V 
w c E 
HN 0jD„ 2 ° 
.E o 
S o 
O O. en 
§ C O i 
£ .2 
W 
E 
o 
03 4J 
« E 
to i ; 
4> O 
3 B 
f z 
£» E 
4) T3 
> eg 
s *s 
£ 4-
^ cs 
E c 
S E 
•w VO C» 
73 
t 
Although, after 12 months, the ALP activity in mammary tissue of EC-II was 
increased to 12.6 units/mg, no effect of TRF was seen (Table 33). These results 
demonstrate that administration of mammary carcinogen to rats leads to the 
formation of toxic substances due to which the activity of ALP increases in the 
liver and mammary gland. This increased ALP activity in the liver is involved in 
the clearance of these toxic substances, which is elevated in the presence of TRF. 
3.10.3 Effect on glutathione-S-transferase activity in different tissues 
Table 34 summarizes the results of glutathione-S-transferase (GST) 
activity in different tissues of chemically induced mammary carcinogenic rats after 
6 and 12 months. Liver showed a significant increase in the activity of GST from 
2.4 units/mg in NC to 4.8 units/mg in EC-1, whereas it was increased from 
2.2 units/mg to 3.3 units/mg, respectively, in mammary tissue. Administration of 
TRF to the carcinogenic rats resulted in a significant decline in hepatic GST 
activity by 30-33% in ET-I and ET-I1, when compared to EC-I. Similarly, a 
decrease of around 20-23% was observed in the activity of GST in mammary 
tissue of carcinogenic rats treated with TRF (ET-I and ET-II). On the other hand, 
other tissues did not register any significant change either in the presence or 
absence of TRF after 6 months (Table 34). After 12 months, GST activity showed 
a substantial increase to 13.0 units/mg in the liver of saline-fed control (EC-II) 
rats. However, feeding of TRF prevented this increase of hepatic GST activity by 
20%. GST activity in mammary tissue was significantly increased to 4.1 units/mg 
in EC-II, which was insignificantly decreased by 3% after the treatment with TRF. 
No significant increase in the enzymatic activities of GST in brain, colon and 
pancreas of saline-fed experimental control (EC-II) rats was observed after 
12 months (Table 34). These results indicate that administration of mammary 
carcinogen to rats substantially increase the hepatic GST activity which was 
significantly prevented by TRF, demonstrating its anticarcinogenic property. 
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3.11 Effect of Tocotrienol Rich Fraction on Alkaline Phosphatase Activity 
in Plasma and Different Tissues and GJutathione-S-Transferase 
Activity in Different Tissues of Chemically Induced Hepatic 
Carcinogenic Rats After 6 and 12 Months of Treatment 
3.11.1 Effect on alkaline phosphatase activity in plasma 
Plasma ALP activity was significantly increased from 273 units/ml in 
NC to 572 units/ml in EC-I. However, feeding of TRF to the carcinogenic rats for 
6 months significantly prevented the increase by 32% and 26% in ET-I and ET-II, 
respectively, compared to saline-fed experimental control (EC-I) rats (Table 35). 
After 12 months, saline-fed experimental control (EC-1I) rats showed a further 
significant increase in the activity of ALP to 620 units/ml which was prevented 
insignificantly by 8% after the administration of TRF in ET-III group (Table 35). 
These results demonstrate that administration of hepatic carcinogen to rats 
substantially increase the plasma ALP activity which is significantly prevented by 
TRF. However, after 12 months, TRF is not effective in preventing the increase. 
3.11.2 Impact on alkaline phosphatase activity in different tissues 
Table 36 show the ALP activity in different tissues of chemically 
induced hepatic carcinogenesis. A significant increase in the activity of ALP from 
15.2 units/mg in NC to 27.2 units/mg in EC-I was observed in the liver. As 
evident, other tissues showed only an insignificant increase in the ALP activity 
after 6 months. Treatment of carcinogenic rats with TRF for 6 months significantly 
increased the hepatic activity of ALP by 46-50%, when compared to saline-fed 
control (EC-I) rats. However, treatment of TRF resulted in the decrease of ALP 
activity in other tissues, but this decrease was not significant (Table 36). Only liver 
of EC-II showed a significant change in ALP activity after 12 months and 
increased to 48.6 units/mg. Administration of TRF further elevated the activity of 
ALP in liver by 12%, but this increase was insignificant compared to EC-II. These 
results demonstrate that hepatic carcinogen leads to the formation of toxic 
substances in the experimentally induced carcinogenic rats, which is cleared by the 
130 
TABLE 35 
EFFECT OF TRF ON ALP ACTIVITY IN PLASMA OF EXPERIMENTALLY 
INDUCED HEPATIC CARCINOGENESIS IN RATS AFTER 6 AND 12 MONTHS 
OF TREATMENT 
Group Specific activity* 
6 MONTHS 
NC 273.3 ± 8.4 
EC-I 571.8 ±10.0 
ET-I 387.8 ± 13.5 
(-32.2%)* 
ET-II 420.9 ± 15.8 
(-26.4%)* 
12 MONTHS 
EC-H 620.2 ± 20.2 
ET-m 567.8 ± 21.5 
(-8.4%) 
* Values are mean (nmole/min/ml) ± SD from plasma of individual no. of rats as given in 
experimental procedure in each group. 
NC, normal control; EC-I, saline-fed control for 6 months; ET-I & ET-II, given 
10 mg TRF/rat/day 2 weeks before and after carcinogen treatment, respectively, for 
6 months; ECU, saline-fed control for 12 months; ET-III, TRF treatment of 10 mg 
TRF/rat/day was initiated 6 months after the administration of carcinogen and continued for 
6 months. 
Significantly different from EC-I at *p<0.001. 
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liver as indicated by the increase in die enzymatic activity of ALP by the 
administration of TRF. However, after 12 months, the efficacy of TRF in terms of 
clearing the toxic substances, is significantly decreased. 
3.11.3 Effect on glutathione-S-transferase activity in different tissues 
As seen in Table 37, rats in the EC-I showed a significant increase in 
hepatic GST activity as compared to normal control rats. It increased from 
2.3 units/mg in NC to 8.0 units/mg in EC-I. On the other hand, TRF had a 
significant effect in preventing this increase in GST activity and was decreased by 
35-39% in both the treated groups, ET-I and ET-II. All other tissues registered an 
insignificant change in GST activity after 6 months of carcinogen administration, 
when compared to normal control (NC) rats. Supplementation of TRF also did not 
affect the GST activity of these tissues in both the treated groups (Table 37). There 
was a further increase in the activity of GST to 13.4 units/mg in the liver of EC-II 
after 12 months. Treatment of rats with TRF decreased the activity by 21% in 
comparison to saline-fed experimental control (EC-II) group. There was only a 
moderate increase in the activity of GST in brain, colon and pancreas of EC-II, 
which was insignificantly reduced (6-8%) by the administration of TRF when 
compared to EC-II (Table 37). These results indicate that hepatic carcinogenesis is 
associated with a substantial increase in hepatic GST activity, which, however, is 
significantly decreased by the feeding of TRF. 
3.12 Gross Morphological and Histological Studies in the Liver of DMBA-
Induced Carcinogenic Rats Without and With 6 and 12 Months of 
TRF Treatment 
3.12.1 Gross morphology of liver 
No obvious morphological differences in the livers of normal control 
(NC), experimental control (EC-I) and TRF treated, ET-I and ET-II, rats were 
observed after 6 months. However, livers of the DMBA-induced carcinogenic rats 
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(EC-1I) showed off-white patches on the surface after 12 months. The number of 
these patches was less in TRF treated (ET-III) rats. 
3.12.2 Histological studies 
As depicted in Figure 3.2, Panel A and B, staining with hematoxylin and 
eosin showed no obvious difference in the morphology of the livers of TRF treated 
rats, ET-I and ET-II, as compared to the livers of the normal control (NC) rats 
(Fig. 3.1, Panel A). As seen in photomicrograph (Fig. 3.1, Panel B), treatment of 
rats with mammary carcinogen caused some untoward changes in the structure of 
the liver cell nuclei of EC-I rats after 6 months. The shape of the nuclei in liver 
cells of EC-I rats were elongated than the nuclei of normal control (NC) rats. 
However, after 12 months, shape of the nuclei in liver cells in EC-II rats were 
highly irregular (Fig. 3.3, Panel A), and these changes were substantially 
prevented by the administration of TRF in ET-III rats (Fig. 3.3, Panel B). These 
results demonstrate that TRF is highly effective in maintaining the normal 
morphology of liver cells in DMBA-induced carcinogenesis upto 12 months of 
treatment. 
3.13 Gross Morphological and Histological Studies in Liver of Chemically 
Induced Hepatic Carcinogenic Rats Without and With 6 and 12 
Months of TRF Treatment 
3.13.1 Gross morphology of liver 
The livers of the experimental control (EC-I) rats showed off-white 
patches on the surface as compared with the control livers (NC). However, there 
were no patches on the surface of the livers of rats treated with TRF for 6 months 
(ET-I and ET-II). The number of these off-white patches were increased in 
experimental control (EC-II) rats after 12 months. On the other hand, after 
12 months of TRF treatment (ET-III), there were fewer number of off-white 
patches on the livers of rats. 
135 
Fig. 3.1. Panel A. Photomicrograph of control liver. The shape of nuclei is round 
and smooth. 
Panel B. Photomicrograph of DMBA treated liver after 6 months of 
administration. The shape of nuclei is slightly irregular and 
elongated. 
Fig. 3.2. Panel A. Photomicrograph of DMBA treated liver after 6 months of TRF 
treatment, fed 2 weeks before the administration of carcinogen. 
Shapewise nuclei are better than experimental control and are 
close to normal. 
Panel B. Photomicrograph of DMBA treated liver after 6 months of TRF 
treatment, fed 2 weeks after the administration of carcinogen. 
Shapewise nuclei are better than experimental control and are 
close to normal. 
Panel A 
Panel B 
Fig. 3.3. Panel A. Photomicrograph of DMBA treated liver after 12 months of 
administration. The nuclei are severely distorted and irregular in 
shape. 
Panel B. Photomicrograph of DMBA treated liver after 6 months of TRF 
treatment, fed 6 months after the administration of carcinogen. 
The nuclei are still distorted into irregular shape, but in 
comparison to 12 month experimental control, the degree of 
distortion is significantly less. 
Panel A 
Panel B 
i<M^ 
• . • > 
3.13.2 Histological stu dies 
As seen in Figure 3.5, Panel A and B, the nuclei of the liver cells in TRF 
treated, ET-I and ET-II, rats were elongated as compared to cells from normal 
control (NC) group (Fig. 3.4, Panel A). However, no other major structural 
difference in the cell integrity was observed. On the other hand, liver cells of 
experimental control (EC-I) rats treated with hepatic carcinogen showed 
significant changes in the cell structure with highly irregular shape of nuclei 
(Fig. 3.4, Panel B). These changes were further aggravated after 12 months of the 
administration of carcinogen in EC-II (Fig. 3.6, Panel A). Feeding of TRF to 
ET-III rats moderately prevented these changes (Fig. 3.6, Panel B). These results 
indicate that hepatic carcinogen cause substantial changes in the cell structure as 
well as shape of the nuclei in the liver. These untoward changes are significantly 
prevented by the administration of TRF, for 6 months. However, after 12 months 
of treatment, the anti-tumour impact of TRF was reduced. 
The combined results presented in the thesis indicate that daily intake of 
TRF/RBO may be useful in the prevention and treatment of atherosclerosis as well 
as in certain forms of cancer. 
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Fig. 3.4. Panel A. Photomicrograph of control liver. The shape of nuclei is round 
and smooth. 
Panel B. Photomicrograph of DEN/AAF treated liver after 6 months of 
administration. Nuclei are severely distorted and are no longer 
smooth and round. 
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Fig. 3.6. Panel A. Photomicrograph of DEN/AAF treated liver after 12 months of 
administration. The nuclei are severely distorted and no longer 
smooth and round. 
Panel B. Photomicrograph of DEN/AAF treated liver after 6 months of 
TRF treatment, fed 6 months after the administration of 
carcinogen. The nuclei are less distorted and shapewise are much 
better. In comparison to 12 month experimental control, the 
degree of damage is significantly improved. 
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The results presented in the thesis demonstrate that a rapid, efficient, 
reproducible and cost-effective methodology has been developed for the isolation 
of tocotrienol/tocopherol rich fraction (TRF) from rice bran, crude rice bran oil 
(RBO) or refined edible grade RBO. Methods published previously for the 
isolation of TRF involve time consuming multiple steps, including saponification 
of the oil (Sharma and Rukrnini, 1987; Shin and Godber, 1994). Our method 
simply involves the extraction of TRF from rice bran/RBO in methanol (Beg et al, 
1996b). Precaution is taken that within 24 h of milling brans from raw paddies are 
soaked in hexane, because during milling lipase enzyme is activated which 
hydrolyzes triglycerides to free fatty acids (Migura, 1989). The rise in free fatty 
acid in raw bran is very rapid, 6-10% in 24-48 h of milling. However, in parboiled 
bran, there is only 2-3% rise in 48 h, apparently due to partial inactivation of 
lipase enzyme by parboiling. A 4.3% yield of TRF isolated from refined edible 
grade RBO is consistent with the value reported earlier (Sharma and Rukmini, 
1987). However, me percent yield of TRF varied between 5.8 and 8.4 when 
isolated from crude RBO, extracted from brans of raw and parboiled Sarju-52 and 
Mansuri cultivars. This variation in the percent yield of TRF is indicative of the 
feet that types, a-, p-, y- and 8-tocotrienols (T3) and tocopherols (T) and their 
quantity may vary in the raw and parboiled brans representative of two cultivars of 
rice. A significantly lower yield of TRF (4.3%) from refined edible grade RBO 
isolated by the above methodology suggests the possibility of removal of some 
T3/T during refining procedures of the commercial edible grade RBO. The yield of 
purified TRF, purified on silica gel bed from TRF of crude RBO from raw and 
parboiled cultivars, was in the range of 3.9-5.0%, which is on an average ~ 62% 
higher than 2.8% yield of purified TRF obtained from TRF of refined edible grade 
RBO. The combined results indicate that the isolation of purified TRF from crude 
RBO by employing the above methods yield a significantly higher quantity of 
value-added products, tocotrienols and tocopherols, in comparison to purified TRF 
isolated from refined edible grade RBO. In addition, the cost incurred in the 
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isolation of TRF from crude RBO derived from brans of different cultivars of rice 
is far less than the cost involved in the isolation of TRF from commercially 
procured refined edible grade RBO. 
The combined content of a-, p-, y- and 8-T3 and T, as quantified by HPLC, 
in TRF isolated from refined edible grade RBO was 29.2% and 39.1%, 
respectively, whereas for purified TRF the total content of T3 and T was 42.2% 
and 57.9%. The increase in percent content of the combined T3 and T in purified 
TRF was consistent with ~ 35% of the non-T3 and T contaminants removed during 
the purification of TRF. Similarly, the increase in combined percent yield of T3 
and T in purified TRF of two cultivars of rice was in agreement with the ~ 35% 
contaminants associated with TRF. Since it is known that y- and 8-T3 are most 
potent in terms of their hypolipidemic (Pearce et al, 1992; Qureshi and Qureshi, 
1993), antioxidant (Suarna et al, 1993; Kamat and Devasagayam, 1995; Kamat et 
al, 1997) and anti-tumour (Komiyama et al, 1989; Goh et al, 1994; Elson and 
Qureshi, 1995; Guthrie et al, 1997; Nesaretnam et al, 1998) activities, the 
combined percent content of y- and 8-T3 present in purified TRF of Sarju-52 and 
Mansuri was significantly different than purified TRF of refined edible grade 
RBO. 
A detailed investigation of TRF and purified TRF, as isolated above, on 
cholesterol dynamics of normolipidemic and hyperlipidemic rats has been carried 
out. Feeding of tocotrienols as TRF, isolated from refined edible grade RBO, to 
normal rats for one week was associated with a significant decline in plasma and 
lipoprotein lipids. It is interesting to note that both TRF and purified TRF 
mediated a significant decline in total and esterified cholesterol levels, with no 
significant change in free cholesterol. The results demonstrate that decrease in 
plasma total cholesterol level is apparently due to a significant decrease in 
VLDL-C and LDL-C levels. Administration of TRF or purified TRF caused a 
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significant decline in plasma apolipoprotein B associated with LDL. Although no 
significant change in HDL-C was observed, but its subtraction, HDL2-C, which is 
considered to be a strong predictor of presence and extent of coronary artery 
disease (CAD) (Drexel et ai, 1992), was significantly increased. Consistent with 
no change in HDL-C, its apolipoprotein A-l level was not affected. 
In general, our results are consistent with several scattered reports 
indicating hypolipidemic action of tocotrienols in normolipidemic animal and 
human models, administered as RBO, palm oil, barley oil or TRF isolated from 
either RBO or palm oil. Feeding of diet containing 5-20% RBO to normal rats was 
associated with a significant decline in serum total cholesterol, LDL-C and 
VLDL-C (Sharma and Rukmini, 1986; Purushothama et al, 1995), whereas 
triglycerides and HDL-C levels were not significantly changed (Sharma and 
Rukmini, 1986). Earlier findings from our laboratory (Beg et ai, 1996a) related to 
hypolipidemic action of dietary RBO in normolipidemic humans are consistent 
with the results reported in the thesis. Our results are also consistent with a decline 
in plasma cholesterol in hamsters fed 9% RBO for 3 weeks (Kahlon et al., 1992). 
Diet containing 35% RBO when fed to normolipidemic monkeys also resulted in a 
significant decline in total cholesterol, LDL-C and apoB, with no change in 
HDL-C (Nicolosi et ai, 1991). Feeding of TRF (50 ng/g of diet) for 6 and 8 weeks 
to normolipidemic swines was associated with a significant decline in total 
cholesterol, LDL-C and apoB, with no change in HDL-C and apoA-1 levels 
(Qureshi et al., 1991a). Consistent with hypocholesterolemic action of TRF in rats, 
Pearce et al. (1992) have demonstrated a significant hypolipidemic impacts of 
a-, y- and 8-T3 in normolipidemic chickens. Feeding of a-, y- and 8-T3 (20 jig/g of 
diet) for 4 weeks resulted in a significant decline in serum total cholesterol and 
LDL-C levels, with no change in HDL-C. As expected, hypolipidemic impact of 
a-T3 was lower than y- and 5-T3 (Qureshi and Qureshi, 1993). Feeding of dietary 
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palm oil (15-20%) to normolipidemic rats resulted in varied effects on 
triglycerides, total cholesterol, LDL-C, HDL-C and HDL-C/total cholesterol ratio 
(Pereira et al, 1990; Sundram el al, 1990; Osim et al, 1996). Similar results were 
observed when 70% dietary palm oil was fed to normolipidemic humans (Sundram 
et al, 1992). However, feeding of one capsule/day of 18 mg tocopherols and 
42 mg tocotrienols in 240 mg of palm olein for 30 days to normolipidemic 
humans, resulted in a significant decline in total cholesterol and LDL-C, with 
insignificant change in triglycerides and HDL-C levels (Tan et al, 1991). 
Similarly, feeding of barley oil to normolipidemic chickens significantly reduced 
the levels of plasma total cholesterol and LDL-C with no change in triglycerides 
and HDL-C levels (Qureshi et al, 1986). 
Next, we investigated the role of purified TRF in the prevention of 
experimental hyperlipidemia in rats. Feeding of an atherogenic diet for 3 weeks to 
rats was associated with a severe hyperlipidemia. The results demonstrate that 
7 days after the withdrawal of atherogenic diet, plasma lipids, triglycerides, total 
cholesterol including esterified and free cholesterol, VLDL-C, LDL-C including 
apoB, HDL-C and its subtractions, HDL2-C and HDL3-C levels were significantly 
reduced. ApoA-1 level was reduced insignificantly. Feeding of 16.25 and 
32.50 mg of purified TRF/kg/day to hyperlipidemic rats for 7 days resulted in a 
further significant reduction in the plasma and lipoprotein lipids including apoB, in 
comparison to untreated hyperlipidemic control rats. The significant decline in 
total cholesterol level mediated by purified TRF is due to a significant decrease in 
VLDL-C and LDL-C levels. The combined results demonstrate that hypolipidemic 
impacts of purified TRF at 16.25 and 32.50 mg/kg/day for 7 days were similar, 
indicating that an optimal dose of TRF may be significantly lower than 
16.25 mg/kg'day. 
In order to find out a minimum dose of TRF which can exert a maximum 
hypolipidemic effect, we investigated the impacts of 4, 8 and 12 mg of 
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TRF/kg/day on cholesterol dynamics in hyperlipidemic rats for 7 days. The 
combined results indicate that administration of TRF to hyperlipidemic rats for 
7 days was associated with a dose-dependent decline in plasma triglycerides, total 
cholesterol including esterified and free cholesterol, VLDL-C, LDL-C and apoB. 
No effect on HDL-C and HDL3-C levels was observed at the above three doses of 
TRF, whereas a significant decrease in the levels of HDL2-C and apoA-1 at 8 and 
12 mg TRF/kg/day was seen. The combined results demonstrate that a maximal 
hypolipidemic impact of TRF is exerted at a dose of 8 mg/kg/day in 
hyperlipidemic rats. 
In general, our results are in agreement with other reports indicating 
hypolipidemic effect of tocotrienols in hyperlipidemic animal and human models, 
administered as RBO, palm oil or TRF isolated from either RBO or palm oil. Our 
results are supported by earlier studies where RBO (10%), TRF (0.2-0.4%) or y-T3 
(50 jig/g of diet) were fed to rats along with cholesterol-rich diet for 6-8 weeks, 
which prevented significantly the increase in total cholesterol, LDL-C and 
VLDL-C. However, TRF did not affect significantly HDL-C and triglycerides 
levels (Sharma and Rukmini, 1986 & 1987; Seetharamaiah and Chandrasekhara, 
1989; Watkins et ai, 1993). Similarly, feeding of tocotrienols together with 
atherogenic diet to rabbits for 12 weeks, prevented significantly the increase in 
serum total cholesterol and LDL-C levels (Teoh et ai, 1994). Analogous to 
hypocholesterolemic impacts of TRF in experimental hyperlipidemic rats and 
rabbits, a significant decline in total cholesterol, LDL-C and apoB was observed in 
pigs, with inherited hyperlipidemia, fed TRF (50 ug/g of diet) isolated from palm 
oil for 6 weeks. Similar to our results in rats, no significant affect on HDL-C and 
apoA-1 was observed in genetically hyperlipidemic pigs treated with TRF 
(Qureshi et ai, 1991a). Feeding of a diet supplemented with purified a-, y- and 
8-T3 from palm oil (20 p.g/g of diet) to hypercholesterolemic chickens, 
significantly reduced serum total cholesterol and LDL-C levels (Qureshi and 
147 
Qureshi, 1993). Consistent with our results, TRF/T3 exhibited more potent 
hypocholesterolemic action in inherited hyperlipidemic swines and experimental 
hypercholesterolemic chickens when compared to normolipidemic swines and 
chickens (Qureshi et al, 1991a; Qureshi and Qureshi, 1993). The hypolipidemic 
effects of dietary RBO, TRF or y-T3 in hyperlipidemic humans were consistent 
with our results observed in hyperlipidemic rats, and reported by others in rat 
(Sharma and Rukmini, 1986 & 1987; Seetharamaiah and Chandrasekhara, 1989; 
Watkins et al, 1993), rabbit (Teoh et al, 1994), pig (Qureshi et al, 1991a) and 
avian (Qureshi and Qureshi, 1993) models. Earlier findings from our laboratory 
related to hypolipidemic action of dietary RBO/TRF in hyperlipidemic rats (Beg et 
al, 1996a) and humans (Khan et al, 1994; Beg et al, 1995 & 1996a) are 
consistent with the results reported in the thesis and published, in part, elsewhere 
(Beg el al, 1997; Minhajuddin et al, 1999). Intake of dietary RBO as a cooking 
oil for 2 and 4 weeks by hyperlipidemic humans resulted in a significant decrease 
of plasma triglycerides and total cholesterol levels (Raghuram et al, 1989). In 
another study, feeding of 200 mg TRF/day from palm oil or 200 mg y-T3/day for 
4 weeks to hypercholesterolemic humans was associated with a significant 
decrease in total cholesterol, LDL-C and apoB levels, whereas no affect was seen 
on triglycerides, HDL-C and apoA-1 levels (Qureshi et al, 1991b). Treatment of 
patients, with hyperlipidemia and carotid stenosis, with TRF (240-360 mg/day) 
isolated from palm oil for 12 months revealed a significant apparent carotid 
atherosclerotic regression with no change in serum triglycerides, total cholesterol, 
LDL-C and HDL-C (Tomeo et al, 1995). 
The hypocholesterolemic action of TRF and purified TRF in 
normolipidemic and hyperlipidemic rats is mediated by a decrease in the 
enzymatic activity of HMG-CoA reductase, the rate-limiting enzyme in the 
biosynthetic pathway of cholesterol. A concomitant decline in immuno-reactive 
HMG-CoA reductase protein mass appears to be the reason for a decrease in 
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enzyme activity and a consequent decline in cholesterol production. 
Administration of TRF and purified TRF for one week to normolipidemic rats was 
associated with a significant decrease in the enzymatic activity of HMG-CoA 
reductase and its protein mass. Feeding of cholesterol rich (atherogenic) diet to 
rats for 3 weeks resulted in a sharp decrease in the enzymatic activity and protein 
mass of HMG-CoA reductase. These results are consistent with the well known 
negative feedback inhibition of HMG-CoA reductase mediated by feeding of high 
levels of cholesterol. Seven days after the withdrawal of atherogenic diet in 
untreated hyperlipidemic control rats, the enzymatic activity and protein mass of 
HMG-CoA reductase were significantly increased due to the release of cholesterol 
feedback inhibition (Rodwell et ai, 1976). However, the decline in total 
cholesterol and LDL-C levels by administering several doses of TRF or purified 
TRF for 7 days to hyperlipidemic rats is apparently mediated by a significant 
reduction in enzymatic activity of HMG-CoA reductase, which in turn is reduced 
by a decrease in its protein mass. Consistent with maximal hypolipidemic impacts 
of TRF, an optimal reduction in the enzymatic activity and protein mass of 
HMG-CoA reductase was obtained at 8 mg TRF/kg/day. The combined data 
provide evidence that tocotrienols present in TRF exert their hypolipidemic effects 
in normolipidemic as well as hyperlipidemic rats by a common mechanism 
involving the reduction in HMG-CoA reductase activity, which in turn is reduced 
by a decline in its protein mass. 
The combined results presented here indicate that tocotrienols are highly 
effective in lowering blood cholesterol and LDL-C levels by repressing 
HMG-CoA reductase. It has been established that the suppression of HMG-CoA 
reductase requires two regulators, cholesterol delivered by receptor-mediated 
uptake of LDL and non-steiol product derived from mevalonate. The former is 
expressed predominantly through the changes in the rate of transcription of the 
HMG-CoA reductase gene, and the latter by modulating the efficiency of 
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translation of HMG-CoA reductase mRNA or by degradation of the protein 
(Goldstein and Brown, 1990). The exact mechanism by which tocotrienols act in 
vivo at the cellular level has not been established. However, in normolipidemic and 
hyperlipidemic chickens, TRF/T3 have been shown to suppress the hepatic 
HMG-CoA reductase activity (Pearce et al., 1992; Qureshi and Qureshi, 1993). 
Similarly, en2ymatic activity of HMG-CoA reductase in adipose tissue of 
normolipidemic and hypercholesterolemic swines was reduced after TRF treatment 
(Qureshi et al., 1991a). Our results in normolipidemic and hyperlipidemic rats 
demonstrate that TRF suppresses the hepatic HMG-CoA reductase activity by 
reducing its protein mass. These studies represent an initial demonstration of the 
TRF mediated in vivo mechanism of HMG-CoA reductase activity suppression, 
involving a concomitant reduction in the protein mass. The decline in protein mass 
may be achieved by inhibition of HMG-CoA reductase synthesis and/or enhanced 
degradation. Similar to our in vivo results, y-T3 has been shown to mediate the 
suppression of enzymatic activity and protein mass of HMG-CoA reductase 
through decreased synthesis (57% of control) and enhanced degradation (2.4 fold 
versus control) of the enzyme in HepG2 cells (Parker et al., 1993). Thus, 
tocotrienols influence the mevalonate pathway in mammalian cells in vitro, by 
post-transcriptional suppression of HMG-CoA reductase, and appear to 
specifically modulate the intracellular mechanism for controlled degradation of the 
reductase protein (Parker et al., 1993). These activities of tocotrienol in HepG2 
cells, mirror the actions of the putative non-sterol feedback regulators derived from 
mevalonate in cultured cells (Goldstein and Brown, 1990). Tocotrienol rich 
fraction mediated in vivo mechanism of inhibition of enzymatic activity and 
protein mass of HMG-CoA reductase in normolipidemic and hyperlipidemic rats, 
as demonstrated in the present study, may be analogous to the mechanism shown 
in HepG2 cells (Parker et al., 1993). Taken together, the available information 
indicate an association between the suppression of hepatic HMG-CoA reductase 
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and cholesterogenesis, and the observed plasma cholesterol lowering activity of 
TRF in animal models. However, elucidation of precise in vivo mechanism(s) of 
TRF mediated inhibition of HMG-CoA reductase at molecular level remains to be 
investigated. 
A growing body of evidence has linked processes involving oxygen-derived 
free radicals with the initiation and propagation of atherosclerosis. In particular, 
the oxidative modification of LDL enhances its atherogenecity (Steinberg, 1988; 
Duthie et al, 1989; Palinski et al, 1989). Recent studies have demonstrated that 
oxidized lipids, especially oxidized fatty acids and cholesterol in the diet are 
atherogenic (Staprans et al, 1998). An inadequate intake of foods containing 
antioxidant vitamins could result in the oxidation of LDL-cholesterol. 
Antioxidants, especially vitamin E (tocopherols), have recently received 
considerable attention as potential anti-atherogenic agents. Several studies have 
demonstrated the ability of tocopherols and other antioxidants to prevent ex vivo 
and in vitro LDL oxidation and to reduce significantly the development of 
atherosclerotic lesions (Carew et al., 1987; Esterbauer et al, 1991; Mao et al, 
1991), risk of coronary heart disease (CHD) (Rimm et al, 1993; Stampfer et al, 
1993) and ischemic heart disease (Gey, 1995). As the TRF, isolated from RBO, is 
enriched with T3 and T, and tocotrienols are known to be more potent antioxidants 
than tocopherols (Suarna et al, 1993; Kamat and Devasagayam, 1995; Kamat et 
al, 1997), we have investigated the antioxidant impacts of TRF in normolipidemic 
and hyperlipidemic rats. 
Feeding of TRF and purified TRF to normolipidemic rats for 7 days was 
associated with a significant decline in microsomal lipid peroxidation (TBARS) 
and plasma LDL oxidation (conjugated dienes). These results are consistent with 
earlier reports indicating an inhibition in the formation of TBARS and conjugated 
dienes by TRF' or individual tocotrienols and tocopherols when added in vitro in 
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rat brain mitochondria (Kamat and Devasagayam, 1995) or rat liver microsomes 
(Kamat et ai, 1997). Indirect support to our results was obtained from an earlier 
report indicating an inhibition in the formation of lipid hydroperoxides in rats and 
humans treated with a- and y-T3 (Suarna et a/., 1993). 
Since antioxidants may have a role in the prevention of hyperlipidemia and 
amerosclerosis, we also investigated the antioxidant impact of TRF on microsomal 
lipid peroxides (TBARS) and plasma LDL oxidation (conjugated dienes) in 
hyperlipidemic rats. The increase in oxidative stress, evoked in experimental 
hyperlipidemia, is reflected by an increased formation of TBARS and conjugated 
dienes. Treatment of hyperlipidemic rats with 16.25 and 32.50 mg purified 
TRF/kg/day for 7 days not only caused a significant decline in lipid peroxides and 
conjugated dienes, in comparison to untreated hyperlipidemic control, but further 
reduced these levels below normal values. In agreement with earlier results, 
treatment of hyperlipidemic rats with 4, 8 and 12 mg TRF/kg/day caused a dose-
dependent decline in lipid peroxides and diene conjugates below the normal 
values. These results demonstrate that strong hypolipidemic impacts of TRF in 
conjunction with a potent antioxidant property can provide additional therapeutic 
benefit in the prevention and treatment of atherogenesis. 
Our combined results demonstrating a strong antioxidant impacts of TRF 
(containing mixture of tocotrienols and tocopherols) in hyperlipidemic rats are in 
agreement with earlier reports indicating that feeding of atherogenic diet to rats, 
supplemented with y-T3 (50 jig/g of diet) for 6 weeks caused a significant 
prevention in the formation of plasma TBARS. In addition, feeding of an 
atherogenic diet along with 500 ug/g of a-T significantly prevented the formation 
of lipid peroxides (TBARS) in comparison to rats fed only atherogenic diet. These 
results indicate that y-T3 exerts a significantly more potent antioxidant impact as 
compared to a-T (Watkins et al, 1993). Support to our results is also obtained 
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from another study where feeding of a mixture of tocotrienols along with an 
atherogenic diet to rabbits was associated with a significant reduction in the 
formation of serum lipid peroxides (Teoh et al, 1994). Treatment of patients, with 
hyperlipidemia and carotid stenosis, with TRF (240-360 mg/day) isolated from 
palm oil for 8 months caused a significant decrease in TBARS, an ex vivo 
indicator of maximal platelet peroxidation (Tomeo et al, 1995). 
Vitamin E (tocopherols) is well accepted as the first line of defense against 
lipid peroxidation, protecting polyunsaturated fatty acids in cell membranes 
through its free radical quenching activity in bio-membranes at an early stage of 
free radical attack (Horwitt, 1986; Van Gossum et al, 1988; Packer, 1991). 
Studies in animal and human models have indicated that plasma ct-T 
concentrations are highly correlated with plasma total lipid levels. In addition, 
vitamin E is transported in the plasma solely by lipoproteins; there are no other 
specific plasma transport proteins (Rubinstein et al, 1969; Carr et al, 1993). 
Similar to tocopherols, tocotrienols are also transported in the blood in association 
with circulating lipoproteins, as has been demonstrated in rat and human models 
(Suarna et al, 1993). Therefore, it appears that TRF exerts its antioxidant effect on 
plasma LDL oxidation while being attached to LDL particle. 
There are scattered reports indicating that neither rice bran nor RBO 
lowered cholesterol levels. These observations were explained by findings that 
some, but not all, rice cultivars contain tocotrienols which exert powerful 
hypolipidemic action (Qureshi et al, 1986; Qureshi et al, 1989). Because of 
these variation in types and content of T3, one finds corresponding variation in the 
lipid lowering affects of RBO/TRF isolated from different cultivars of rice. Out of 
a-, p-, y- and 5-forms of tocotrienol, y- and 5-T3 have been found to be most 
potent in terms of their HMG-CoA reductase inhibition as well as cholesterol 
lowering effects. The efficiency of hypocholesterolemic action as well as the 
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degree of inhibition of HMG-CoA reductase activity mediated by a-T:j was 
substantially lower than y- and 8-T3 (Pearce et ai, 1992). (3-Form of tocotrienols 
failed to exhibit any anticholesterol activity. Similarly, tocopherols failed to inhibit 
cholesterol synthesis at the level of rate limiting enzyme, HMG-CoA reductase, in 
chickens, rat liver hepatocytes and HepG2 cells (Pearce et ai, 1992), hence do not 
lower cholesterol. Earlier studies in humans demonstrated that tocopherol 
supplementation to ones diet had no effect on serum cholesterol concentration (Isai 
et ai, 1978; Schwartz and Rutherford, 1981; Ehnholm et ai, 1982; Kesaniemi and 
Grundy, 1982; Stampfer et ai, 1983) or actually resulted in slight increase in 
serum cholesterol concentrations in some individuals (Chase et ai, 1980; Howard 
et ai, 1982). Similar observations were made in chickens, where administration of 
tocotrienols blended with increasing concentrations of tocopherols, significantly 
attenuated the inhibition of cholesterol biosynthesis (Qureshi et ai, 1996). 
Therefore, the hypocholesterolemic effect of TRF (containing tocotrienols and 
tocopherols), isolated from palm oil, is exerted through the tocotrienols (Tan et ai, 
1991). Consistent with these reports and our results, the observed hypolipidemic 
impacts of TRF, isolated from RBO, is apparently mediated by tocotrienols. In 
addition, our results indicate that the total percent content of tocopherols present in 
TRF is not sufficient to attenuate the anticholesterol action of tocotrienols. 
Based on our findings, indicating that 8 mg TRF/kg/day exerts a maximal 
hypolipidemic and antioxidant action, we investigated the hypolipidemic impacts 
of purified TRF isolated from two cultivars of rice, raw Sarju-52 and Mansuri, 
which differ in their y- and 5-T3 content. Based on the total content of y- and 5-T3 
present in the purified TRF of each cultivar, efficiency of purified TRF at a dose 
of 1.22 and 2.44 mg/kg/day from raw Sarju-52 and 3.32 and 6.64 mg/kg/day from 
raw Mansuri was investigated in hyperlipidemic rats for 7 days. The above 
calculated doses will be equivalent to combined concentration of y- and 8-T3 
present in 3 and 6 mg TRF from refined edible grade RBO. In addition, this 
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calculation of TRF dose from two cultivars of rice is based on the observed 
maximal effect of 8 mg TRF/kg/day from refined edible grade RBO. As expected, 
feeding of above two doses of purified TRF from each cultivar to hyperlipidemic 
rats for 7 days was associated with a significant decline in plasma triglycerides, 
total cholesterol including esterified and free cholesterol, VLDL-C, LDL-C, apoB 
and enzymatic activity and protein mass of HMG-CoA reductase. It is important to 
note that at 6 mg equivalent dose of purified TRF/kg/day from both the cultivars, a 
twofold decrease in total cholesterol and LDL-C was observed in comparison to 
the hypolipidemic effect seen at 3 mg equivalent dose. In general, a dose-
dependent impact of TRF on the above lipid parameters was observed. These 
results indicate that the hypolipidemic impacts of calculated doses from purified 
TRF of two rice cultivars are consistent with the observed effects seen at 4 and 
8 mg TRF/kg/day. The results also demonstrate that efficacy of hypolipidemic 
action of TRF or purified TRF is directly related to the total content of y- and 8-T3. 
Similar to our results, y- and 8-T3 were the most potent hypocholesterolemic 
agents in normolipidemic and hyperlipidemic avian model (Pearce et al, 1992; 
Qureshi and Qureshi, 1993). The combined results also show that the TRF lowers 
plasma cholesterol concentrations more effectively in hyperlipidemic rats as 
compared to normolipidemic rats. Based on the combined results, one can 
calculate an optimal dose of TRF in terms of its maximal hypolipidemic effect in a 
given cultivar, which will be proportional to the combined quantity of y- and 8-T3 
(Table 15). Consistent with earlier results, administration of 3 and 6 mg equivalent 
doses of purified TRF/kg/day from two cultivars of rice to hyperlipidemic rats for 
7 days significantly reduced the formation of TBARS and conjugated dienes in a 
dose-dependent manner. Antioxidant effects of TRF coupled with its hypo-
lipidemic property in normolipidemic and hyperlipidemic rats underline the 
importance of TRF in the prevention and treatment of hyperlipidemia and coronary 
heart disease. 
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The combined results presented in the thesis provide considerable evidence 
that TRF isolated from RBO as a non-saponifiable fraction exhibit a potent 
hypolipidemic and antioxidant activities in normolipidemic as well as hyper-
lipidemic rats. Tocotrienol rich fraction used in the present investigation is rich in 
both tocotrienols and tocopherols. Previously published reports have suggested 
that tocotrienols mediate a potent hypolipidemic activity when administered in the 
diet to animals, including humans, an attribute not observed with tocopherols 
(Pearce et ai, 1992; Qureshi et ai, 1995). Side-chain unsaturation, which is absent 
in tocopherols, is important for this activity of tocotrienols (Pearce et ai, 1992; 
Parker et ai, 1993). In studies, directed toward a possible mechanism of action, 
Qureshi et ai (1986) observed that the plasma cholesterol lowering effect by TRF 
from barley in chickens and rats was associated with decreased levels of hepatic 
HMG-CoA reductase activity. Furthermore, the structure-activity relationships for 
the hypocholesterolemic activity of tocotrienols revealed that the natural and 
synthetic tocotrienols lacking the 5-methyl ring substituent, viz. y- and 8-T3, were 
highly active as suppressors of HMG-CoA reductase activity and cholesterol 
biosynthesis in primary rat hepatocytes and human hepatoma HepG2 cells (Pearce 
et ai, 1992). In general, our results are in agreement with the reported findings 
that presence of y- and 8-T3 in TRF is mainly responsible for the strong impact on 
cholesterol dynamics of normal and hyperlipidemic rats. In addition, our results 
demonstrate that efficacy of TRF in terms of cholesterol lowering activity varies 
due to the difference in the quantity of y- and 5-T3, which varies from cultivar to 
cultivar. Based on these observations, an optimal dose of 8 mg TRF/kg/day, 
fractionated from commercial refined edible grade RBO, which exerts a maximal 
hypolipidemic impact in normolipidemic and hyperlipidemic rats has been found. 
Similarly, based on the 30.5% and 11.2% combined content of y- and 8-T3 in 
Sarju-52 and Mansuri, respectively, an optimal dose of 3.20 and 8.85 mg purified 
TRF/kg/day in hyperlipidemic rats was found. In addition, based on the above 
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results and the combined content of y- and 8-T3 in a given cultivar, one can 
calculate a dose of TRF for maximal hypolipidemic activity. For example, an 
optimal dose of 3.04 mg purified TRF/kg/day has been calculated for cultivar, 
Basmati, based on total y- and 8-T3 content present in TRF (Table 15). 
Our combined results demonstrate a strong hypolipidemic action of TRF, 
when administered to normolipidemic and hyperlipidemic rats. In particular, total 
cholesterol, LDL-C and apoB, which are positively associated with CHD, were 
significantly reduced. Levels of plasma HDL-C and apoA-1, which are considered 
as anti-atherogenic, were not influenced in normal and hyperlipidemic rats treated 
with different doses of TRF or purified TRF. However, in normolipidemic rats 
treated with TRF and purified TRF, HDL2-C, which is a strong predictor of the 
presence and extent of CAD (Drexel el al., 1992), was significantly increased. 
Several epidemiological studies have demonstrated that elevated triglycerides level 
is associated with increased risk of CHD (Albrink and Man, 1959; Hulley et al, 
1980; Aberg et al, 1985; Freedman et al, 1988; Austin, 1991), a risk that is 
especially high in subjects with low HDL-cholesterol (Castelli, 1986). However, 
the status of triglycerides as an independent risk for CAD continues to be 
controversial. In our studies, TRF and purified TRF also mediated a significant 
decline in plasma triglycerides level of both normolipidemic and hyperlipidemic 
rats. In the Lipid Research Clinical (LRC) Trials, every 1% decrease in serum 
cholesterol resulted in a 2% reduction in the risk of CHD (Lipid Research Clinic 
Program, 1984 a&b). Therefore, if the results of LRC Trials can be extrapolated to 
the present studies dealing with hypolipidemic action of TRF in rats, a 25% 
decrease in plasma total cholesterol levels observed with TRF, fed to 
hyperlipidemic rats for 1-3 weeks, would indicate a 50% reduction in 
cardiovascular risks. 
157 
Based on our combined results, indicating a strong hypolipidemic and 
antioxidant properties of TRF, we have investigated the anti-tumour activity of 
TRF in experimental carcinogenesis of mammary gland and liver. The impact of 
TRF on initiation and/or promotion/progression of cancer in the above two models 
has been investigated. We have utilized the carcinogen, DMBA, which is known to 
induce mammary (Elegbede et ai, 1984; Elson et ai, 1988; Sundram et ai, 1989), 
skin (Perchellet et ai, 1985), buccal pouch (Shklar, 1982; Weerapradist and 
ShkJar, 1982) carcinogenesis and hypercholesterolemia (Albert et ai, 1977; Bond 
et ai, 1981). As expected, 6 months after the administration of DMBA, a 
significant increase in plasma triglycerides, total cholesterol including esterified 
and free cholesterol, LDL-C and apoB levels was observed. It is interesting to note 
that increase in LDL-C of experimental rats was twofold in comparison to normal 
rats. Feeding of TRF (10 mg/rat/day) to rats, two weeks before and after DMBA 
administration, for 6 months was associated with a significant decline in the above 
lipid parameters. However, HDL-C and apoA-1 along with HDL subtractions, 
HDL2-C and HDL3-C levels were not affected by DMBA administration and 
consequent TRF feeding. Twelve months after the administration of DMBA, 
plasma and lipoprotein lipids did not register any further significant increase in 
comparison to hypercholesterolemic control (EC-I) rats at 6 month. Six months of 
TRF treatment to hypercholesterolemic rats, initiated 6 months after the 
administration of DMBA, caused a significant decline in triglycerides, total 
cholesterol including esterified and free cholesterol, LDL-C and apoB levels. 
DMBA-induced hypercholesterolemia in conjunction with mammary 
carcinogenesis is consistent with earlier results (Albert et ai, 1977; Bond et ai, 
1981). Our results represent an initial demonstration of hypocholesterolemic action 
of TRF in rats induced with hypercholesterolemia coupled with carcinogenesis. 
In the second model, 6 months after the induction of hepatocarcinogenesis 
by DEN/AAF, unlike mammary carcinogenesis, lipid levels were not affected. 
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However, TRF treatment for 6 months, initiated two weeks before, two weeks 
after and 6 months after the administration of hepatocarcinogens, significantly 
reduced the plasma triglycerides, total cholesterol, LDL-C and apoB levels. This 
hypolipidemic effect of TRF seems to be similar to, as observed in normolipidemic 
rats (Table 3 and 4). 
The experimental hypercholesterolemia induced in rats treated with DMBA 
was due to a significant increase in hepatic HMG-CoA reductase activity, which 
was due to an increase in the protein mass of the enzyme. Consistent with the TRF 
mediated reduction in plasma total cholesterol and lipoprotein lipid levels, 
enzymatic activity and protein mass of HMG-CoA reductase was significantly 
reduced. Our combined results suggest that the mechanism of hypolipidemic 
action of TRF, involving a reduction in HMG-CoA reductase activity and protein 
mass, in experimental hyperlipidemia induced by the administration of either 
atherogenic diet or carcinogen, DMBA, was similar. Similarly, mechanism of 
hypolipidemic action of TRF in DEN/AAF induced hepatocarcinogenic rats is 
mediated by a decrease in the enzymatic activity and protein mass of HMG-CoA 
reductase. This mechanism of hypocholesterolemic action of TRF in hepatic 
carcinogenic rats appears to be similar to, as observed in normolipidemic rats. 
In response to oxidative stress, evoked in experimental mammary and 
hepatic carcinogenesis in rats, as reflected by increased formation of lipid 
peroxides (TBARS) and conjugated dienes of LDL oxidation, was significantly 
blocked by TRF treatment for 6 months. The antioxidant impact of TRF was 
equally effective when fed either during initiation or promotion. However, 
12 months after initiation, the concentrations of TBARS and conjugated dienes 
were further significantly elevated in comparison to 6 months experimental control 
(EC-I) rats. TRF treatment for 6 months of carcinogenic rats, initiated 6 months 
after the administration of the carcinogens, was associated with only a slight 
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decrease in the levels of TBARS and conjugated dienes. The increase in lipid 
peroxidation in mammary and hepatic carcinogenesis is consistent with previously 
published reports in cell culture and animals (Cook and McNamara, 1980; Prasad 
and Edwards-Prasad, 1982; Borek et al, 1986; Shklar et al, 1987; Trickier and 
Shklar, 1987). The antioxidant effect of TRF, exerted during initiation and 
promotion stages of carcinogenesis, is apparently due to quenching of free radicals 
or reacting with their products (Cook and McNamara, 1980; Prasad and Edwards-
Prasad, 1982; Borek et al, 1986; Shklar et al, 1987; Trickier and Shklar, 1987). In 
addition, it has been demonstrated in animal and cell culture studies, vitamin E and 
C, acting as scavengers of nitrite compounds prevented the formation of cancer-
promoting nitrosamines (Tannenbaum and Mergens, 1980; Lathia et al, 1988). 
Our results are in agreement with an earlier report indicating that a- and y-T3 had 
inhibitory effects on lipid peroxidation in vitro of microsomes isolated from 
murine tumours (Komiyama et al, 1989). On the basis of these results, it may be 
inferred that an undesirable chronic level of peroxidation occurs in the cell 
membranes and other tissue components after 12 months of progression of 
carcinogenesis and that lipid peroxide concentrations were not lowered by TRF 
supplementation, 6 months after the administration of carcinogen. In addition, 
these results point out that presence of TRF in the body as a source of antioxidant 
is essential before the initiation and/or promotion of carcinogenesis. 
Various ways of monitoring the carcinogenic process have been reported, 
including gross morphology, histology and ultrastructure (Weerapradist and 
Shklar, 1982) and determination of the preneoplastic marker enzymes, glutathione-
s-transferases (GSTs), alkaline phosphatase (ALP) and y-glutamyl transpeptidase 
(Sato et al, 1984; Moss, 1986; Hendrich and Pitot, 1987; Yamamoto etal, 1988). 
Glutathione-S-transferases are involved in the metabolism of foreign compounds 
including carcinogens (Chasseaud, 1970) and glutathione, the primary substrate for 
the GST, plays an important physiological role in the maintenance of cell integrity 
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(Chasseaud, 1970; Meister and Anderson, 1983). Alkaline phosphatase, a marker 
enzyme in the liver function test, has been reported to be useful as a marker of 
neoplastic transformation (Moss, 1986). 
Treatment with DMBA resulted in the formation of neoplastic nodules, 
which is evident from the appearance of multiple tumours on mammary glands of 
the carcinogen treated rats, 6 months after the DMBA administration. However, 
12 months after the administration of DMBA, greyish white patches also appeared 
on the livers, whereas the severity of carcinogenesis in mammary glands was 
further enhanced. Morphological examination of rat livers, 6 and 12 months after 
injection of DEN followed by administration of AAF, revealed the appearance of 
greyish white patches. Histological examination of livers from rats treated with 
DMBA for 12 months and rat livers, 6 and 12 months after treatment with 
DEN/AAF, revealed damage to the cells, particularly the nuclei. The degree of 
irregularity of the nucleus was reported to be related to the degree of malignancy 
of the cells or to the extent of damage (Henderson and Papadimitriou, 1982). 
Consistent with morphological and histological examinations, elevated ALP 
activities of the carcinogen treated rats are indicative of the severity of mammary 
and hepatic carcinogenesis (Chasseaud, 1970; Moss, 1986; Hendrich and Pitot, 
1987). Similar to liver, ALP and GST levels in mammary glands of rats treated 
with DMBA were increased. Long-term feeding of TRF, two weeks before and 
two weeks after carcinogen adrninistration, reduced the severity and extent of 
neoplastic transformation in the liver and mammary glands of the rats investigated. 
These results support the earlier findings that TRF is capable of reducing the 
severity of hepatocarcinogenesis (Ngah et al, 1991; Shamaan et al, 1993). Palm 
oil (Sundram et al, 1989) or tocotrienol (Gould et al, 1991) is also reported to 
increase tumour latency in rats treated with DMBA to induce mammary tumours. 
Tocotrienol rich fraction or individual tocotrienols have been shown to suppress 
the proliferation of several cancerous cell lines, such as breast cancer cells, 
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EBV EA Raji cells and murine B16 melanomas (Goh et al, 199A; Nesaretnam et 
al, 1995; He et al, 1996; Guthrie et al, 1997; Nesaretnam et al., 1998). Dietary 
intake of y-T3 suppressed the growth of B16 melanomas implanted in mice (He et 
al., 1996). It has been shown that tocotrienol has anti-tumour activity against 
sarcoma 180, Ehrlich carcinoma and IMC carcinoma (Komiyama et al., 1989). 
Kato et al. (1985) showed that y-T3 has anti-tumour activity on IMC carcinoma of 
mouse-transplantable tumours. 
Elevated levels of liver and mammary GST activity of carcinogenic rats 
were significantly inhibited in both the TRF treated groups for 6 months. Twelve 
months after treatment with carcinogens, the GST activity in liver was increased 
by 5-6 fold in comparison to normal control rats. Six months of TRF treatment, 
6 months after the administration of carcinogens, resulted in a slight decrease in 
hepatic GST activity. On the other hand, GST activity in mammary tissue, 
12 months after the administration of DMBA, was increased only by twofold in 
comparison to normal rats, with no significant effect following TRF treatment. The 
reduction in GST activity in TRF treated carcinogenic rats is in agreement with 
earlier reports (Rahmat et al, 1993; Shamaan et al, 1993). 
The combined results demonstrate that feeding of TRF, 2 weeks before and 
2 weeks after the administration of both the carcinogens, for 6 months equally 
suppressed the severity and extent of neoplastic transformation, suggesting a post-
initiation suppression of tumour growth by TRF. We also present evidence 
suggesting that TRF failed to exhibit a significant chemopreventive activity when 
- administered to rats after the progression stage of hepatic and mammary 
carcinogenesis. Determination of plasma LDL oxidation in tandem with the ALP 
and GST activities might provide a reliable indicator for mammary and hepatic 
carcinogenesis. Our studies also provide sufficient evidence that DMBA induced 
carcinogenesis is accompanied with hypercholesterolemia. TRF treatment, in 
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addition to its anti-cancer and antioxidant impacts, also exerted a strong 
hypocholesterolemic action, indicating a linkage between atherosclerosis and 
cancer. 
The coupled impact of TRF on cardiovascular disease and cancer may be 
explained by the mevalonate-suppressive action of constituent isoprenoid end-
products of plant secondary metabolism. Assorted monoterpenes (Clegg et al, 
1980 & 1982), carotenoids (Moreno et al., 1994) in vivo and tocotrienols (Pearce 
et al., 1992; Parker et al, 1993) in vitro, post-transcriptionally down-regulate 
enzymatic activity of HMG-CoA reductase, a key rate-controlling enzyme in the 
biosynthetic pathway of cholesterol. A modest decrease in cholesterol synthesis is 
associated with a concomitant lowering of LDL-C. The HMG-CoA reductase 
activity in tumour tissues differs from that of liver in being resistant to sterol 
feedback regulation, thus causing an increase in the enzymatic activity and protein 
mass of HMG-CoA reductase (Azrolan and Coleman, 1989). However, tumour 
HMG-CoA reductase activity retains sensitivity to post-transcriptional regulation 
(Elson and Yu, 1994). As a consequence, the TRF mediated-suppression of 
mevalonate synthesis depletes tumour tissues of two intermediate products, 
farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are incorporated 
post-translationally into growth control associated proteins (Fig. 4.1). The 
cholesterol content and the rate of cholesterol biosynthesis are elevated in 
proliferating normal tissues and tumours. Cholesterol biosynthesis happens much 
before DNA synthesis, and inhibiting cholesterol biosynthesis inhibits cell growth, 
suggesting a linkage between cholesterol and DNA synthetic pathways. Recent 
evidence that the farnesyl moiety in the cholesterol biosynthetic pathway is 
necessary for the activation of G-proteins and of the ras oncoprotein p21 has 
provided a basis for understanding this linkage through signal transduction 
pathways. Thus, farnesylation of G-proteins and ras oncoprotein p21 underscores 
the importance of the cholesterol biosynthetic pathway in cell growth and 
163 
HMG CoA 
reductase Tocotrienols 
HMG CoA 
f 
Mevalonic Acid 
O OH 
It V 
HO | OH 
• 
Isopentenyl pyrophosphate 
I 
-OPP 
Dimethylallyl pyrophosphate 
-OPP 
Farnesyf pyrophosphate 
-OPP 
Dolichols Cholesterol 
Isoprenylated 
proteins 
S 
i 
C H , 
« 
C H 
s >» 
II 3 
O 
S-farnesyl 
Cysteine methyl 
ester 
Fig. 4.1. The isoprenylation of proteins by intermediates in the cholesterol 
biosynthetic pathway. 
The farnesyl group, derived from mevalonate (red), modifies the cysteine amino 
acid (blue) at the carboxyl end of the ras protein. Tocotrienols (black), which 
lower cholesterol may block the farnesylation of the ras protein. [Adapted from the 
Journal of NIH Research (1990) Vol. 2, p-61]. 
carcinogenesis. Without farnesylation, the ras protein does not bind to the plasma 
membrane and does not function. In its inactive state ras binds GDP. When the 
cell receives a growth signal, ras binds GTP and changes to its active 
conformation. But in cancer cells a single mutation in ras prevents the hydrolysis 
of GTP and ras remains in a perpetually active state, which lead to uncontrolled 
growth and tumour formation (Fig. 4.2). The activation of ras protein would be 
aided by continuous farnesylation due to stimulation of the cholesterol 
biosynthetic pathway in tumours (Casey el ah, 1989; Schafer el ah, 1989; Maltese, 
1990; Elson, 1995; Elson and Qureshi, 1995; Rao, 1995). 
Our results demonstrate that administration of TRF blocks the 
initiation/promotion phase of DMBA induced carcinogenesis in liver coupled with 
a reduction in hypercholesterolemia. Hypercholesterolemia in DMBA treated rats 
was induced due to a significant activation of HMG-CoA reductase. It is intriguing 
to postulate that increase in HMG-CoA reductase activity may have resulted in the 
increased formation of mevalonate and hence farnesyl pyrophosphate. As 
discussed above, farnesylation of ras protein is one of the prerequisites for its 
activation. In cancer cells, a single mutation in the ras oncogene impairs the ability 
of the ras protein to turn off its signal transduction activity and it continues to 
stimulate the cell to grow (Fig. 4.2). Therefore, the hypocholesterolemic and anti-
cancer activities of TRF apparently involves the inhibition of HMG-CoA reductase 
activity, thus reducing the formation of both farnesyl pyrophosphate and 
cholesterol. Decreased availability of farnesyl pyrophosphate will inhibit the 
proliferation of cancerous cells. In addition, TRF apparently also exerts its anti-
cancer effect by inhibiting the farnesyl transferase enzyme, which is involved in 
the farnesylation of growth proteins (Fig. 4.1). This mechanism of TRF mediated 
anti-tumour activity is supported by a recent report indicating a strong inhibition of 
farnesyl transferase by TRF/tocotrienols in ras-transformed NTH-3T3 cells 
(Guthrie et ah, 1996). Our combined results indicate that TRF being a potent 
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Fig. 4.2. Binding of the ras proteins to the plasma membrane. 
The ras protein is modified by a farnesyl group (red), prior to binding to the 
cytosolic surface of the plasma membrane. Without farnesylation, the ras protein 
does not bind to the membrane and does not function. In its inactive state, ras binds 
GDP. When the cell receives a growth signal, ras binds GTP and changes to its 
active conformation. Mutations in ras prevent the hydrolysis of GTP and ras 
remains in a perpetually active state, which leads to uncontrolled growth and 
tumour formation. [Adapted from the Journal of NIH Research (1990) Vol. 2, p-62]. 
antioxidant, hypolipidemic and anti-tumour agent, can be used in the prevention 
and treatment of both cardiovascular diseases and certain types of cancer. 
In summary, the combined results presented in the thesis provide sufficient 
evidence that administration of TRF, isolated from RBO, to normolipidemic and 
hyperlipidemic rats was associated with a significant decline in plasma and 
lipoprotein lipids including apoB. The hypolipidemic action of TRF is apparently 
mediated by a decrease in the enzymatic activity of HMG-CoA reductase, the rate-
limiting enzyme, which in turn is modulated by a reduction in its protein mass. 
Formation of lipid peroxides (TBARS) and conjugated dienes (LDL oxidation) 
was significantly reduced in TRF treated normolipidemic rats. In response to 
oxidative stress, evoked in experimental hyperlipidemia in rats, as reflected by 
increased formation of TBARS and conjugated dienes, was significantly prevented 
by TRF treatment. The hypolipidemic property of TRF is dependent on the percent 
content of y- and 5-tocotrienols present in TRF, which vary from cultivar to 
cultivar. 
Determination of marker enzymes, ALP and GST, lipid peroxides and 
examination of gross morphology and histology suggested that TRF feeding did 
offer significant protection and did reduce the severity and extent of neoplastic 
transformation at post-initiation level in the liver and mammary glands of 
experimental carcinogenic rats. In DMBA-induced carcinogenesis, which is 
accompanied by hypercholesterolemia, TRF, in addition to its anti-cancer and 
antioxidant impacts, also exerted a strong hypocholesterolemic action, indicating a 
linkage between atherosclerosis and certain forms of cancer. The results indicate 
that chemopreventive actions of TRF in atherosclerosis and cancer are apparently 
mediated by reducing HMG-CoA reductase, thus limiting the availability of 
mevalonate-derived products required for cholesterol production and tumour 
growth. 
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Based on present study and previous studies in normolipidemic and 
hyperlipidemic humans in our laboratory, TRF (vitamin E), potent antioxidants, 
can be used in the prevention and treatment of hyperlipidemia and atherosclerosis. 
In addition, the results also demonstrate that TRF may be used in the prevention 
and treatment of certain forms of cancer. Daily intake of 8 mg TRF/kg body 
weight will provide a maximum therapeutic benefits. Rice bran, an inexpensive 
milling by-product largely used as animal feedstock, is potentially an underutilized 
resource of value-added products. India is the major rice producing country in the 
world, but only a fraction of rice bran, rich in oil and several beneficial 
micronutrients, including tocotrienols and tocopherols (vitamin E), is utilized as 
health food. Based on TRF mediated multiple therapeutic benefits, refined edible 
grade RBO, which has a fatty acid and glyceride composition similar to peanut oil, 
can be used as a major source of edible oil on daily basis. Daily use of RBO by 
normal population will prevent the occurrence of hyperlipidemia and 
cardiovascular diseases as well as initiation and promotion of certain forms of 
cancer. Furthermore, daily consumption of RBO as cooking oil by subjects 
suffering from lipid abnormalities and/or certain forms of cancer will be useful in 
the treatment of hyperlipidemia and CHD as well as in carcinogenesis. In addition, 
variety of other traditional edible oils such as mustard oil, peanut oil, soybean oil, 
corn oil, safflower oil, sunflower oil, etc., which lack in tocotrienols, can be 
supplemented with an optimal dose of 8 mg TRF/kg/day for multiple therapeutic 
benefits. Use of TRF-supplemented vegetable oil on daily basis will provide all the 
health benefits without compromising ones oil of choice. Furthermore, use of 
RBO, TRF or TRF-supplemented other edible oils will be an excellent source of 
vitamin E with substantial antioxidant activity. 
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India is the major rice producing country in the world, but only a fraction of 
rice bran, which is an inexpensive milling by-product and largely used as animal 
feedstock, is utilized as health food. Rice bran, rich in oil and several beneficial 
micronutrients, including tocotrienols and tocopherols (vitamin E), is potentially 
an underutilized resource of value-added products. A rapid, efficient, reproducible 
and cost-effective methodology has been developed, for the isolation of TRF from 
rice bran, crude RBO or refined edible grade RBO. The TRF, thus obtained, is 
purified involving a single step purification procedure. A significantly higher yield 
of TRF and purified TRF was isolated from crude RBO of two cultivars of rice, 
Sarju-52 and Mansuri, in comparison to TRF and purified TRF isolated from 
refined edible grade RBO, when the above methods were employed. The 
combined percent content of y- and 8-T3, as quantified by HPLC, present in 
purified TRF of Sarju-52 and Mansuri was significantly different than present in 
purified TRF of refined edible grade RBO. 
Feeding of tocotrienols as TRF and purified TRF, to normal rats was 
associated with a significant decline in plasma triglycerides, total cholesterol, 
VLDL-C and LDL-C, including apoB, levels. Although no significant change in 
HDL-C was observed, but its subtraction, HDL2-C, which is considered to be a 
strong predictor of presence and extent of coronary artery disease, was 
significantly increased. Consistent with no change in HDL-C, its apolipoprotein 
A-l level was not affected. 
Feeding of an atherogenic diet to rats was associated with a severe 
hyperlipidemia. Seven days after the withdrawal of atherogenic diet, the plasma 
and lipoprotein lipids including apoB and apoA-1 were reduced. Treatment of 
hyperlipidemic rats with different doses of TRF or purified TRF resulted in a 
further significant reduction in triglycerides, total cholesterol, VLDL-C, LDL-C 
and apoB levels. However, only at higher doses of TRF administration, apoA-1, 
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HDL-C and its subtractions, HDL2-C and HDL3-C, were also significantly 
reduced. After investigating several doses of TRF for its hypolipidemic efficiency, 
the minimum dose of TRF required to exhibit the maximum hypolipidemic impact 
in hyperlipidemic rats was found to be 8 mg/kg/day. These results indicate an 
excellent efficieny of TRF in the treatment of experimental hyperlipidemia. 
Feeding of purified TRF from raw Sarju-52 and Mansuri to hyperlipidemic 
rats was associated with a differential hypolipidemic impacts, which is due to the 
difference in their y- and 8-T3 content. Based on the total content of y- and 8-T3, 
present in the purified TRF of each cultivar, hypolipidemic efficacies at an 
equivalent dose of 3 and 6 mg TRF/kg/day (calculated on the basis of combined 
content of y- and 8-T3 present in 3 and 6 mg of TRF from refined edible grade 
RBO) caused a dose-dependent decline in plasma and lipoprotein lipids, including 
apoB. 
The hypocholesterolemic effect of TRF and purified TRF in normo-
lipidemic and hyperlipidemic rats is mediated by a decrease in the enzymatic 
activity and protein mass of HMG-CoA reductase, the rate-liniiting enzyme in the 
biosynthetic pathway of cholesterol. Feeding of cholesterol rich (atherogenic) diet 
to rats resulted in a sharp decrease in the enzymatic activity and protein mass of 
HMG-CoA reductase, apparently due to negative feedback inhibition of 
HMG-CoA reductase. However, after the withdrawal of atherogenic diet, the 
enzymatic activity and protein mass of HMG-CoA reductase were significantly 
increased due to the release of cholesterol feedback inhibition. Seven days of TRF 
and purified TRF treatment to hyperlipidemic rats, after the withdrawal of 
atherogenic diet, caused a further reduction in the enzymatic activity and protein 
mass of HMG-CoA reductase, when compared to untreated hyperlipidemic rats. A 
concomitant decline in immuno-reactive HMG-CoA reductase protein mass 
appears to be the reason for a decrease in enzyme activity and a consequent 
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decline in cholesterol production. These results represent an initial demonstration 
and indicate the involvement of TRF mediated long-term control by modulation in 
protein synthesis and/or degradation of HMG-CoA reductase. Based on combined 
results, it can be concluded that cholesterol lowering property of TRF in 
normolipidemic and hyperlipidemic rats is due to the suppression of enzyme 
activity and protein mass of HMG-CoA reductase, which is optimal at 8 mg 
TRF/kg/day. 
Administration of TRF, rich in tocotrienols and tocopherols, was associated 
with a significant decline in microsomal lipid peroxidation (TBARS) and plasma 
LDL oxidation (conjugated dienes) in normolipidemic and hyperlipidemic rats. 
Feeding of an atherogenic diet for 3 weeks was associated with a significant 
increased formation of lipid peroxides (TBARS) and conjugated dienes (LDL 
oxidation), which were reduced 7 days after the withdrawal of atherogenic diet. 
Treatment of hyperlipidemic rats for 7 days with TRF and purified TRF not only 
caused a significant decline in the formation of lipid peroxides and conjugated 
dienes, but further reduced these levels below normal values. These results 
underline the importance of TRF as a potent antioxidant agent. The combined 
results demonstrate that strong hypolipidemic impacts of TRF in conjunction with 
its potent antioxidant property can provide an additional therapeutic benefit in the 
prevention and treatment of hyperlipidemia and atherosclerosis. 
Based on strong hypolipidemic and antioxidant properties of TRF, we have 
investigated the anti-tumour activity of TRF in experimental carcinogenesis of 
mammary gland and liver. We have utilized the carcinogen, DMBA, which is 
known to induce mammary carcinogenesis and hypercholesterolemia. As expected, 
administration of DMBA, caused a significant increase in plasma triglycerides, 
total cholesterol, LDL-C and apoB levels. Feeding of TRF to rats, during pre- and 
post-initiation stages, was associated with a significant decline in the above lipid 
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parameters. However, HDL-C and apoA-1 along with HDL subtractions, HDL2-C 
and HDL3-C levels were not affected by DMBA administration and consequent 
TRF feeding. In the second model, after the induction of hepatocarcinogenesis by 
DEN/AAF, unlike mammary carcinogenesis, lipid levels were not affected. 
However, TRF treatment significantly reduced the plasma triglycerides, total 
cholesterol, LDL-C and apoB levels, in a manner analogous to normolipidemic 
rats. 
The experimental hypercholesterolemia in conjunction with carcinogenesis, 
induced in rats treated with DMBA was due to a significant increase in hepatic 
HMG-CoA reductase activity, which was due to an increase in the protein mass of 
the enzyme. Consistent with the TRF mediated reduction in plasma total 
cholesterol and lipoprotein lipid levels, enzymatic activity and protein mass of 
HMG-CoA reductase was significantly reduced. These results represent an initial 
demonstration of hypocholesterolemic action of TRF in rats induced with 
hypercholesterolemia coupled with carcinogenesis. 
Experimental carcinogenesis in rats was associated with an increased 
formation of lipid peroxides (TBARS) and conjugated dienes of LDL oxidation, 
which was significantly blocked by TRF treatment. The antioxidant impact of TRF 
was equally effective when fed to rats either during initiation or promotion. 
However, 12 months after initiation, the concentrations of TBARS and conjugated 
dienes were further significantly elevated in comparison to 6 months experimental 
control (EC-I) rats. TRF treatment for 6 months of carcinogenic rats, initiated 
6 months after the administration of the carcinogens, was associated with only a 
slight decrease in the levels of TBARS and conjugated dienes, indicating a 
niinimal effect of TRF during the progression stage of carcinogenesis. 
Treatment with DMBA resulted in the formation of neoplastic nodules, 
which is evident from the appearance of multiple tumours on mammary glands and 
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greyish white patches on the livers of the carcinogen treated rats. Morphological 
examination of rat livers, after injection of DEN followed by administration of 
AAF, also revealed the appearance of greyish white patches. Histological 
examination of livers from rats treated with DMBA for 12 months and rat livers, 
6 and 12 months after treatment with DEN/AAF, revealed damage to the cells, 
particularly the nuclei. Consistent with morphological and histological 
examinations, elevated ALP activities of the carcinogen treated rats are indicative 
of the severity of mammary and hepatic carcinogenesis. Similar to liver, ALP and 
GST levels in mammary glands of rats treated with DMBA were increased. Long-
term feeding of TRF, two weeks before and two weeks after carcinogen 
administration, reduced the severity and extent of neoplastic transformation in the 
liver and mammary glands of the rats investigated and also decreased significantly 
levels of liver and mammary GST activity. Twelve months after treatment with 
carcinogens, the GST activity in liver was increased by 5-6 fold in comparison to 
normal control rats. Consistent with antioxidant impact of TRF, 6 months of TRF 
treatment after progression of carcinogenesis, resulted in a slight decrease in 
hepatic GST activity. 
The combined results provide evidence that analysis of marker enzymes, 
ALP and GST, lipid peroxides and examination of gross morphology and histology 
suggested that TRF feeding did offer a significant protection and did reduce the 
severity and extent of neoplastic transformation during both initiation and/or 
promotion in both the liver and mammary glands of experimental carcinogenic 
rats. TRF treatment, in addition to its anti-cancer and antioxidant impacts, also 
exerted a strong hypocholesterolemic action, indicating a linkage between 
atherosclerosis and cancer. The dual chemopreventive actions of TRF in 
atherosclerosis and cancer are apparently mediated by reducing HMG-CoA 
reductase, thus limiting the availability of mevalonate-derived products required 
for cholesterol production and tumour growth. 
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Based on TRF mediated multiple therapeutic benefits, refined edible grade 
RBO can be used as a major source of edible oil on daily basis. Daily use of RBO 
by normal population will prevent the occurrence of hyperlipidemia and 
cardiovascular diseases as well as initiation and promotion of certain forms of 
cancer. Furthermore, daily consumption of RBO as cooking oil by subjects 
suffering from lipid abnormalities and/or certain forms of cancer will be useful in 
the treatment of hyperlipidemia and coronary heart disease as well as in 
carcinogenesis. In addition, variety of other traditional edible oils such as mustard 
oil, peanut oil, soybean oil, corn oil, safflower oil, sunflower oil, etc., which lack 
in tocotrienols, can be supplemented with an optimal dose of 8 mg TRF/kg/day for 
multiple therapeutic benefits. Use of TRF-supplemented vegetable oil on daily 
basis will provide all the health benefits without compromising ones oil of choice. 
Furthermore, use of RBO, TRF or TRF-supplemented other edible oils will be an 
excellent source of vitamin E with substantial antioxidant activity. 
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